2-1.4
=6.6%;
▁10.7
erogenic
▁Wash
▁349
ilial
erance
▁clem
vulsive
▁4000
▁IBS
▁fibrillation
omiph
11
▁0.34-0.
bend
olality
▁underst
▁65%.
▁-2.7
▁1058
ytoc
inum
▁clomiph
▁acrivastine
iases
ortable
1%;
▁ultrasonography
▁9,
-4.20
-2.8)
50%),
layed
▁privileges
▁alre
▁absorpti
▁clom
=-13.9
▁covariates
▁HBsA
▁prolonged
inete
▁88%-93%
▁opioid
▁obstetrical
atriptan
apart
▁PEFR
▁adjustment
▁inappro
▁abb
▁allergen
curac
▁idiop
▁CDC
▁29%
▁427
▁NP
<.05)
▁1281
hine
=.4
▁cephal
▁optimis
▁infr
astol
=.007
-3.7;
ihy
oyl
.14).
▁tine
▁0.58-0.9
▁compou
▁limb
▁encephal
▁(68%
▁Checklist
▁glyc
vandia
-4.9]),
ease
▁8.4
ersb
56%
▁isonia
▁guidebook
▁cleanlin
▁Belgian
=90%;
▁suscep
▁experim
thacin
▁fasciitis
ndar
hythmia
▁malignant
▁tazarotene
lac
erenc
▁uncon
▁anomalies
▁(71%)
antar
uitary
▁exhaus
▁Blind
71,
▁sleepin
terqu
agiti
acup
difference
▁neoplasm
axatives
▁antico
▁0.71-0.9
thasone
rombo
riu
▁podophyll
1.7;
▁1032
1.4
ocytopen
enopathy
▁systemic
tress
verestimate
▁2006
▁Manufacturing
ioed
4.7;
▁periop
▁anesthetic
iclopi
tivator
▁malarial
▁Overfeeding
eim
adone
ority
▁beli
▁98
265)
▁bic
acch
inizing
rocus
▁intentionally
itiat
87;
▁1.2,
▁nonhypertensive
abdomy
rogenic
▁biased
=55
agnosis
▁10,00
]=1.8
asized
ealth
▁docus
▁78
56)
pig
dos
▁methylm
=0.29;
utamic
▁strokes
▁invasiveness
▁RS
▁fungus
▁ine
nati
traumatic
verag
-99%),
▁DCA
egular
-57.
▁specul
▁colposcopies
▁pec
▁femal
ydrox
▁acce
▁BMD
▁compro
▁abstracts
roxyz
othi
▁48-22
▁40-60)
30)
chial
▁tympanostomy
▁Irbesartan
Silvadene
▁LM
▁latency
orkp
pep
orrhag
▁identifi
thly
▁MCI
Motrin
=7.4%
88
oron
idated
glycopro
▁quantif
6-1.44),
=0.9
▁rof
▁bismuth
▁interpretations
phoric
▁methim
▁1.4-
herence
51/36
▁Odds
antial
▁Norvas
Season
ltr
=0.74;
▁1.02-
linical
▁objec
opies
-1.54).
exC
uran
chitect
▁thromboemb
loyment
-2.20).
▁alco
▁pyelone
italiz
▁expedited
▁sodium
esin
yroidec
=4.6),
▁inquired
ciclovir
▁Reoper
▁heavi
-10.9).
▁unmet
▁gland
60).
▁meticulously
▁900
▁(2.4%
entamic
▁7.5%
▁oss
▁extre
orrhage
▁chann
▁theor
▁antiat
▁nonco
▁>50
4%-1
▁infants
▁1.8-191).
hie
ofulvin
loroace
assium
▁100,00
▁(71%
loroacetic
versed
▁fluticasone
ocardiogram
▁2437
610
uminuria
-1.20).
asti
steo
▁Rates
50.89
▁ralox
lus
stion
▁ventil
2.66
=2245).
▁enrolle
▁Tramadol
pain
▁discl
hydrochlor
▁ineffective
▁thickener
▁89%-92%),
▁assessments
▁overwe
5%-
tionat
12
▁0.497
levis
opian
▁Biopsy
Rs
▁pressures
iagnosed
▁antichol
▁31%
▁alpr
venty
erectomy
▁cystitis
▁<232
▁Polyp
▁levoth
5.5).
▁osteopenia
▁midtrimester
▁Neuro
=2.0-2.8
abo
terans
Bri
xter
▁Serologic
▁<1
0,8
▁<6
▁expiratory
▁degre
▁Doses
▁aneurysms
▁correspondingly
lorh
ndomet
▁Subgroup
ensiti
acyc
eriority
oscopies
▁IUD
▁nutritive
<.0007
nted
feedback
▁Unli
16
0/0.96,
▁circulatory
ornia
▁resect
zep
atent
▁naprosy
uctive
▁400-8
▁antihistamines
13.
▁outc
▁esterase
ouraging
=83%
rography
▁triam
▁immunocomprom
=2.26),
▁Dra
ociet
linician
alment
▁dextro
▁sensitiz
quency
▁skinfold
▁sonogram
3.67,
]=2.17;
chedule
▁appoin
▁Guidel
▁1.07-1.86)
▁expressing
<.004
▁Epidem
amide
inite
▁gonado
▁63.5%;
67),
880
vered
ablet
3.4%
▁3).
▁melanomas
▁antagonist
tiology
▁nasopharyngeal
xually
▁556
infants
35),
ributable
atot
cab
▁attendant
▁averaged
▁cyclical
▁unsaf
▁esophag
-2.7]),
isolated
METS
EPD
-18
ibia
Lop
74
▁0.64-0.8
exyp
egis
▁36.80)
alent
▁(85%)
azodone
▁reflex
osol
▁hypothetical
▁(1.25
roubl
opam
ordings
▁(24.3
▁diu
llium
Ve
▁0.63;
▁0.6;
partic
-1.0
-1.78)
criptive
vastine
▁<90,
▁4.7
▁3.7
▁sensitivi
erobic
cM
rofessionals
ocerv
▁97.09).
ospic
onis
▁occurren
thall
▁neurogenic
4%-93%
▁alm
/9
itored
placebo
95,
hec
ixture
▁(87%
▁amil
ectro
▁homeopathy
▁practitioner
eroid
-2.33).
ections
▁psoriatic
entile
▁uncommon
▁(2.4%)
acquired
▁Sonography
▁dyspnea
mpres
tiv
▁adhered
▁antigli
▁31,5
ticl
▁1.5-4.4]).
awb
▁proges
▁CN
▁regim
▁Cognitive
▁Few
▁8.28-20.
lactams
▁GADAb
]=0.83;
▁aggl
=2.34;
▁0.65-1.0
▁insufficiency
86).
9,
▁53
regate
▁wheezing
▁2633
▁pravastatin
▁>70
▁0.4-2
tection
enis
▁tolmet
▁nonsteroidal
26;
▁pseudoephedrine
yphilis
uloma
▁clamping
▁McM
combination
=47.67;
ydrop
44,8
=62%
007
▁postnatal
▁friction
▁(1:
-2.67),
glucosid
atox
▁remaind
▁resuscit
▁ligament
▁promp
▁(40
▁impul
=12,603
Schlatter
ausation
inesterase
▁alth
idrin
terial
esom
▁immunogenic
compared
teinu
afib
icability
▁nervousness
▁areat
etone
hazard
ranberry
heumat
=5.
76%
elog
▁sugges
eterans
-4.8);
▁nontreat
▁relap
▁135
▁prognostic
7-1.
ACI
lul
yprog
▁malignan
-2.7
▁86%;
▁opioids
▁adenot
▁cefac
▁28%),
▁6-
▁85.
Vist
tigat
pazine
esthes
77
-1995
omethacin
▁substern
ventricular
-5.85).
esize
▁antisp
roth
omoc
▁Exacerbation
lexor
ococc
▁categorized
,427
▁33%
ongest
1-4
onsive
omati
▁IgM
nipa
zetim
umping
▁Theref
▁anticonvulsants
▁devic
▁antiatherogenic
lycemia
54;
07).
▁4.9
▁contig
▁4.8%
omalies
▁91,
=6).
]=0.
=3.9;
▁carcinom
ecoxib
nders
luid
▁antifungal
coated
▁1.52-9.12),
aniti
viated
▁tiz
▁IUDs
ytoin
unti
endaz
▁546).
osyl
▁Sodium
▁predom
▁enamel
actating
▁psychophys
▁67
▁incomp
heny
logic
▁Ey
▁palsy
▁rats
▁-6.
▁pelvic
▁refus
=143
ighest
ubin
▁ceftriax
3-2.42)
7.6%
▁goit
▁(150
-3600
elone
cine
arthritis
▁mucosa
-99.6%.
▁2.61-26.97).
isease
imaz
menop
tie
▁alon
.002
romis
oride
uou
yin
alop
▁1.4-101.
-0.3
tide
▁51%
▁unchanged
▁(69%).
▁cesarean
-0.42).
▁enteral
erion
=1.67;
ultant
ndia
llin
hydrox
=21.2
▁citrate
▁chloramp
=10,8
▁37%
▁severity
atript
▁bronchodil
▁1.1-1.
ulmin
<.000
▁predictors
▁PVCs
▁LT
▁0%,
▁1.32
yclosp
▁diaz
6,19
▁sugars
▁unav
▁Screened
▁0.81-2.1).
▁restarted
▁66-7
=0.8;
▁searches
▁radiography
▁86%
ophyll
EIB
▁valve
teinuria
idered
tamin
erious
alv
603),
▁Transi
toth
▁unexpla
tico
leu
viti
boem
apable
▁spasm
▁31;
sition
▁microenc
▁subdural
▁1.30-1.73).
ISE
▁43
ioec
allergen
2.6
ocalized
lavicular
chosocial
quires
=0.54;
▁gastroplasty
trimester
ausea
USPST
▁critiqued
0.4%
Cou
naproxen
particular
▁(8.45
▁intram
2-1.8
▁96
coagulable
▁5)
001
▁3.9-1
.07
▁wou
omnograph
▁Benz
▁239
ransverse
idemic
478
yom
▁dermatos
ococci
obilization
trihexyphenid
=2.1
▁25%.
icid
efor
bap
diure
▁intran
-7.
apin
endations
Far
▁tas
▁eryth
▁91.8%).
gias
▁(72
zan
▁textural
▁1.02-1.25)
aglandin
ysl
▁endar
▁statins
▁differed
8-1.26).
▁investigators
▁0.5-0.8)
eign
itons
ourage
uates
▁319
▁treadm
menopausal
▁stringent
-2)
▁distorted
mox
mpan
vaccin
▁inser
▁neurocognitive
▁aure
retable
-1.40)
▁otitis
▁precursors
▁Allergy
fal
-0.6
▁mitral
-99.
Celexa
,000/
reakf
erties
▁>2
▁sulfonylurea
▁crackles
hylax
▁1.16
erms
terpret
eplon
abilizers
▁Sys
ziness
]=0.27;
=2.95%
ooperative
▁6.9
2-2.22),
▁orresponding
risk
▁enrolling
▁Duc
▁psychomotor
▁-0.1;
▁0.05
ndrom
▁progestogen
ymptomat
ogenicity
-1000
-0.23).
arit
561
pecif
▁elas
acti
▁AFCA
eterogeneity
▁(75%
45.
▁saiboku
▁0.14-0.5
▁hypogonad
osmolality
rih
tapering
▁3.1;
ptors
oderate
▁1.04-3.
▁(19
WBC
uebec
▁Adequate
▁lymphocytosis
cholesterolemic
▁intraparenchy
2.5%;
▁tigh
▁epstein
osac
▁nasoph
RRR
▁Nystatin
nitive
iotro
osit
supraspinatus
▁0.90
onec
5)..
00=
anul
=1.33;
▁11
ephalex
▁Alend
afl
=933)
▁progesterone
▁genotypes
▁deli
4%,
27.
▁coh
▁prospectively
ndo
▁negatives
▁(6
ercising
enderness
▁postcoital
65;
▁hasten
▁21%
▁Incontinence
▁hypomagnesemia
▁77%-85%),
▁0.99),
molality
4%-8
▁gestational
-8.7),
]=5).
phic
adycard
(8
▁deterior
▁1.1-2.8)
▁egophony
▁ulnar
▁freez
▁(28%)
]=-20.
▁dosing
▁cereb
erologic
▁refill
iterature
▁consisten
▁bruising
paste
resection
asteberry
▁antimic
▁nont
reinforcement
▁rotator
-0.84),
30
▁Madd
▁CST
adually
▁Targ
edati
▁SIDS
rared
▁Readjustment
▁infarction
genase
▁(1.9
copro
-2.58
mip
▁erad
orized
.04.
▁meticulous
▁perce
andomly
▁lesion
▁57-245
▁chlorh
=192)
anip
otonic
relax
▁atheroscler
▁reticul
choc
▁Antimalarials
▁decarbox
administered
enopaus
ulv
▁Nugent
▁peritoneal
-1.92;
▁skel
▁carr
▁1.52
▁(500-1
▁indicators
Eu
▁Centor
▁carbo
unotherapy
eptin
-1.79).
iolytic
▁essenti
eac
-56.89),
rimin
▁differenti
uestion
-19.
retroviral
▁trichomon
oqu
▁glucos
▁spu
traep
▁progestog
▁buckwheat
▁Clinician
zide
rri
titud
.2
▁unnec
1%-6
ronchod
▁1.
▁siz
▁Candida
ormally
ortun
▁shap
chemic
▁Chlamydophil
33;
▁1.08-1.29).
=19)
▁stimulant
<.05
epith
,000),
▁39,
▁(68%)
novascular
valpro
0/30
oconstric
▁(>5%)
onegative
etas
electasis
▁(19%-4
=.04.
atea
ilatation
▁3339
]=6
loxacin
produces
=.004)
▁unreliable
ysic
▁leukotri
vary
otran
▁948
▁820
=4.4).
elg
▁fluoridated
▁lifel
oxifene
umcis
▁0.93.
.04
▁(1.39)
71.
▁tacrolimus
ournals
ramingham
▁sulfameth
henhyd
8.7),
relates
antially
=603),
▁hepatoxic
▁7.0%).
▁Statistical
▁cyclooxygenase
=2-4
iou
▁17).
elivery
roin
=-0.38
▁47,22
Mes
oscopy
▁Hispanic
ibroid
▁25.1%
▁(500
▁Calcium
▁Guidelines
signs
▁osteoporotic
▁ez
alantamine
▁omeg
▁predictive
/1
▁Aj
▁vals
▁amniotic
▁0.63/0.
5.5%).
ndat
onograp
cic
▁Postm
-4.5
tort
=100
▁nutritional
▁MHI
rophilic
5.3).
4.20
efulness
onid
▁Warfarin
ulfis
opical
odological
ographically
▁Mortality
specificities
▁obser
inkles
▁Rif
ecular
▁0.70/0.
alit
asal
Depakote
▁subth
resented
▁receiv
▁doses
▁recr
▁ASC
=26).
ixation
.06
menting
▁67%-9
691
baseline
IDNT
▁Cen
cetyl
thmatic
ardial
orac
lacement
cytosis
onchi
▁secondh
▁lowers
▁bumetanide
▁tumor
wice
▁hyperth
▁marketed
▁Nutritionists
uctured
aminas
imesulide
tolytic
enhy
▁133
uvaRing
927
isil
arenter
2).
▁542
iome
▁thromboembolism
▁Pharmacologic
▁Tyloph
▁microscopic
▁Atyp
▁Therap
edtime
orcement
amisil
▁terbin
glycer
-50
120
efloxacin
▁incontinence
04;
years
▁ICU
aerob
▁efficacious
▁suspec
raditional
6%
7,
yclics
oglob
▁solu
arad
6,193)
essenti
eful
=.2).
▁subsc
85%
▁snoring
▁arthroscopy
▁impair
6-0.
artments
ylind
onary
quas
-2.4
OMM
=2.7).
▁serog
▁bronchod
▁awaren
▁citing
erectom
▁83%
17,
▁usef
▁10.0
▁expul
▁excr
tiat
8.
▁inhibitor
▁disseminated
▁75%,
enia
▁carbonic
utoim
▁<4
▁157
pressing
▁petrolat
thro
▁35.4%
▁TMP
elae
▁naproxen
1.
▁nefazodone
▁(34.
▁secondhand
▁thos
▁nigricans
fibro
▁(2.6
proe
▁Affec
▁70.
48%
Stro
aminated
▁adop
plifying
tular
▁1.03-1.
roidism
2.5).
teriz
ortan
▁690,000
ogues
▁1243
▁Patients
▁methotrex
otranscobal
odeine
71)
ergot
Revised
▁1.21
▁Ajoene
▁10%-54%;
▁nifedipine
63,
dverse
▁turbinate
-0.82).1
▁(3.8%
94;
▁Anticoagulation
acq
▁inac
▁Chlamydia
▁diabetic
▁0.58
▁Systematic
▁0.80-1.09).
ronchosp
ypop
▁BV
30-1.73).
trogen
,825
▁oth
▁terf
▁hepato
ipment
▁FD
▁15-
retics
=3-6
▁2.35
0-2.
cision
liad
▁postcatar
▁tetrac
▁Reflex
▁adhering
arox
▁avail
▁Furtherm
-1.63).
98%
cobal
▁3.5%).
7.5%
▁urtic
rowing
Age
-56.
▁Exacerb
ethasone
uffered
87)
teroid
▁5.2-8.
usor
ayed
ecur
▁thes
▁flor
▁oxytocic
79).
akly
▁DMARD
▁42%
6.8
ongl
balamin
▁vasoc
▁0.4-1.
▁Danes
essional
icensed
OAb
completely
4-0.20
fine
eus
enig
5-1.05).
ibit
▁injected
▁0.01-0.42).
xicity
▁competence
clud
hyllin
aceous
oprol
rician
▁translum
ribonucleic
izin
estive
isin
▁1.02-1.94).
▁acad
Bs
rometry
▁hospitaliz
etu
▁ascorb
splitting
▁ciprofloxacin
▁percussion
▁0.99-1.3
▁0.28-0.89
rhonchi
=10).
8%),
=.94
▁phar
apul
▁proti
▁unblinded
OA
▁dexamethasone
traum
ophor
sulf
▁1.04-4.94).
▁antacids
icyc
choles
▁sati
kness
umoc
curring
▁LVH
=178)
Ven
uality
resen
▁daugh
▁dementia
▁positioning
asber
asalaz
▁gend
eil
DHD
orrheal
prevalence
▁ahe
26
▁stripe
-72
▁0.66
ultation
ocu
xer
2-0.99).
▁1.09-1.57;
▁42.9%
▁Lactobacillus
▁(250
▁Orthovisc
▁Interestingly
apil
▁aPL
443
▁hyperbil
▁Antimalar
-26.
▁causation
Vasot
titut
-24.
epsi
▁strati
urti
opc
▁0.8
▁0.9-3.6).
ptor
▁79%,
▁0.57-0.9
onorrh
▁institutes
izophrenia
▁77%
ogmatic
-1.6).
ocalcemic
▁CAB
-1.6
▁hypercal
▁aPT
wab
ormation
zac
▁prematur
▁diverged
▁ispag
3-1.19).
oskeletal
chool
▁Groo
worst
enna
▁ventilation
39;
lyam
14
7%
-19
▁postinjury
emoc
aifenesin
abap
86%
▁remedy
▁fash
▁airf
31;
raming
▁0.3/
Viox
alopathy
▁833),
ndr
36
TOR
▁66%.
assage
xio
▁proch
/32
▁1.24-1.74).
vice
admill
▁perfor
50);
otherap
▁42
8%;
▁49,
▁13.2
▁145,811
▁549
=.4).
13;
boc
3.9
omach
▁codeine
-7.4
48,
57.
anation
88;
omew
▁9
▁2004.
▁quadruple
titution
itiv
▁1
ioid
Teg
▁47%-4
onor
20.
▁kidney
estri
owered
▁glycem
saf
ipi
econd
▁4
OSCOP
-4%
arres
esign
▁Pati
gation
redi
51).
▁Stroke
▁(87.
exual
dip
▁0.01).
tipation
▁47
▁glomerulopathy
▁hirsu
smokers
▁pyoderma
/15)
idid
▁0.09
ortem
▁cramping
adjusted
-95%).
00-1.4
sul
troa
ucin
]=0.4
▁DMPA
▁unclassified
hts
ditionally
pil
=1.5
▁islet
▁11.8
dinburgh
8%
▁preeclamptic
omog
iased
dentif
▁2.3%
vidual
arbonate
icen
plementation
▁antiseiz
erti
eppermint
teria
75
ficial
mented
indings
▁Diagn
480
Tro
▁(97
▁inflammatory
▁Alzheimer
▁bipolar
hilic
▁26.7
nivers
22),
irox
ductor
halic
▁hypogonadism
3.3%).
▁4.3.
lowed
tensin
▁tuberculosis
anate
=0.26
▁Catastrophic
inine
▁undergone
ptoc
orating
<.03
▁menstrual
ophi
elc
roly
rati
<.00
ariat
▁myomas
▁0.69
Colace
barr
cinomas
arker
tiont
05)
▁subarachn
ymptomatic
ledgeable
▁vomiting
▁endoscopically
ynovi
pharmac
▁malform
▁rehy
]=25.
▁footb
▁Tric
chloride
▁HLA
mpicil
eraz
▁atopy
▁interf
▁0.72-1.01).
urban
cogn
▁suic
]=10.
▁nausea
laims
▁(0.4
▁carpal
▁Formal
▁PPDs
▁22%,
▁cyclooxy
▁histology
▁noncalc
▁80-8
proxim
erior
gment
actere
acture
tential
2-14.5
▁metatarsal
reward
ixt
olesterol
▁-3.54).
▁viral
▁optimally
▁onetime
umar
positi
▁64%
60.
▁unbi
examin
▁naftifine
idance
▁nim
▁postural
,881
▁1.95-2.54).
▁Theoretically
▁pemoline
hythmias
rope
▁Angiotensin
elis
ionine
udat
tuft
=18,241),
▁37%-
loramp
=1.5)
▁argues
pilot
titrated
edron
isox
administ
=2.3
▁3000
▁summarized
▁-0.7)
▁anticoagulated
phosph
.002;
trac
▁caroti
icacy
eriv
▁14.8%
orizontal
xap
ewhere
youn
952
▁>20
uspirone
encep
unoc
▁tightness
lactam
apanese
=7370),
apolate
ganism
▁535
▁77.8%
apine
omerular
trin
38%
▁35-66)-
TDI
▁12%,
▁tantr
▁lesions
astes
▁attenuating
alp
tives
ternate
nip
rime
▁indap
▁(5.8
▁Tongl
▁intake
bumin
▁gonococcal
phenid
4-1.51).
inished
▁dor
roer
74.
uver
▁ome
▁renin
yclov
▁(3)
▁LMWH
▁ValH
-1.68),
▁worsening
▁(24%)
▁Valproate
NB
7-1.20).
=.043).
5%
oretical
volves
-0.97).
rts
recep
orar
mise
▁recommending
▁(11.
ermomet
▁significan
GADA
▁actin
▁misad
▁undef
giene
ughter
▁0.04-0.74).
adication
onged
▁sulfadiaz
-45)
agland
noring
▁nonexperimental
▁Atypical
-0.91
cessf
▁transv
44)
▁7%)
=16;
▁Holotrans
entia
▁pioglitazone
▁gath
▁Ade
amphen
-3.77).
5/10
etoconazole
-3.7)
eom
▁1.5-8.
nowled
▁1:30
▁9/100
ipecac
▁nonsolid
pectancy
-83.3%).
alphenazone
=.03)
▁(63
oxine
▁behavioral
▁soldi
▁randomization
detection
▁nebulizers
▁Bezafibrate
ifested
▁titrating
▁ecological
▁Tram
▁diarrhea
▁0.79
.7
veill
ollowing
ocortic
-3.34)
erangement
▁hypoglycem
16;
▁125
▁701
uidel
ulness
itri
oures
▁methodological
▁24-
▁2)
▁plaster
▁(45%);
▁12.4%
alem
▁practic
0.5%
▁15.8
ayn
emer
astolic
dwe
=87)
vat
din
▁factorial
▁isom
accination
▁specificiti
idaz
▁10.3%
▁overes
unctivi
▁Theo
▁(5/
▁6%).
▁otherw
olated
060
onists
<.05;
traceptiv
-9.
productive
▁HbA
ekly
▁exag
▁penile
urac
aleplon
▁buckwhe
imu
▁20-5
▁orres
ortript
▁defibro
▁orrespond
▁(7.4
▁singlet
▁bacitracin
olus
]=3.5).
▁80%.
]=4).
xan
8.9).
boo
ncop
=9373)
rimar
▁desatur
aq
1-137.26).
▁unpredict
Diflucan
▁intermittent
2]=5
lure
▁nonex
.007).
80-5.
▁hys
50,000
▁590
▁peri
▁192
▁(0%).
▁analyz
▁Hepatorenal
▁revacc
▁computerized
alpro
opo
▁1.42
▁myocardial
amethasone
achn
▁leuk
33).
▁(56%
▁0.12-0.96),
▁salb
orrhoid
ticenter
hep
▁284
itially
ecis
▁restenosis
aem
▁100
]=0.46;
alid
▁Esophageal
lamydial
paction
▁underpowered
▁atrial
▁47.4%
▁plateau
▁CBC
▁Azas
akened
▁miln
odic
ifl
▁Consensus
7.1).
9%).
=0.8
53
▁0.14-0.
iotomy
▁130
▁defibrotide
▁defici
▁tec
6);
dac
rear
▁agglutination
▁glycer
itrofur
nually
atement
▁fremitus
rozac
itripty
eaked
▁arrhythmia
igital
osses
77)
23.3
▁0.04
▁SNR
99%
etrac
eplace
pecified
▁CAD
dosed
vidone
ecol
▁recipients
▁inconcl
6.0
▁Complications
=0.58).
▁characterizes
▁3/1
00,
▁908
408
▁transcer
▁32%
▁exacerb
▁hyperplasia
▁1.22%
Dop
ereas
vaR
ovement
everity
▁mycological
hronic
▁3.9-10.7).
eosporin
=126
▁postnasal
inders
-1.69)
aminosalic
44,
artere
alance
ioam
unoth
▁consul
ormational
▁(>1
regulation
▁preserving
▁antagon
isdi
-0.96)
rexate
orbid
62)
385
-0.4;
=.02,
-24).
nap
▁anter
bohyd
striction
▁tT
▁ciclopi
▁1.2-8
▁1.2-1
▁condensed
▁excisional
▁Pengo
expos
3-
ittaci
5-1.3
=24.
buride
▁microal
ervical
▁Nineteen
▁caff
itiation
▁psychopathology
▁plaf
▁(72%)
=11;
▁misadventure
olidays
▁ORs
erbate
▁pati
▁conceive
erioration
▁gynec
>5%)
▁intrapartum
▁5-3
▁Respir
termenstrual
prednisone
exCAP
▁25-
▁mec
▁triath
0%-7
-600
ransi
▁7.5
▁>78
etro
▁deo
▁saphenofemoral
428);
▁concussed
yrox
▁confers
▁symptomatic
DAb
=.005).
2.2).
=27)
▁orthopedist
-1.7;
▁tig
▁Hispan
unster
SOAPP
▁hypomanic
▁0.13-0.26).
▁merit
ulmon
▁ala
=.25
▁endotracheal
▁(>3
=6.4
▁Hypocalcemia
ifici
agmus
ionizers
▁(71.
▁Cros
▁164
terolem
reo
ummarized
▁benzyl
etform
rictest
apride
ondence
ipos
▁choos
itonin
petence
molecular
▁(28%
ithm
fecox
=3
▁effecti
racture
▁encopres
=.8
ifyll
▁acan
orticoster
▁intentionto
▁uncomplicated
alatoplasty
▁superi
▁formoterol
▁INR
intile
erape
spective
▁569
▁1991.
]=0.56
cholesterol
7.
▁neurot
Bec
=.051).
2-9.12),
0.9,
nds
elography
▁crossover
▁sonohyster
bulating
.03
▁Rayna
▁nonantib
enous
ercep
▁2.10-3.7
▁biopsychosocial
onorrhea
▁Sle
reh
alli
kop
getables
▁56%,
▁pyridoxine
▁246
▁6.2
▁Colle
ronidazole
▁1.15-3.14)
arachn
oramoxicillin
erin
USPSTF
▁spit
oneg
ataf
▁agg
0).
elanoma
▁bactere
tron
=1162;
▁(0.49
▁deregulate
goal
onin
▁endoscopic
▁11.5
essi
utan
ilian
ifamp
.2).
rolat
Ter
xif
▁Beresford
uably
33)
▁0.80-1.0
▁pren
▁Epidemi
Educ
atif
▁deviation
▁25,
estrogens
▁0.00-1.4
▁polysomnogram
-8,
rophil
▁1.13
ransit
5-1.0
onog
econ
▁(70%
ensitivity
iminating
-45.
▁(76%
2.6%
efi
epsia
tant
enorrhea
ravastatin
.0-1
6,2
rimo
ecation
istop
osage
▁(8%),
▁flourish
owork
▁assesses
irritant
terc
plasty
▁tric
assi
▁antibiotic
ezaf
irsutis
▁reassess
ricans
stratif
obron
uniti
]=13-1
otox
bout
▁exudates
idespread
▁17.
atherm
-0.
enafil
▁oste
▁321
▁hypon
atorenal
3.6).
▁TIA
ulfameth
▁outcom
unsc
ochrom
ecom
▁12-
riti
▁Nip
utrin
-10.3
▁slows
nable
urin
tionnaire
=.004),
▁acute
▁antip
ogeneity
opositive
▁572
▁angiography
05%
Au
tention
followed
Bres
olon
athro
giotensin
▁undershirts
▁encompassing
▁workp
iciar
-800
ighty
45%)
-69.
agnose
erro
Lef
▁uteri
oiter
▁isl
valvular
trau
breas
likelihood
▁perinatal
ofibrate
▁chorionic
▁2900
promot
▁0.34-0.99).
cis
▁pathoph
▁reas
▁0.52
inment
ufacturing
▁nonfasting
dren
afood
▁pyl
7.2-9
9%-
follicle
Wi
ndon
▁Varicella
Roc
DCAs
aryngeal
▁hepatore
etical
▁RR
syst
▁(448
onazol
▁0.42-0.9
apulopustular
=2.36;
▁shampo
▁ligamentous
▁(1000
▁xyl
amisole
▁924
earn
anis
▁oxytocin
opa
▁5.11-21.2
stol
urren
ovag
=1.6;
▁145,
▁-1.58
dre
▁Benefits
▁hemorrhagic
▁phon
proteinur
▁-0.03
issi
▁mathematic
▁antidepressant
pectively
tender
=24-31).
2]
ryon
orbent
▁comorbid
▁cramps
▁protime
▁malignancy
ocusing
▁eccentric
▁Framing
▁inver
▁stati
▁squam
▁229
botic
=4060),
▁glargine
2.7
▁(25%-50%)
80-1.0
fecoxib
.45
▁Caucasian
5%.
eresford
▁-1.21
▁unin
vu
itonsillar
NHAA
3.8
▁noncompliance
ophren
otential
▁268
▁Urine
▁esters
▁kneeling
fenofibrate
Women
▁17.3
rious
ucing
2.7).
gis
7.10)
yclovir
▁5.9%;
=48)
▁cerebrovascular
limb
▁4.91-137.2
▁exhaustion
7.2%,
hibiting
umat
-4.4
▁antepartum
erit
▁menstr
▁nightly
▁osteoarthritis
▁Acet
▁Examination
▁Neuropsych
▁1.04),
▁8.6%,
▁(3.7%)
▁8.0
nig
orin
pine
rur
opathy
▁421
▁sci
▁1.0-1
exercise
▁foll
▁observational
Lovenox
▁0.75-1.0
omatosis
▁(1.58-5.
25),
▁diphen
andia
-0.79)
histamin
▁regardl
▁tizanidine
▁confus
▁Varonen
▁edema
▁2758
▁116,0
▁0.45
ydia
▁<3.2
.05)
ximal
esm
▁60.5%
▁ligation
▁prein
▁sulfasal
idne
▁benzodiazepine
]=1.44%;
▁127
garis
=121)
/70).
aep
Dip
=25;
ergies
etrospective
▁0.9%
utr
muniz
ideline
inant
▁antipyretic
▁1986
▁55-
▁(4.0,
▁fewest
stim
▁(82
▁TM
▁40.
-0.0
arv
▁>19.6
rhythm
▁normo
pectant
emfibrozil
▁(1),
Norvasc
▁cholines
▁CI
▁creatinine
amphetamine
acic
▁misdiagnosis
58-5.
ufacturer
Relaf
]=15;
alations
▁worsened
▁streptococcus
ipation
▁hypoall
=40),
ilm
MSE
Ov
usitis
▁erg
▁rectal
-7.0;
tscreening
=18,
▁docu
viat
responders
▁optimum
▁labo
▁procalcitonin
▁gabap
▁phoned
▁hydrophilic
▁anox
ulfad
NIDD
▁11.3%
▁estradi
troduction
▁Belcaro
hea
erestingly
=0.36;
<.05),
▁regimens
astroin
preventable
▁sickness
▁22
▁anaerobic
▁intubations
558)
▁endometritis
▁probab
structive
06
(1
aniz
▁adequ
▁methimazole
▁nonantibiotic
ioprine
825
▁absc
oidable
roo
=0.32;
kic
▁6796
▁47%.
oated
linder
06;
odel
ruited
Wors
▁pressu
▁terti
▁nonsyst
pretations
▁9/100,000
▁Generaliz
struation
ostm
affec
▁PTSD
tinguished
Rou
failures
▁restless
tivity
▁prophy
▁Staphyl
▁strangulation
▁restl
▁0.12-4.
patients
▁Bronch
▁whic
tihypertensive
=33%,
▁suppressive
▁Scandinavian
-0.43;
17).
▁comparative
▁immunoglobulin
=0.4;
▁69%
=0.50;
2-8.
iscon
estos
tith
▁fossa
gies
▁1.07-2.8),
-5.2
▁resis
▁progn
▁saturation
▁FOBT
▁(74%-93%)
entering
Cer
ldopa
oil
▁methylmalonic
▁heterophile
2-0.9
=.2)
▁48-
▁1.19-7.6),
0.7).
]=20
toly
▁538
▁bacteri
esti
▁genit
osocomial
▁0.42.
=93.8%
-1.06).
enin
▁1.04-4.9
▁36%
▁(8-12
▁etre
ienti
tino
inalys
aucas
venti
▁femor
utures
inol
▁pyelogram
▁-0.33).
▁1990
▁stepw
▁circumcis
▁3.85%
-57.9
▁838
resu
▁simil
oD
etec
sally
exercis
gagement
▁<.0
▁37%-86%)
▁improvem
Fo
acology
▁postpr
sons
▁Interrater
85.
▁hypokal
reatitis
]=0.02)
oddlers
3-3.
▁counterirrit
riction
▁poore
efit
terv
0%-33.0%).
lives
▁(90%-100%
6-0.92;
▁caffeine
▁27
▁unlimited
entable
▁peron
levating
▁1.0).
edtim
▁52-144;
anoma
▁ina
▁blisters
xpect
▁Terbin
=-1.
▁492
▁-2.54
epress
▁Infant
▁schooling
=.26)
▁carbamazepine
▁calcified
10,
ultured
keletal
▁adre
▁antise
ibitor
orgest
▁3.4%;
vening
oplac
rovement
▁3350
▁1.29-1.54).
damycin
▁capill
=96,193)
▁intermed
▁onset
▁anticholinergic
▁aminotransfer
14).
teb
-11.9]),
ceou
▁10%-
▁2005
▁sulfonamide
cautery
▁(10/68)
andaging
heumatic
▁postop
77%
ipri
▁pituit
1-5.3
▁nicot
osphon
▁perih
▁Regard
roidectomy
▁decongest
▁MMS
▁tran
vival
sist
yang
syll
marized
▁35-
-0.91).
-3.9
amazepine
▁Ear
▁3.34-6.0
=.05)
▁unn
usp
▁recept
▁proximal
144)
bution
▁escitalopram
▁Corticoster
rosso
▁(50
6,0
▁scientif
▁gradual
ylit
olerant
cortis
▁confounder
alospor
▁(12/
▁0.74
▁inh
▁outpatients
▁rotavirus
probability
▁antifracture
▁feath
ROCAM
picillin
0),
odif
▁dexter
iry
eas
3-1.00).
-0.70).
bacter
-66)-
edim
▁VALU
▁lactul
breastf
ropathic
ractionated
utlin
uag
▁laxative
▁55.0
emo
puted
32-526.
0%,
.47
tition
iconazole
▁1.44-2.9
85)
108)
▁acrom
elstick
mend
▁amputation
6)-
▁lax
▁privi
aicin
▁-23.2
-50),
ightfor
mpir
anemic
▁568
▁tuboovarian
▁6.41
posures
▁ThinPrep
enting
40-2
▁cohosh
olp
▁hysteroscopy
lain
thop
llerg
▁sepsis
▁migh
▁multist
idation
-89).
omery
imin
▁1.1-6.
chlorper
ricyclic
▁Divalproex
=0.80
istle
▁unresp
reinf
▁dysrhythm
▁asymmetric
▁decreased
bronchodil
▁labs
inov
amati
▁terfenadine
ipul
▁(2.
▁dosages
▁aqueous
▁0.23-0.
▁1.06-1.44),
uating
▁oxyt
▁tympan
osmolar
▁endocervical
6-7.0).
▁chlamyd
=.036).
▁anembryonic
▁radiological
47
▁Finnish
/19)
ysterectom
▁mycoplasm
21%
endazol
tinued
xpec
pectr
▁peop
▁brom
▁zol
▁refractory
ortions
▁Stimulants
▁Erad
▁(83%);
▁ossicl
▁20.
6/
57,
=0.17;
▁71%-8
▁subscapular
idit
▁20)
▁(8.8
gth
pooled
▁<2
▁-0.2
▁-4.52
08).
ffered
ipril
endoc
▁(21%).
▁ECG
0.1%
▁5.0-15.8).
rative
▁8.2-2
erficial
,000
▁1050
encap
opposed
utum
▁Efficacy
=0.23).
amamelis
▁Wiscons
▁preprandial
=55).
itrogen
rele
64
▁reinforcement
3.3
=3.38,
hter
atches
anidine
odilators
vig
opaus
▁compartments
Mep
entab
enzap
adal
4.4).
utri
▁Leukotriene
urement
Derm
umbos
▁Affective
▁resol
roph
▁deox
▁0.09-0.29).
Aj
▁seroton
▁Cheil
incidence
ctive
▁meningitis
TSD
112
/7
Tap
opard
axati
▁Anoth
luox
▁0.1/
yri
▁rea
5-1.6
▁0.66-0.96)
=1.3
▁interacted
▁pulmon
Mi
reatening
pirone
7-7.86).
▁Fetters
upiro
ducation
▁substances
=23,613),
waves
IgA
▁46,808
▁Hysteroscopy
▁Varon
=19.
▁Taiwanese
onsens
8-13.
▁acces
▁Improvement
▁imipramine
enings
nalizing
ALT
ochran
idam
▁0.17-1.04
▁careg
pran
vular
urred
urvi
allenge
]=0.8
▁(16%)
3-0.6
▁periph
lop
utp
riene
specifically
-23.21
tionn
adon
▁Tylophor
nific
bine
▁endeavor
Ur
oporotic
▁kidne
zol
▁deleteri
rength
▁abductor
▁substan
mortality
atl
▁86.6%,
tosis
▁203
).6
▁1.63-4.56),
▁<7
▁(266,0
=59).
▁Extracorporeal
▁Unpubl
▁enlarg
coital
4%-93%)
/170
▁balloon
curacies
tatistic
▁Dys
▁(8%
lyamine
cinyl
5).
▁differentiate
eteri
▁522
▁3.5-4.
urine
onias
ytology
ildly
enase
owes
idney
▁daltep
▁synovial
ysical
ximately
▁hospices
iciti
ugmentation
aminosalicyl
9.7.
igarette
3.7;
▁supr
▁promptly
▁0.23-0.7
vag
CAH
▁postn
terograp
asic
▁0.84-0.9
▁(80
holin
-2.05).
renter
▁aten
=4.
▁transi
▁0.40-0.9
▁18.3-42.4)
agnetic
▁4.9%
-15.8)
▁tis
▁unres
1/
tiolog
-1.5
blood
▁(18%)
otably
=1.50
ventable
/4
VH
=7.
versity
▁(2300
reefold
▁arthral
USP
-0.9),
redis
▁0.36-0.7
▁diazepam
zema
▁Prospective
micro
redic
▁histological
]=5.
▁chewing
atectomy
▁propionate
ulner
▁(7
Vag
cad
74).
STAR
trical
▁acupuncture
actobac
▁98.
xac
ortal
▁Cutaneous
▁74
weighed
trimoxazole
umatic
itho
olidined
=0.59;
nisone
▁<80
chondroit
LTS
llul
▁deat
=40
▁1.8-18.
▁Mayo
▁cesare
arial
efold
98;
Ni
roxyprog
▁Systolic
▁upri
▁emph
▁Scand
▁<1.3.
▁Medications
concentration
▁73%)
=21.
ropean
▁15,
acit
▁263
blin
andm
adenopathy
reter
▁endometrial
▁AMA
▁eradicated
hyla
sulfamethoxazole
eor
▁56%)
▁questionnaires
yliti
ifor
pects
▁208
▁hazel
mom
TCA
▁clu
umbersome
centration
holog
▁4.1
▁cardiac
▁0.50
▁0.026
epres
▁erratic
▁1.5%
▁simultaneous
2%.
bronchodilator
bilify
▁rehydrating
-5.28).
35;
▁trog
ransbronch
▁unexpectedly
andin
tassi
lance
uir
tual
tram
ostn
▁physiotherapy
ulopustular
▁hypoglycemia
▁micon
▁antih
ogel
1%
ransmission
etent
28-20.6).
▁efficacy
timalar
esity
▁97.0
5.4)
iazepine
=8).
utl
▁37%-8
ffex
▁(31%
pst
ultination
reased
haz
86
▁ticlop
%).
▁18,5
erlin
iclof
protein
deficiency
=1.07;
▁myc
▁1987
▁capsule
rouped
▁favoring
▁necroti
5%-50%
▁underp
▁heterosex
▁Metronidazole
proex
▁76%,
▁specification
genic
ytop
eiz
wives
iciaries
▁1/200
.0]).
▁oxymet
-99;
▁salm
▁exhibiting
▁0.7,
ulsi
▁enzyme
timibe
inor
ooled
▁0.71-0.8
eration
08
ALUE
lasm
▁0.2-0.8).
-1.40
▁0.03
▁(49
ormiti
▁unsc
2.5%
▁antisep
1-3.3
reit
unblind
trapartum
▁fluoroqu
=.034).
7%.
eec
▁lability
omn
▁palp
bacco
enic
=7.3%;
racti
▁95%]
▁0.17-1.0
▁Stimul
▁york
▁lowmolec
ocrom
neumoc
▁0.75-0.94)
▁concur
▁magnes
-49%.
▁Bronchitis
ydial
▁husk
▁initiating
▁familial
▁25,927
▁reduc
Remic
]=0.68;
acrol
▁100,000.
▁glycopro
▁20-35
cursors
yet
▁CABGs
osporine
▁1.7%
▁ambul
8,241),
resist
ultiv
▁lar
▁tonsillectomy
rimazole
▁whoop
enile
▁Muns
mentou
ussi
▁sertraline
escent
▁52.8
headach
6.4%
▁1.02-1.94).8
▁unilateral
▁acro
ultu
(5
=3)
vedil
/344)
sists
7.8%;
ARR
ingitis
83;
▁-10
apazole
▁(3.0
▁(18.9%)
▁-0.17%,
ehavior
amid
▁2002).
▁attenu
▁microencaps
▁methyldopa
-1.34).
▁0.23-1.
Gas
▁2.2
timated
8/0.
enyang
ABR
▁embolism
alanced
▁effor
troac
dum
ankle
▁-4.59).
opause
▁nominal
uitable
timately
36).
ulti
ronidazoleor
sific
acu
edion
▁hormone
sionals
▁diagnose
rush
▁Impressions
molar
viral
erbinafine
3-2.74),
30-63).
▁thistle
▁acne
bdominal
TAB
▁excori
cellent
emically
orther
▁6,
5%);
▁licor
utions
▁35.8
▁0.45-0.79)
▁palat
▁(89
=.81
tir
▁1.02),
inerg
zoles
chop
▁5.1
=-9.4
▁coli
brachial
▁norf
▁Benign
▁dysph
omorb
gested
▁8.5,
opping
apazol
▁200)
ostication
llo
▁Fourteen
▁accep
etine
teer
00-1
▁febrile
▁(88%
▁Bres
restr
▁decarboxylase
tilizing
2,6
notic
henazone
▁endotr
▁Lifest
▁Magnetic
Rin
▁0.13-0.6
▁sedation
▁Specifically
▁spre
▁0.09-0.3
▁0.24-0.9
▁(39/18
olesterolemic
▁35
▁Strept
Lor
timally
▁1.1-7
▁classify
▁0.21-0.85)
▁88%),
▁(36%)
78).
hydrate
<.01;
▁650
Trimo
▁microor
ophy
entox
▁1/
otab
▁MIC
▁relapse
929),
▁titers
▁0.55-0.97;
55;
▁glucocor
erci
onadal
etan
▁attenuation
rams
▁80-84).
eregulate
2]=57%
ustained
cerated
▁Fract
ourescence
ypical
ypos
mely
▁(41.2%
1]
▁Sensitivity
▁ureter
rimip
▁antis
metazol
4-4.
romyc
▁individualized
ikelihood
ipop
>0
▁olamine
-1.25)
▁Tissue
▁5000
▁innercity
dg
▁mainstay
▁0.03-0.19)
ershirts
40/
▁promin
otiv
▁stratified
echocard
aphy
aterials
▁indica
mopress
ticaria
usively
65)
9.0
▁0.36
▁hyperactivity
▁553
65%
▁9/100,000),
1.6%,
▁Endpoin
idere
roj
trati
timulating
dor
=29
▁MRSA
=.1
monitoring
▁Osteopor
▁normotension
▁0.0-0.8).
=.009).
=0.26;
▁2.5,
urgery
▁dysl
lococcus
▁Diab
▁tTG
erum
▁miconazole
7%-9
dil
▁airw
▁0.47
▁plaques
gression
alan
▁criterion
ablets
▁0
▁macroad
▁empir
ocript
▁(18%
azap
▁clon
estational
=1.6
gthen
▁kinase
amuscular
roent
itiate
=0.31;
liximab
-2.6
▁miscarriage
▁Wadd
eduling
▁Concentrations
tionally
Wom
restricted
70),
owever
▁intraparen
▁Older
▁2050.
▁Atar
omorbid
/0.7
▁requi
▁150
92%
ouc
armacists
Gar
▁dyslipidemia
▁bronchial
zil
▁0.00-1.44)
▁Sexual
▁reticulocyte
tomies
▁(4893
▁47%).
▁precordial
97-0.97)
▁fibromy
odophyll
▁MEDLI
▁77%-8
italop
pecial
tap
isoxazole
▁(51%
iclopidine
iprazole
▁transluminal
▁weaknesses
WEET
▁nonph
luenz
7%-4
▁hyperandrogenic
4/
▁singleton
icond
ractions
hle
▁57.2%
▁stimul
niz
.001)
contro
▁deviations
824
▁intol
▁13.7%
atoplasty
▁-0.45)
iability
▁enam
enla
coag
9-1.15),
▁dehyd
▁1.1-6.4).
▁MRFI
Arthro
-92%).
9.6%.
esting
4-3
9%-7
▁2.7-5.7).
anization
▁1995.
elts
-1.6),
iotom
nees
▁3.7%
▁salbutam
oak
▁chl
adism
7%).
iclopirox
▁0.07-1.4
]=1.50;
oox
▁Banglad
hemoly
▁nitrofurantoin
asb
3.0%).
▁immunoglob
osphonates
▁PHN
▁validated
▁uncompl
▁HPV
▁amin
▁immunocompetent
▁1.13-1.6
▁inad
rofurantoin
formin
2500
▁(16.7),
enteral
▁STIs
pecially
▁excruciating
ecessary
▁lymphadenopathy
ndre
orw
ticasone
yu
gou
3)
▁emo
pleas
exor
ovis
6.1
▁7.84
etus
▁estrogenic
vidu
iograp
▁(9.9%)
▁ceftri
ervatively
▁biloba
▁84%-9
albumin
inorrh
▁22.
actorily
imult
▁microorganism
▁27.6
initis
▁0.12-0.44).
▁4.0%)
vaginal
irds
ctly
dinary
▁carc
▁melanom
▁PROSPER
▁75
▁sexually
▁normalization
]=0.08;
▁nigh
epressant
▁cefixim
▁0.65-1.02).1
prothromb
Bre
=0.34;
xone
orag
itamin
▁noncompl
miconazole
ysm
0,000
verg
osterone
roxyprogesterone
uati
▁1.4%;
▁orthoped
▁OCs
▁1.07-2.
okinetic
=2.4;
▁tibia
odilation
enil
▁saphenopoplite
=31)
▁recurred
3-1.18),
▁0.66,
▁5.3.
▁ValHeF
anol
▁hypogonadal
2;
▁pyogenic
oluble
▁McMurray
67,
CAHT
llment
▁2.14
363)
thors
▁outf
▁81%;
▁0.17
▁1.4-3.
▁0.5-1.
▁Detectable
-42.
onvention
▁65%
androgenic
=1.1
0-1.
▁postmenopausal
▁teleph
]=4
ospices
▁encom
.26
rotein
apitis
▁tuberos
▁lumbos
-11.2%
omyces
▁Nipple
▁32%,
▁(88%)
lso
▁ket
=944
ounted
▁Pentox
▁(6/109)
lase
endom
,40
inac
▁macros
locker
retin
tih
▁appra
▁HBsAg
-0.38;
7.5%,
gesic
endp
2).1
▁10.8
oconazole
Arth
arcin
mou
repres
domyolysis
latter
▁901
DCS
ereditary
▁conclusive
verity
Wound
sear
▁apprais
<.001;
ofem
▁devi
▁straining
samin
soph
▁hysterec
▁1.6
anage
orat
olines
ighes
-1.51).
pingitis
▁(3.8
▁0.51-0.8
RCTs
ependent
▁rickets
▁arousal
teri
▁mefloquine
ranb
▁strept
▁synthes
▁valerate
▁plasmacell
▁visi
laxis
roergot
85).
econdh
280
valences
-14.7%)
relim
Rat
▁unrelated
amcinolone
linici
▁eac
cour
andomiz
15)
uage
▁itrac
2.1).
psych
orazine
veraged
▁transaminase
iptical
otrin
▁>10,
▁abo
onn
respondence
▁10.4%
▁29.7.
=5.78).
▁titrated
▁termination
ypog
=32;
85
67).
aminoph
itript
Ou
▁mono
▁gases
▁oxymetazol
rhy
▁heterozy
▁(0.9%)
▁12,5
▁durab
▁serolog
80-5.37),
28-20.
▁disturbances
▁guideline
yoly
49%
onat
ronchitis
Fs
▁<.05).
▁loz
▁dopamine
▁vulvovaginitis
▁1.09
▁mycologically
mort
enicity
igox
3,613),
produc
▁Copenh
▁5.5%
=338)
hostility
uptures
vasiven
▁nondrug
=24.6).
posure
72-41.8)
chlorperazine
etect
oraz
▁pharyngitis
▁Subcutaneous
▁2.82
▁clopid
5-
dent
ostility
athi
fes
603
acr
▁3.5%
=884
6-0.96)
▁mak
▁anecdotally
▁(5
CEL
▁tendencies
oulder
yb
otine
vach
▁multisite
vasc
tiom
▁heterog
ylitol
66-1
corrected
▁conjun
imazol
traceptive
wly
omag
▁defic
▁21%.
iminated
▁antac
leag
laimed
▁cen
vand
▁desm
neon
ealand
▁peripartum
apule
elsink
▁pep
]=0.7
▁latent
▁(1237
▁1.2-2.7).
▁1.04-1.07),
▁weightbearing
ofen
iseofulvin
iotensin
ociety
▁(-0.
▁emulsion
1-2.
▁physiological
]=1.31,
=4.6
▁phosp
38;
▁evaluates
▁conjunction
38
calce
omox
8,755
ceeded
▁clinician
▁5%
3-4.56),
▁81).
stitutes
-1.64
ifam
▁DTS
icien
chil
astatic
▁sampl
▁euthyroid
earan
40).
▁Nys
▁(85.1%
▁transcervical
ropion
ilet
▁proton
acell
8.3)
aseline
ylen
efficacy
amag
retations
ensuring
oods
▁Thia
Nu
aliti
lucan
tiss
▁(83%;
▁0.26
▁immunoblot
4%
erapies
endos
▁somew
▁hypnosis
1-1.5
79.
▁prophyl
elong
restimate
▁irrig
cturnal
▁CNBS
▁irri
▁Postmarket
▁aminotrans
▁incompetence
▁(2
aifen
flexxa
siz
▁Elevated
▁Capsaicin
▁625
▁rigor
bese
inical
▁hydroxyz
▁mucate
▁folate
-6.2).7
▁hyperaro
▁67%
▁Acros
=.009
laxing
▁recurren
▁glar
epe
▁jaund
43).
▁atel
ytologic
EG
eum
36%
=1.95,
iotics
▁0.5).
ulonephritis
-6,
andages
otransco
▁18.3
▁Adolescents
etiriz
aparen
onservative
bam
▁enalapril
37),
▁misadvent
▁Banglades
0.6).
▁acetyl
▁arrhythmic
▁Iberogast
abas
urant
ltrasonography
▁Penhall
▁midwives
▁oi
▁reflec
▁42,
▁114
▁1010
oxyl
CAs
▁anem
-2.85).
76)
meg
▁parathyroid
37.
tenat
seudoephedrine
▁Recommendations
ovirus
▁effici
efici
49;
-8.1).
▁homocysteine
rosis
0.15;
▁Increasing
algia
58-
ormone
▁1.61-3.41)
▁noncomparative
quamous
▁usu
▁quartile
=-2.38
▁13.9-15.
kbased
-48%
=0.87;
udesonide
efic
ordination
-66
oten
=3.7)
▁arguably
▁dosag
▁immun
▁ezetimibe
▁hypn
▁20-3
▁7
▁nonsmoking
0%-1
ackup
▁18,790
uling
,13
taw
▁taz
tracorporeal
▁fluc
▁decarbo
▁0.09-0.
.0-9.4)
▁thrombosed
ylphen
ydroxyzine
▁163
▁biopsi
-33.
,888
=.0043)
▁successive
oplite
renergic
▁prophylactic
▁analgesics
▁Ottaw
▁twofold
▁2001,
▁Meperidine
▁nonce
=1.2
dj
LG
▁pum
▁0.2
autery
alation
cemic
ertile
▁69
ulfid
▁unsuit
ticon
lebitis
▁exces
ophys
▁chemically
59;
▁vasoconstric
lavul
eop
▁qid
▁286
▁lifetim
6.7).
▁cranial
▁Tanner
dayc
.4).
cef
ransfer
542
0]
agus
steoporotic
79;
▁plasminogen
efa
Dou
▁reinf
taining
cyc
29).
abapent
▁anes
odopa
ypo
74%
yper
oxic
▁cess
entoxifylline
▁ester
▁jaundice
44),
▁66
ofil
▁generalized
oncent
▁1.33-2.42)
▁408
▁positives
ichia
ROC
.1%
5.3
▁20.5
Naftin
agnes
▁Subsequently
7),
erma
▁Graphical
▁Ostenil
▁detec
▁Impair
lal
loral
▁0.13-0.
oflox
▁probes
oupl
6.6%;
comy
ofemoral
9.4)
iters
-72)
bronch
▁(30/30)
olized
ifel
(6
75;
▁NN
▁multidisc
▁unpleasant
▁Tolerance
▁fibros
oxidants
▁avul
4.4
83.
▁135/
ressively
▁1.32-1.4
▁262
▁surrou
harmacologic
50,
▁HOPE
▁exacerbations
rocyte
plann
▁consec
▁myoc
opharmac
ostp
▁pyrazin
unre
lyc
ourte
-1.29).
imiting
ycin
▁-0.14;
holinergics
▁arip
▁0.6/
▁crutches
▁secreted
6%)
4%-81%
▁leukot
▁ARBs
▁1034
vements
▁>32.2
tiary
omile
rehensive
▁enzy
=1%
▁IVP
57;
hensi
7.67;
0-1.2
orps
130
acet
chill
▁intranasal
eeth
4.5.
=1.39;
7.4%
onococ
▁antep
▁warts
▁explorations
▁(3/15)
▁antigen
▁93%.
▁certainty
oidance
▁indep
-0.79);
9.4-57.
▁8385
▁blinding
▁rhabdomyolysis
▁celand
▁oxyquinoline
ataflam
acterial
▁embryoplacental
▁275
▁betamethasone
▁233
enefit
▁0.35-0.97;
99)
▁cumb
62).
iccoated
odium
▁quadrup
hary
tenti
▁aripiprazole
=935)
omogene
umcision
designed
ETS
▁orthostatic
kf
verit
▁AO
tien
▁sumatriptan
,9
openh
▁orl
espir
▁hysterectomized
uod
Ol
kag
uthors
lity
▁irb
ymph
oim
-2
isoning
ooking
stab
ternati
tice
▁bipol
▁amit
9/18
▁prostaglandin
ochester
obulin
▁Thyroid
,1
revox
udents
▁11-220).
operating
▁elicits
-1.58).
▁myal
zul
-76%
iglit
2.4%
=.003).
rani
ingent
▁-1.2
▁24,529
-2.0)
erant
▁dermatolog
ilder
ectomy
▁(55%
=0.88;
ticulocy
▁intraep
olesterolem
amilt
▁withdrawals
-6
▁etanercept
▁teratogenicity
▁capsaicin
vailable
onogr
▁nes
▁conclud
▁lessened
=91.4%;
▁3192
▁Cyclical
erw
▁ramip
vating
4.3;
▁testic
irri
▁Abn
-1.4
neez
78%
▁2.7%
▁36.
acerbating
▁27,456
histology
orias
▁Achilles
▁inconclusive
ralizing
jus
-3
▁revascular
5-0.7
▁Oste
uclide
▁779
▁45
naires
▁1564
▁(69%)
urab
VTs
ffectiveness
▁ESR
ription
▁hypernatremia
▁tenoxic
▁16.0%
▁59%-76%),
▁nec
▁Decreases
%),
ocard
▁benign
▁flora
▁0.01-2.9
▁physicians
▁mell
▁Approximately
-20.6).
Dri
rimeth
utination
4-0.99).
▁limbs
verestimated
▁steroids
tity
▁Identif
▁necro
CEP
▁levon
▁malabsorption
wife
ominal
eterminate
ezing
-6.29).
1-2.7
▁tretin
osart
apr
=224
Ba
▁-0.1
cisional
abum
vocal
ilver
▁3.48,
idymitis
ronical
erican
▁methodology
0.5
▁filtration
olter
▁16/20
1,2
ientif
obl
itourinary
▁contractions
4%-81%).
ttaw
▁speculation
▁hyperten
ecia
▁disclosed
depressant
ideation
▁308,755
▁percentile
▁LMW
Prep
osal
▁disabl
ggest
▁naprosyn
▁demen
▁clind
▁Trial
-5.8).
<1
▁1.1-2.0)
ormo
▁ery
▁transplant
novial
▁Bac
egison
▁Hydroxyzine
▁20-4
▁12.2%
▁glyburide
pensity
-220
▁172
▁Mild
reus
▁otoac
▁Extensive
▁migraine
hritis
▁metron
▁equivalency
]=-
eprazole
adders
fasting
]=25.96;
19.
iscl
▁orc
▁electrom
palp
▁cortisol
▁62%
ithd
▁digoxin
]=0.9
ailures
17
hips
▁filtr
▁(57%
=-1%;
▁(892
▁psychotherapy
-0.97
▁byp
02;
centr
▁0.90/0.
thys
yth
romazine
▁Lute
▁58
▁13,44
ldop
▁dyspl
▁(82%
8-0.
olum
▁0.9-3.
▁gestation
tentionally
▁1.2-1.6)
▁noninsertional
00
▁unip
alosporin
olone
ospasmolytic
▁1.44-2.99;
▁2.66).
arre
▁Reasonable
▁23,
▁resten
Cy
61
onazole
2.8%
▁cotrimoxazole
reop
15.
enal
ipocytes
terest
lth
▁0.18
sweetened
.4
▁0.94-1.69)
▁(0.7%
▁23%
▁escalating
▁unpredictable
-1.44
▁circu
▁1.52-
▁couns
estog
▁empl
acut
▁adipos
▁multiparous
▁dilatation
uteal
▁indurations
▁anteri
▁(25
▁positi
inally
ulvovag
hieve
naud
▁doxy
iline
▁postnat
▁dereg
▁immunogenicity
]=14
0.0%)
ilk
-3.7
▁98%.
4-0.52),
reptococ
▁kic
▁enoxap
entific
laqu
▁96%
6.76)
▁dair
etters
▁96%.
heat
ximet
rthro
▁unsched
nating
▁overused
8,2
▁graf
24;
tensive
riaz
rospective
27;
endoscopically
ERD
illin
▁infus
rates
▁Enuresis
▁guine
sensi
4%;
▁SOAPP
,3
▁188
=4.6;
alex
vit
▁substud
▁syphilis
▁8-12
onding
=514
▁classific
ipoph
leeding
robi
upunct
lite
iogr
▁0.70-1.09);
▁prescrib
▁MDI
cholesterolemia
chotherapy
=5144)
▁metabolic
▁5.6;
▁scarring
67;
▁demonstrable
▁3500
vou
▁Outcom
▁116,094
voth
).9
▁osteopen
etronidazole
▁20-
ropioni
▁herp
etermined
oclopram
▁tubercul
55.
xag
7.5%)
/70
▁calcif
▁treatm
▁waking
▁intrav
llip
echanical
sweet
▁distill
55)
ioglitazone
tance
▁subjec
oxazol
▁1715
-21.
▁AFF
▁curren
sequent
mental
ppos
responsive
igment
▁thrombos
-1.20
gestin
ertainty
ranas
arative
▁0.20
orning
-12.
ulariz
▁cessation
▁19,
/3
iazep
-4.4]).
438;
▁Parag
WOS
omenon
▁Unfort
erately
quely
evere
throu
ibul
zyl
▁nonresp
▁1.2-8.0
ogis
▁sunsc
eospor
▁elig
▁predictor
50)
▁142
gnos
2-1.86).
enog
▁0.56-0.94).4
▁quan
sag
utab
▁euth
▁1-
umeral
eith
5-8
▁48%
uterol
▁supplementation
Wo
▁nonb
igit
veloc
iovascular
▁satisfact
▁chloramphenic
▁74%
▁97.2
weeks
▁Intention
▁TI
rangulation
terle
erich
esearch
▁noninvasive
▁opio
▁Disorders
manic
▁nasopharynx
▁ect
▁delinquency
▁Lyme
trihexyphenidyl
▁decong
▁NCE
oore
▁antiarrhythmic
▁antidepress
▁79
/0.83,
▁NPH
Pri
▁infancy
▁sonography
▁0.28
▁0.34-0.9
▁responsi
bivol
▁morbidity
amel
▁>1.7
anical
▁musc
ocytosis
achexia
opid
▁(19/108)
taneous
sies
▁impos
▁dysr
▁Combinations
▁urod
▁articl
etri
alidity
▁alanine
▁Insufficient
▁breakth
orpti
▁2.8%.
=78%;
oug
▁120
▁86
iphas
▁23.2%
ylinder
hene
▁Unp
3-1.
von
izophren
▁ND
=1437)
iculopathy
▁0.67-5.9
positional
▁lateral
▁7.2,
mptom
edocrom
utation
▁embry
utritionists
2-0.2
Dys
cry
atings
▁1.17-1.95)
-54%
heav
▁whi
eclamptic
▁protim
▁121
▁trichloroacetic
inogen
▁11.
hypertensive
rimarily
xide
yroid
ipran
tis
▁(<6
▁servings
▁PPD
alities
chloroth
romyalgia
30-6
▁detects
▁recep
▁(1.2%
<.002).
▁Barrett
]=0.89;
▁orchiopexy
ghter
veys
ismu
onaz
Few
▁outl
▁concurrent
▁simult
=11)
]=3.5
▁Gaviscon
▁0.72/0.83,
80-5.3
tein
ulfasal
propanol
▁dips
▁(0%-4%)
;.
sycho
▁biopsy
ysms
Lon
24
edul
▁unadjus
iazolidined
▁Markov
▁(12/99)
▁93.5%
-16.0]).
▁64;
▁300
▁(251/367;
=61%
▁arose
▁SID
232
-70%)
▁(66.
cuff
▁intractable
emerg
theroscl
=125
corb
▁inversion
▁dropou
roxet
adox
iousn
▁noreth
▁76
bohy
bran
▁0.35-0.9
▁hematuria
ontro
aum
veno
76;
assessed
gesterone
enop
labor
tolerated
.0-3
adre
1-1.9
-191).
91.
odified
%]
arous
ilv
formerly
umol
4-1.69)
▁-50.
ortive
▁Avoiding
isop
vanc
toler
▁(4-6
▁UPDRS
ucle
▁0.88,
,0
▁fetal
▁(21
▁blister
▁transthoracic
ulid
▁(47
yor
quiring
=.005
timis
]=63;
▁glycos
extur
▁reactive
▁amox
▁EE
ibup
rhythmia
eS
esear
arach
orsion
▁hernias
▁norges
ermat
▁1204
▁41.2%
▁ulc
▁5,
▁0.09-0.2
pidemiological
▁Buffered
plored
▁cardio
oar
4-0.7
▁flunarizine
inked
]=-2
▁metoclopramide
▁veg
icant
8-5.
eved
pip
.003
▁0.6
▁55
▁herb
-20.43
-0.94
levi
tiative
▁200-400
=61
.3-4
utro
partate
orges
gulate
=.0055)
iati
pectations
▁1.1-7.0;
9.1).
3%),
▁neuropsych
ewes
▁biphas
▁(33
odop
8,297
establ
▁bypass
0-1
Issac
enceph
▁uvul
zulfidine
6.2
▁clinici
▁clop
▁toothpaste
▁transamin
▁imaged
▁captopril
▁Estimates
▁309
iprof
onam
bable
▁0.06-0.2
▁nonvertebral
ockers
00/
▁0.20-23.21)
aparin
MH
actro
ioten
4.3).
▁sonograph
ceo
▁biofeed
gths
▁econ
erapist
▁(1406
▁subd
▁Bangladesh
▁anxio
entory
▁acnes
utam
iffic
▁Fib
▁2003,
▁(0.0
echanism
linary
ingoc
▁desi
▁Invigorating
Given
▁Norther
eptic
▁CFC
iparous
78/43
▁swit
▁31,567
▁amo
otherapists
▁5.7%
▁allele
preh
abetes
▁1.47
=0.2
ceptive
lobal
atural
valents
umon
▁bolus
0%-2
vei
ulfasalazine
cture
▁mefloqu
ffe
7-5.4)
▁1.09-3.
itiative
3,7
alam
ecret
▁Neosp
▁(0.05%);
ensi
accinated
iacin
imed
▁perip
tiguous
▁microinvasive
etermin
▁Parents
▁20%,
▁substantially
5%-50%)
▁0.72/0.8
▁adversely
6.9
amyc
▁plasmin
▁ineffec
terin
▁(49.8
biti
=13
17%
volving
ricular
▁sebaceous
trogenic
▁naftif
ulfon
taint
atig
ondylitis
mU
▁Californ
55
▁mc
▁>30
atop
▁nystatin
lele
▁2.9.
▁Alz
▁irbesartan
SAIDs
3-1.40).
ividualized
idosis
▁glut
▁dairy
lixim
▁triathl
▁Pregabalin
elv
▁(18
igorous
MDI
▁dipstick
cinom
tenu
urbinate
ivol
▁canth
▁88%-9
0,
▁40,23
alemia
nP
emand
▁electrodes
sychological
itaz
ipulative
zal
▁nonsignificant
▁doz
munof
▁myom
2.9
endazole
▁medicated
4.3
ifedipine
▁conveni
vertebral
▁(489
isopro
▁histopath
attera
▁ofloxacin
iazolidinediones
99
▁(10),
▁neon
profound
▁acetamin
orst
▁Therapy
=.03
olescent
Son
3-2.
8%)
gol
▁rhy
dell
▁Epworth
▁(1672
▁psychop
coun
Vit
=9.96,
oprolol
▁commerci
▁nebul
▁blocker
,82
▁yielded
enism
apal
▁1926
ecutive
centric
▁stabilizers
▁quotient
,80
=136
estations
▁quo
orward
▁Geor
▁trimethop
▁endoscopy
jects
▁nonstress
▁Aer
0.2%;
162;
=.49).
hran
▁hydrochlor
▁Lojand
▁spirometric
ostc
▁Ralox
4-1.5
olism
▁implants
▁hyperven
37
▁noncontrast
aracter
tack
▁donep
86;
]=40).
▁nonoperatively
367;
WMD
▁10.1%
titis
▁Nitrofurantoin
▁insomnia
ritical
▁adhesi
Lamis
lym
▁280
▁malformations
▁iprat
54%
lications
▁1.2
▁electr
opex
▁assis
▁tertiary
alif
=29)
▁11,427
seudoephed
=.04),
eson
istently
isedron
=0.3;
cline
▁100%
▁0.13-0.2
onsill
▁11.0
▁antiath
▁14,8
▁Clof
otro
munities
)..
]=1.2-10.9,
obenz
oroth
inforce
plem
dra
zheim
▁1.61-3.
▁metab
Azulfidine
▁440
▁suicides
1.4%;
▁nonrespond
inence
iard
enzodiazepines
▁dorsal
urnal
meas
ounting
▁positional
▁bact
9.12
ropout
▁spasmod
entati
▁48-224).
acological
opharyng
ransl
207
nograp
21;
iric
revis
▁substernally
scer
hys
▁triglycerides
erbin
▁Reason
▁11-2
raclavicular
▁Caro
▁Helsinki
▁cic
]=3.125;
▁tendons
▁53.
lis
▁Thou
▁(20/68)
trihexyp
18,
-7
▁2.0.
voke
▁Abnormalities
quenced
bjec
atol
ormer
▁referen
-41.
▁3;
▁0.21-0.8
▁Copen
▁statistic
azilian
uice
omf
EPDS
erge
▁lowere
▁>7.
▁regur
restim
onstrated
▁spleens
thisterone
▁uvulopharyng
macy
lti
▁diagnoses
yptor
▁31,
10-0.
hyth
▁<35
dose
▁OBP
HbA
cest
-5.34;
▁endometrium
-7.41;
4-1.74).
=6.0).
▁Findings
▁>20,000
▁0.84-0.97).
▁dietary
-0.1;
▁Pooling
vertic
sly
liminating
ubit
▁250,000
otonia
rites
veil
▁0.76
▁tiss
structions
▁retrospective
allium
tul
examination
cti
xati
▁(84%
promoting
lys
▁retin
▁0.35
▁salbut
therw
apsaicin
nalysis
▁exudative
▁bedrooms
▁Laser
▁polym
indol
▁1200
ophilus
utral
bup
3.15
SIL
munic
▁detri
▁alternating
scher
weigh
ouraged
▁Adding
idin
▁4582
▁30.
isd
▁54%
▁restraint
essors
androgen
▁0.36-10.3
atologic
▁coated
eF
▁bronchodilators
▁85%
257
-0.77)
▁TDI
▁Lisuride
494
▁GABHS
▁warmly
▁<.001)
▁5.3
▁162,000
▁assessing
PPV
individual
=1.9
▁(46
▁hypoman
lling
tration
▁levamis
▁abduc
erent
unw
▁(5.0
Pap
▁12-80
=2-45
▁mildly
▁remo
cla
▁Algorithm
▁adolescence
amoxifen
=1.0
▁Antim
▁3165
=6.7
▁underw
▁azoles
ribonuc
tinence
▁coag
thos
lary
▁sweats
Ace
romyalg
▁carotid
inear
onri
▁0.1%
▁0.5-7
▁pyrid
▁standardizes
mati
▁tors
ysteine
ogens
hether
feeding
buminuria
icin
▁measurable
▁staging
▁emis
▁unexp
onado
astropl
▁antipsychotic
▁preterm
▁(0.14
▁polymyx
▁cultured
▁menstruation
acologic
ourin
entally
-2.3
ryp
▁propensity
acrolimus
panol
▁homeopathic
=-9.42;
▁8.2
▁hos
orsen
proac
arcerated
reactive
▁Stim
nst
riat
▁gum
arct
TG
▁Nystagmus
lose
▁disti
LR
▁nonsm
▁bronchodilation
▁>90
ingococ
>.0
fidence
-4
▁0.70-1.0
vities
umbers
enaf
Bef
rece
vom
▁premen
ulants
▁Bacitracin
vous
▁sten
tiple
▁acarb
▁artifact
ifteen
▁29%;
-3.65;
Prav
1.6%
▁contac
hever
10.
▁OD
quan
▁Resp
=3.4,
▁unavoidable
▁Hysterectomy
=39%
adin
tage
entl
▁cantharidin
Ny
ydamine
-96
▁unspec
▁estolate
=1250).
▁aided
ffecti
etf
headache
=16)
▁recurrences
▁20,
bacteri
▁(28
inaf
>8
<.010
▁vagin
16-1.7;
500
tiate
levate
oquinolones
onglulo
edocromil
▁45%-48%
orptiometry
▁improves
utaneous
TCAs
]=2.1
actation
▁audiological
tifact
▁mycop
oscopically
.1).
5.5;
aynaud
▁unscheduled
chers
fortif
=140)
esigned
.6
poscopy
april
coprotein
bilirubin
ococcus
▁activi
=50
ampo
epressive
▁serotyp
▁0.75%
ecommend
couraged
roma
89%
▁secrete
=0.4).
ctivi
arax
adict
▁routinely
crease
=.005),
▁osteopor
BEST
▁1.3-5.3).
▁(6),
-60)
▁appr
ificities
ulfate
ormance
▁midw
▁Surgical
iogram
▁unfractionated
▁shorten
quenti
▁48%)
ysts
▁immunosorb
▁1.17-1.98),
▁1.45;
asmod
predominant
owm
▁(2%
▁colitis
▁equivalents
suited
▁0.83-1.
▁(89%)
▁glands
-90.
iography
iffere
▁13%;
omized
4.6;
▁Conventional
▁resectoscopic
controlled
/0.
=62%,
▁punched
esq
▁(16.
▁unexplained
9-1
athiop
tand
-0.98).
▁paradoxical
▁microhem
▁94
oxazos
▁11.6%,
▁(6/
▁traum
=15).
▁Projec
ertr
amus
▁Unable
HOP
ethox
Sen
▁outb
ucated
5.8%
tening
tac
-93%
▁uncirc
▁quinine
ndpoin
▁Rifampin
=2]
arjalain
▁epste
▁abbrevi
erou
▁angelica
▁diffic
▁psori
▁75%-89%),
▁700
atisfied
▁logis
▁Comparing
dull
▁hyperac
▁desmopressin
orkers
6.7%,
cebo
▁direc
43;
▁0.83-1.19).
▁29,133
romil
▁leptin
pecul
▁47,228
▁186
56;
ecess
▁19.2%
90,
▁91,5
▁DEET
▁screened
urvival
ytosis
tinal
inolone
▁2002,
▁detrimental
owere
8.9%;
▁(1.6%),
▁HI
emotherapy
89,
tense
acitrac
▁moderately
▁artery
reata
2,4
osely
enopausal
▁asymptom
ydroxyz
▁proving
vestigators
▁413
▁(700-800
▁(33.
omann
antibiotic
▁1.06-1.
earned
biologic
▁<0.
ritten
▁possi
isition
ubjec
onesian
10
thral
erience
rain
▁epile
2-9
hron
▁CIs
▁Positive
▁>1.5
454;
=.003
stati
▁oxy
9500/
farction
ovulation
▁35.8-7
78,
▁0.18),
omogeneity
▁Consequently
upd
▁Ghan
razolam
NBSS
=13).
▁>5
▁(<1
▁attemp
▁Euflexxa
-13.7),
onsmokers
▁17-2
▁allergens
hances
▁azath
929
▁streptococci
233
▁118
irone
2/
aar
isphosphon
epartum
▁autoantibody
-3.3).
▁construc
ignancy
ulvovaginal
▁Experts
▁Triaz
adine
hydration
▁hypoventil
▁cardiomegaly
8%).
▁ech
▁magnesium
cluding
sored
▁<11
-20
▁monon
▁nitrogen
hieves
▁quinol
7]
▁30%.
▁dermal
▁70-100
yloid
ordance
▁alen
=255
12-2.
▁(16
▁gon
▁numerousre
unv
ecule
ximetry
▁celi
▁2000)
▁Brevoxyl
ulan
yste
atoma
riptan
▁corresp
▁Gynecologists
olones
▁30/70
▁SNRIs
valv
median
▁68.3-90.9)
▁2.66-10.67)
▁21%-5
-5.6
iitis
caus
▁Clomipramine
▁0.88
parin
▁4.4,
ogonad
▁antithrombotic
]=1.50
ervain
▁Improve
▁acycl
▁sulb
▁stopwatch
▁thermomet
▁injections
110
adequ
ispan
ecrol
ionate
▁instrumented
▁thyrox
ectasis
icides
munoc
7-2.
proven
uab
ubes
▁1.04-1.0
Amaryl
ovar
ilitation
convul
▁crosso
▁blis
▁(75-8
▁injuri
▁DBP
▁RAS
yte
nisol
enoid
▁12,500
▁2%
=1322),
▁88%-92%).
tussis
utis
=96
doles
omiz
▁947
▁personn
4-9
60),
▁inhaler
manently
▁sulfas
ronid
1-10
▁frem
▁crust
322),
mast
4-2.
ophyllin
▁satisfactor
adver
▁100-
HOPE
▁fecal
4.0
llate
▁neb
astric
▁bleed
▁388
▁0.48-0.9
▁atypical
=115)
otriene
▁gonad
ardur
▁neonates
bber
calcified
▁mirtazapine
]=2.5;
ervis
▁(2)
▁cellulitis
▁breastfe
initi
kp
▁nul
▁Estrogen
urther
▁10.5
=4.5),
▁confinement
neel
▁vancom
apab
PPP
▁syndromes
▁10.2
▁polyethylene
28
▁eaters
▁28)
=1.22;
▁0.87-0.93)
-86%)
▁quanti
ataract
4).4
▁>3.1
▁13%
▁Meper
xative
▁asy
▁0.21-0.4
350
=12,
odolog
▁Tend
▁2067
▁hyperlipidemia
verwe
esoph
dine
▁internally
▁somatic
▁postmortem
enefits
▁9.5
toin
arate
Sel
enit
▁sting
uscle
▁3-
▁reversible
5429.
▁healthc
alating
37.2
▁Nons
8.2
8-0.9
▁triage
inqu
olester
induc
apies
▁cyclosporine
8.1;
mog
hyro
sequences
lometh
rach
ococ
▁0.75,
▁0.13
achial
▁paired
Tu
▁unrespon
▁hyperventil
▁sulfonylure
3-0.1
▁Diabetic
thrombotic
parity
▁Brickner
▁lor
811
ophile
▁Changing
omia
▁1.30
roic
ovascular
onab
mI
▁0.88-1.54)
unif
otrex
▁noncoated
2,471
ieved
papulopustular
▁nonmelanotic
▁junction
▁RCT
obacillus
▁melanotic
exact
▁-1)
adir
ylurea
▁Desquam
othiaz
ograms
▁autoantib
▁0.5%
▁1.5-
-17
▁anemia
▁Eighty
▁elastic
▁ovulations
▁lowm
udation
:1
5.6
Ot
▁colposcopy
ometh
▁explor
6.
=6.7).
▁Preg
▁substudy
visc
trasound
▁(65%
=4.9
63).
aghula
▁Fifteen
iscence
▁pyog
▁13.9-15.8)
6-7.0
▁71
therapeutic
52;
▁40-80
razol
yla
dration
imentally
▁Scoring
▁cruc
▁0.59-0.82).1
eletal
▁glucoc
zit
7-0.93)
munization
▁compressive
-0.88)
evi
▁1.11-1.5
parenteral
=167)
3;
▁glomerul
thromycin
▁frac
irin
▁Pill
=6),
riple
ransm
4-13.
>1.
fung
▁lifest
▁neom
▁72
▁adipon
26)
5%-5
itrate
fies
▁toothpastes
▁theref
ributed
veraging
▁Indonesian
▁ergotamine
laxes
isu
ategies
▁examin
26.7
▁withdre
vad
rine
▁>7.5%,
waren
▁(18.
<.0
68),
troes
▁hypogly
34
▁transcri
▁AFCAPS
▁1.00).
▁(25.8)
osolized
81;
ursing
▁appendic
hate
ephalosporin
▁3.3-6.9)
560)
▁303
kely
exposed
▁imi
afine
37;
▁PEG
▁0.59
▁oxytoc
▁Ischaemic
▁218
ogonadism
justing
5.0
82%
▁326
▁Bisphosphonates
erular
sions
▁serotoninergic
▁creams
ypocal
▁methylp
▁postd
▁antipsych
.6,
▁qualifying
ersome
-38%
facturing
4%-4
1.6).
onsm
irb
mesalazine
yzed
▁analgesic
otracheal
cate
▁Guaifenesin
3,6
▁fibrosis
icab
dram
▁aureus
creatic
ilit
▁217
NAAL
▁4.6%
51;
orbit
ticosteroid
▁polysacch
BMD
ubations
rops
▁Nim
getabl
=.02).
gati
▁eliminating
6;
5.22;
uco
ostur
▁adiposity
weats
▁250
ycy
17),
rocery
avail
▁constell
▁albuterol
nerc
.."
-0.93)
]=14.3).
3-1.9
epressed
horm
entricular
italopram
edation
vage
]=25
ignificant
265).
arents
cyte
-526.
aprine
▁0.05%;
promazine
9-0.9
76
=2.0-3.0)
zulf
▁279
▁57%
▁osmotic
onatre
aund
areg
▁differe
esion
▁genital
▁offspring
edip
unil
]=12.5%;
acis
▁679
ertro
56),
omeg
▁bronchoc
▁menor
▁ramipril
▁hydrogen
lom
▁443
▁Murmur
reaths
ospas
othyroid
erate
▁5804
▁rheumatic
▁12.5%
klist
ndom
hematuria
▁200-6
<.01);
▁1098
▁756
▁Routine
gerated
alized
44).
▁excising
onos
▁Bauer
▁cortisone
▁>90%,
3%
umet
reni
emical
▁1.35
orrh
▁suicidality
vancing
▁tamoxifen
▁seb
▁interleukin
/369)
▁594
<.02).
HERS
▁Tiotropium
▁0.72-1.11).
▁Oth
▁pef
viparin
▁(5.3
roxy
▁POCk
fered
.004
▁antihyp
Fa
,4
domyoly
▁hypothesize
95)
ucted
azoleor
esson
=-13.
monly
ormalities
unb
93.
▁Hels
▁macrocy
▁Hep
▁107
▁1.4-3.8)
▁(64%
▁histop
▁(45%)
▁0.08-1.3
rti
6.7%
resec
remia
▁benefic
▁rotav
▁1.0
▁amniotomy
umulative
efazodone
atab
ocer
utwe
uvaR
▁postur
Pun
exidine
8-1.54).
▁1.5-2.
7.10
▁apne
sre
upr
ximum
ostter
-1.74).
▁endpoin
rimary
edic
▁Screener
▁1.11-1.53).
glycoprotein
LHAT
=2-
hase
▁1%.
▁percutaneous
nephropathy
terir
urr
▁0.55-1.3
-1.11).
▁stren
▁colick
uria
-10.9,
laf
onate
▁seve
▁0.4-0.9
thesized
ranian
▁superf
▁Cozaar
▁Pioglitazone
oxycyc
ouns
andida
ressions
ultis
siu
mally
21.
ruritic
>5
/36
▁amnesic
olis
curate
3-1.00
▁microscop
▁conditioning
▁gonadotrop
▁Lactobacill
▁21%-54%.
okalemia
gges
▁medro
itc
hich
▁oppositional
ocorticoster
▁leukoc
enst
timulant
▁12.
▁1966
▁10.71
▁Evalu
9-0.2
heavy
▁diverticular
ergens
▁Ace
inology
,60
Wit
▁perim
iminished
▁colostomies
▁inconsistent
ibited
=1162)
▁cuto
-5.4)
▁halves
/30)
urro
▁3.8%
/204
▁LEE
▁MRI
▁switches
bulin
=.50
emoline
▁compati
junction
oq
Singul
▁orlist
/0.81,
▁abil
viations
abies
▁impairment
hexyphen
▁>140/90
▁ches
ndoscopy
tivation
=2.95%;
6-7
lutic
missed
▁abscesses
▁reiterated
▁posi
▁systol
lion
▁clamp
▁Biopsies
sives
endr
.0-15.
▁4).
rang
tested
▁vesicl
ittent
irom
ospitalized
possi
▁uniformly
=464)
loroth
▁unmedicated
▁hypox
▁Randomized
▁coordination
eterose
▁4762
▁0.77-1.
<3.
rane
pam
9.5
▁equi
▁ceti
▁incom
▁lup
udative
lder
actobacill
ocio
▁0.20%
fond
azole
2-1.
26-5.
▁metr
eptics
ronchoc
▁devel
▁123
pth
▁increas
▁Multiple
urgit
▁adver
▁lans
quately
estrogen
▁endocrinology
coh
ecent
▁159
▁nondiure
glucos
ificant
▁airway
▁0.8.
oxide
▁quitters
▁indig
igns
13%
nur
vant
▁Postmark
▁measur
uffici
planned
▁SOA
5/
dop
plained
▁knowledgeable
▁Nulliparous
▁inappropriate
ackg
iparo
▁Lik
▁5.9%
osme
▁reticulocytosis
ortant
▁0.70-1.2
▁1.41
▁analogue
▁lowmolecular
▁crus
▁(41.8
rete
▁Sod
=2.9
▁undeterm
erose
olpid
esicl
aclor
bulizers
tinue
-84).
CTs
ersensi
oplasia
▁albumin
aminos
erien
▁pediatric
omnograp
▁chol
.0-9.
▁vaccinated
uminum
anom
arenchymal
copically
-1.09);
97
▁170.
vov
urtherm
riminate
▁399
rogly
▁steroid
▁weighted
▁ELISA
ividually
asmo
▁inten
▁intermen
idants
6.).
▁1.1-1.9).
-0.91),
erec
rofecoxib
▁0.6%
00-3
asone
-1.67).
▁enures
-6.7).
haved
assess
▁3.79
▁mala
ractory
▁Sulf
▁PCO
▁Pant
2%),
▁Clom
asians
approved
onserv
▁bacteriuria
▁dogmatically
▁Hyperactivity
▁coinf
▁misclassified
shaved
gthin
▁ini
42).
▁oxyquin
▁coping
▁worksite
▁0.35-0.5
▁referral
▁responsiveness
▁mE
arynge
▁sulfonam
▁-0.6
▁intest
▁2.
involving
▁5.6%
▁1.11-1.58)
▁etiology
ylori
Mild
liness
▁contaminated
ipartum
▁(60%
arterectomy
▁(4)
2-14.
ologis
▁glycoprotein
▁Triage
=3]).
UPPP
▁Achieving
borrh
<2
▁155
▁rhe
▁Medication
▁doxazosin
=25
gam
▁rup
▁withdrew
▁ulcers
▁intract
▁sero
dosing
▁midd
prove
▁unstable
▁propor
onstrat
Tes
2.34
aminase
compl
berc
osth
▁assay
▁Nug
eeding
▁recor
66,
▁endpoints
tics
0.3
opop
6.0%
00%
▁Valpro
tively
▁(11.2%
▁Alm
gestim
ovarian
enam
-4%)
2%
▁unad
▁0.25%
▁encouragement
isph
▁caraway
progestin
lness
<.001]
oughing
ricyc
ommit
ontin
osin
oec
▁hepatome
▁1998.
veness
-0.5).
eform
003
▁orch
▁Initiative
▁(111
tionnai
▁methylmal
▁-0.6)
▁caro
▁temafloxacin
Abil
bry
munity
qid
▁saffron
▁5.2
individualized
▁Maddrey
-0.28).
bok
oxaparin
▁invasive
reliminary
▁(95/108)
▁7.7%
▁sonographic
▁unrestr
aspberry
▁Helsink
▁82
ooper
12-0.
47).
cure
ifics
ThinPrep
trast
vical
orsem
▁0.34-0.7
=1.7;
▁ticl
▁audited
andar
▁mania
▁1.0-12.
▁21.4%
ulant
▁Estim
▁expec
▁inferi
▁biolog
-61).
-1.21).
▁2.1
terity
▁20,15
atesticular
▁(10%-2
▁prog
▁pneumoniae
culia
]=1.15;
▁13.0%).
-0.94;
▁atenolol
1%)
▁stapled
▁newborns
ROSPER
ulopust
▁0.08-1.34).
ermati
▁furos
=96%,
▁vaginosis
▁hinted
▁aluminum
▁hepatorenal
▁placental
ureth
ysteroscopy
ghly
▁sensiti
▁(32
▁carbohydr
▁stools
ntim
▁0.17-0.9
▁dalteparin
venous
eavor
▁744
▁exac
centrations
▁DASH
▁515
▁discontinue
▁plann
edication
Lum
14,
ilir
▁24%
▁ally
▁uniquely
]=37.
▁coad
pla
▁1.3
nai
▁0.43-2.
elaf
671
ustion
▁interr
38),
ylin
sro
Ul
▁suspen
▁appendicitis
▁997
▁conflicting
wedish
▁nonh
▁2.1%
▁Families
=19
onex
01).
ndic
▁psyllium
▁regimen
ussions
▁contrib
hexyp
▁injur
▁-0.0
udden
dati
conventional
romocriptine
▁1969
ravach
▁579
▁(9.9%
2.5%)
▁systematically
nad
▁suspici
lact
▁noninser
▁restar
oretic
▁1.17-1.68),
▁renders
eo
ruc
▁fathers
=.007)
▁predispos
▁0.17-0.91),
▁hemat
▁cheil
versal
=69)
▁fibr
▁enlargement
xylitol
plified
ostt
▁>1.4,
utional
termen
thyroid
▁sulfa
6.4).
zod
ardl
erive
30,
▁141.7
-24.3).
▁(266,064
▁154
urret
otting
2-2.22
▁3.8
▁Pne
teros
chizophrenia
250
zoster
echni
hial
asmace
]=50
ophar
▁tinea
▁conjunctivitis
sate
▁insign
▁immunization
corn
▁creatin
=30
Hear
▁(112
▁infertile
Blocker
▁23
OAPP
▁tachypnea
▁unbiased
entures
▁0.48-3.03)
▁1.06
-23.2
=0.73;
yretics
▁preop
linar
▁805
70.
52).
>95
=0.6
quo
ustralian
▁impotent
▁(8%)
ycodone
▁retrospectively
▁>27.0
▁(29%
▁nonrigid
▁mitigate
Gyn
▁booklet
-2.09);
▁Summarized
atify
40-2.09);
calor
58;
▁Specificity
ductive
6-6.
▁36
3-0.3
tich
Til
▁persisting
omated
▁balm
▁textur
00-1.
▁3.34
▁radiographic
ipitor
▁0.56-0.92;
infold
▁intrac
-91%
-23).
▁comor
leptin
907
inkgo
▁Acne
▁(32.
▁prodr
▁diuretics
42)
roti
Its
forti
etat
eit
interquartile
▁185
▁suppor
▁ascer
▁postoper
▁0.27)
culosis
-400
▁4.4
▁scab
▁1.5-8.1).
randomized
nbrel
icil
▁retest
▁unavoid
▁generalizable
▁acqui
kend
etuses
▁sulfoxide
ludes
cot
usce
ibial
ripiprazole
8;
▁covari
ouris
sverse
isode
▁estr
▁sulbact
1%,
▁salmeterol
▁cromog
▁thri
entical
6.80
lz
▁Alzhe
▁1.3-1.
riate
orosis
Ring
(0
▁electrolyt
▁knowled
onst
▁hydrocortisone
ticas
▁27.7
adyc
9,40
uprofen
▁64.6,
▁penciclovir
steop
ticuloc
▁7.9
▁Headach
ndice
hical
timib
onvulsant
entations
2.2
=0.37;
.8;
▁drin
▁(61%
]=14.
afet
▁aP
▁discontinuation
▁Hyper
4-6
▁hemofiltration
endi
▁prostatic
▁outlet
11.
erven
illness
appropriate
rescence
okel
ingon
yce
▁questionn
▁Apg
▁1.04-4.
▁parenting
SBP
▁1.2-3.
▁0.79-0.9
.9
147
ctional
▁declin
▁1.07
▁daytim
pharmacologic
▁capitis
▁serocon
itn
1121
aril
annan
oglobin
▁attributable
omagnes
▁metrorrhagia
▁STI
▁prepartic
▁stratifies
▁3/
▁0.4-1.0
▁serogroup
▁Breast
▁97.7%
▁2,
ractice
▁succinyl
itrus
▁(30/30
=7370
▁Punch
▁methy
▁conization
<0.01).
▁atelectasis
▁Enures
▁myopathy
reli
hexyphenid
alig
▁nedocromil
▁hexa
▁Examin
oxig
▁suffers
thim
lorp
▁unipolar
▁(1)
plemented
ogr
welling
▁140.
erbating
thmi
ostati
methacin
▁diag
etersb
ifth
tassium
▁incidence
▁2.9
▁perforation
▁triglyceride
▁grading
▁2.82-14.58).
therl
=.03;
=1.55;
thesia
rected
▁1.0-2.7
▁reframing
▁risedronate
-81%).
5-1
/18
▁41%
78;
anometry
▁tox
redominant
egist
atistically
Nut
▁metronidazole
▁sulf
▁8.8
▁unopposed
<.001]).
ibrill
▁>60
▁treatab
05
▁>24
edited
▁oximetry
▁0.30-63).
▁Consumption
utine
▁0.24-1.51).
-0.85)
▁suture
ribing
thou
=8245)
ormon
sents
ellbut
owest
lpro
▁(48
ticulitis
4%-7
tropl
6.5
▁Beresf
7-7.
inamide
▁564
▁Hamamelis
190
ormaliti
57%
orporated
▁29.3%
▁supervised
,44
▁Professionals
=615)
▁naprox
▁fixation
▁neurobi
zetimibe
▁concep
mography
▁numerousreinf
leic
sychiatry
▁nodules
BMI
▁227
ovastatin
=6
▁halved
orrhe
roor
▁23.
▁baths
enl
▁87
▁SG
▁1.30-1.7
Cu
enterologists
▁1.87
Rimso
▁fati
ualized
]=0.60;
▁26.7%,
iptic
ommends
amet
thysterec
▁0.497-0.9
31).
▁sulfon
▁excep
▁scler
▁1.5-7.
▁HSV
▁sut
▁Preventing
▁Complication
▁fluoridation
▁postoperative
▁8.3-
▁0.2-
▁1.1-2
▁obstructive
▁0.71-1.08).
romet
▁phenotype
▁addres
▁1.66-1.8
phenidate
▁tumors
▁4.7).
-2.1
aif
ardized
thyst
▁Cardio
=0.67;
▁205
▁reten
udied
ipol
ycod
alyses
▁109
▁leu
-12.2).
▁sorb
▁postp
▁malign
ophony
▁468
ransc
=1.45;
35%
ounts
dentified
20).
osensitivity
▁insom
▁(58%
▁hepatomegaly
tinom
vasion
▁thromb
ocor
=-6.
eace
▁erosion
903
7/
volved
ephed
▁1960
▁MEDL
-85%),
▁neutropenia
ylophor
004
▁8.1
▁psychos
parison
▁84
lts
▁postmort
asthm
▁0.70-3.3
Mental
apill
▁1.4-5.8).
▁auditory
lexxa
TIs
lusions
▁allergic
thas
9.4;
arrative
▁deliri
▁fluconazole
▁ferritin
▁hygi
4-3.
hirts
▁Antiseizure
andardiz
CNBSS
▁1.57-7.86).
cording
exCA
oclavicular
▁160
▁intraparench
<3
icac
surg
arathy
▁attain
▁Syst
bip
▁mane
iglitazone
▁(31
ture
▁guinea
4-0.9
▁Exam
▁weakened
▁(93
▁tenosynovitis
ensur
ixty
tati
14;
▁Curren
▁Mixture
ostic
▁substitution
▁sedim
3.10
osorb
asiz
▁peritonsillar
ipant
erul
▁Compl
▁fatty
embran
Pil
▁gonorrhea
▁laparos
▁previ
erli
5.5%
sitivity
▁dogmatic
ipolar
Vio
▁GERD
▁(61.2%
lye
asberg
▁flun
▁otoacous
-1.99),
uthor
ethyl
rhythmic
7.8
lorper
Neosporin
=160),
▁>0.
=0.5%
-31).
▁benzodi
eroc
▁Impres
oldi
amatic
oreo
alents
▁rheum
▁CHF
-4.8)
viors
▁2.5-8.7),
0.9
unip
emog
otoxicity
Vitamin
▁inves
gur
oscl
ixime
specified
plific
1;
=39%;
ixth
▁19.6,
▁reviparin
▁EG
ndos
ynecology
▁738
▁sulfadiazine
rorrhagia
phine
ulop
arti
▁Adolesc
▁recurrence
▁ketoac
mis
hanced
▁1.17-1.6
▁arrhythm
▁52
▁Caroti
▁endo
▁1.5-6.2).
arlic
1-14.5
▁therape
priate
Ra
▁lute
thc
ographies
▁withou
30-1.7
▁0.67;
▁10,000
osclerosis
ergenic
3).
▁PLP
▁intolerant
myograph
▁gris
▁(278
yoma
▁exudation
43
▁Bayley
▁decongestant
8-3
▁prodrome
▁diagnosing
rogr
Tas
zyg
brach
hool
Ris
▁wheez
▁outwe
▁lipid
sting
(9
▁0.43
▁51
ultaneous
▁0.03-0.44;
▁pimecrolimus
▁clinically
iscar
▁1.4%
3%.
=2.07;
ekend
▁modestly
uppressed
▁(14
▁immunob
mature
▁66%
▁treatable
▁VVC
▁1.11-1.40)
erolog
0.9%,
goph
=0.58;
▁unadjusted
imvastatin
vided
cinoma
▁diaries
chid
erab
tel
0.7
lux
▁aspl
▁14
mulation
AID
nge
]=77)
▁-15
▁fallopian
▁hirsutis
oros
▁Antico
vus
79,600
▁conser
pear
▁4.5%
▁yeast
▁abn
▁selec
▁contex
▁Hyster
▁indapamide
▁276
▁colonic
7-1.9
eris
▁influenz
▁tet
▁Chang
-99.6%
▁90%
olysis
▁chew
▁Lund
▁favorably
plenectomy
cult
monary
▁complication
agulated
-1
▁unrecogn
epos
▁bans
▁lorat
▁whichever
▁0.90/0.96,
▁chec
atas
OSCOPS
▁23.6%
.7.
▁disch
bac
▁Meas
▁4.2
diar
olerated
ichever
5.4
006
orary
259).
▁nylon
▁hyperpl
-7.03)
▁141.71.
eclamp
▁13,443
-1.88;
onectin
9%.
28)
▁prostat
arkov
▁ince
zymes
▁9-
iterated
▁acanthosis
▁biases
utics
variates
onist
▁audiometry
▁Improvements
alce
▁hypothyroidism
<.05).
▁benzod
vings
▁16.
▁azithromycin
tigo
ervations
-6.2
eav
▁tolerability
opres
18
verting
▁1198
▁rehyd
mitus
ulla
verview
▁0.22-0.8
▁asthmatic
2-1.9
▁corticoster
47;
▁cardiome
▁53.9.
urrence
-10.6
▁(19%-40%).
=.818),
3.5%;
▁nonanemic
=.259).
7%);
▁Mank
-70%),
ulfa
0.2
▁antihistamine
gia
>10
retic
=78.8%
15).
▁ranitid
aftif
▁32%.
inten
plast
ycline
▁decarboxyl
▁NNT
▁valer
▁Copenhagen
edoc
▁Treatment
▁shamp
Cs
urys
GIC
tiven
▁diarrh
67.
▁356
▁hou
arately
▁impingement
paghula
▁ASCCP
prac
▁simplified
=.046).
▁unvaccinated
]=0.0
▁(>10
inin
▁90.9%,
iae
▁6-3
disabling
▁throm
▁18%
▁pneumonia
▁complications
▁(54%
▁muc
thinning
tator
lorprom
theros
▁-0.03).
▁lumb
▁Hyp
otypes
yces
uspec
yi
/20
9-7.
qually
ilateral
areness
andinavi
pted
▁glyb
▁prostag
▁miscarriages
▁Grooved
▁delaying
verl
▁Expulsion
▁traz
▁92
ouragement
893
EI
▁occurrences
zithromycin
▁penicillin
▁pooling
hydramine
▁2.6%
▁atherosclerotic
▁queti
onan
0.10-0.52;
edem
weekly
NH
upuncture
leukin
▁810
Spectazole
▁adh
▁ultim
▁Vitamin
ficing
▁1,
▁occult
aratript
▁30.4%
tions
▁Euflex
▁pharyn
▁Alg
agin
0.6%
inste
chlorprom
9-15.
mesal
erebral
rednis
▁0.34-0.53;
▁8.6%)
▁felodipine
enyl
Cyl
▁allyl
▁antiather
▁1.72-2.19)
valuated
▁4%
rowth
ificity
=.0
▁disabling
▁Twent
8%-
▁dehy
▁drainage
ransamin
ginal
▁(72)
onglul
▁0.70-1.02).
bogr
▁1.9%
mentous
▁concurrently
▁yor
▁60
▁34%
▁superficially
timiz
Cre
▁wards
=2.6
▁1.00
▁2.4-1
3-1.67).
ingful
acqui
▁unwanted
▁3.6,
▁autosomal
erosol
abilitation
▁Gin
=.003),
▁1.08-1.2
▁beverages
hydroxyp
complicated
mL
▁0.55.
rihex
9.2%
uited
▁defecation
odon
palpation
strated
etened
▁106
ardio
▁42%;
oprazole
0.10
▁1.8-18.9).
ducting
▁17,67
iformly
enzae
teinuri
rbes
▁101
▁excis
▁0.09-0.38;
agonist
chy
nologies
▁cerebro
▁harms
lusion
▁19,000
▁0.13-0.88).
▁neopl
▁alprazolam
▁0.70/
33%
ecall
Tan
itro
utrition
olle
asin
ilol
▁3.4
▁ARR
▁2005)
inational
▁neuroc
sium
▁tympanoscl
hydrating
poc
▁1.95-2.
tropine
▁methodolog
▁92.
▁excretory
ticipation
=0.7
▁piroxicam
▁0.04-0.6
8-4.20).
educational
▁cram
]=1.87;
▁0.24
-0.7
▁Hosp
arable
▁hydrox
ispos
▁olam
▁painfree
etail
▁bucindolol
▁hypocalcemic
▁fluoxetine
▁STOP
pnea
icros
▁chlamydia
▁spacer
adotrop
chosp
▁mup
arrhythm
icotine
87).
2-2.19)
▁bloc
▁73
oene
▁cardiologists
efer
Mast
tidepress
ceptionally
7/344)
onstrating
erapis
2.0
ospitalization
05%);
▁Abnormal
1%).
▁compounds
▁favors
▁cefixime
30).
Hgb
-4.1),
▁exclusion
▁pharmacists
▁crosssectional
-76%)
idu
40.
▁urodyn
▁lep
536
▁(266,
sical
6-0.2
ukot
xed
▁neph
▁89%-92%
▁peripheral
paris
▁amn
▁312
severe
▁tendenc
ginn
▁CURB
▁(123
<.004,
▁progres
ylated
HSI
-1.38),
▁0.55-0.8
xine
▁revaccination
hexidine
=.002;
▁hysteroscopic
ortend
ounder
646
ympanometry
]=0.6
anderb
64;
emoch
▁balding
/85
▁persis
msel
inue
orsi
▁Unpublished
=9;
lated
▁0.77/0.89,
rigation
▁(20/324)
▁-1).
▁Headache
▁encompass
▁palatable
▁0.78
argins
▁Pea
▁SSE
asoph
▁bum
▁enrollment
eparin
tracted
3%);
urp
acolog
▁erythematosus
urat
referred
alloon
▁chil
kot
LLHA
-41.4).
▁9.0-9.4)
-70).
oal
▁dra
=1.5);
sue
ielded
antrums
blad
iru
ielding
1-3.
▁symptomatology
hibited
▁200-4
▁4.0,
▁8636
▁770
▁simv
hoc
▁Seventeen
▁acy
▁macroadenoma
▁0.81
heum
▁nonster
▁8/1
ytolog
▁intraepithelial
empts
▁(19/10
ocellular
▁24.3
cue
▁undi
yridine
▁fulmin
ROS
ouching
▁1.5-1.
▁eld
ulari
▁milkbased
▁-0.4;
▁mastoiditis
▁inap
Hg
esophageal
▁favorable
▁thir
6.0]).
vaccination
butam
oporosis
5-0.57).
▁Tylophora
omotor
thmia
ypro
▁mep
uplex
nthes
▁(9.
idine
mselves
,825),
alsartan
▁NEST
▁10%-5
▁(85%
▁lymphocytes
▁85%,
=1689,
▁7-
▁(25.
▁pedis
▁Varicoce
▁9.7%
▁phlebographic
-3.0)
▁deterioration
2,000
hetamine
▁Comparative
▁nore
▁Neuropsychoph
adotroph
▁outlin
istal
25%
determ
essor
gesia
ukast
jority
▁rabeprazole
<0.0
paral
trol
▁acri
=0.60
dif
▁tac
▁ator
▁asymp
xon
orice
erapeutic
0.00
ailure
riazol
▁(792
▁thereafter
imul
ffective
ateau
▁microh
▁controll
▁0.6-1.92;
▁marginally
▁resistant
▁(3
OPD
thar
▁curett
inq
▁lactobacill
ccur
enat
Ts
▁omega
olest
abits
▁0.58-0.7
▁tubo
▁0.03%
▁LIPID
88).
ipulation
itin
▁3)
average
ecz
▁89%
▁citrus
edure
tinine
alene
bladder
▁dissemin
▁0.9-1.7).
▁duod
cium
those
iopsy
▁suppres
tology
▁exer
Mas
strain
urated
▁4500
ystol
entify
iuria
▁(32%
ioem
▁>9
15
▁79.6%
.001).
▁39,40
odin
▁gastropl
rocin
▁Propion
thir
7-0.
▁experimentally
▁peroneus
unar
▁ison
xce
▁pitocin
▁syncop
olace
▁pretreatment
▁(81.3%).
▁synthesize
ullip
titch
0.01).
bination
▁irbes
orati
▁Localization
roerg
omaly
ibitive
▁6%)
▁0.56
imecrolimus
elograp
sover
,500
emophil
▁subf
rivi
ammography
7.2%
▁lymphocyt
ingt
tervention
▁viruses
▁appeti
▁equivocal
screened
ospasm
trated
rro
▁prolact
ulat
▁Inj
▁paroxys
frequent
hey
▁200,
▁disturbance
emetics
ussis
ryot
onization
▁(27
-125,
▁introd
▁suppos
ithel
.7%
orbic
▁readings
rogate
▁chlorpromazine
▁mitig
▁chlorp
essity
▁ottor
onatal
tero
▁Dip
bent
.0
▁blinded
▁tolerate
3.8%
▁Insu
.3
aflex
▁0.34-0.5
▁(67
▁nonselective
bolic
mly
▁acros
iterranean
▁excessively
pectazole
10)
▁6.8%;
▁anatomic
8-4
icot
holinergic
oprotein
▁revi
60-0.8
queous
]=0.73;
▁1000-1200
itrit
8-2.0
ordin
▁ovulated
▁nyst
▁nig
-0.97)
pecifically
▁suffici
ezetim
▁ipec
▁hepatotoxicity
=1.13;
▁staple
▁unreported
econdary
▁rubs
48)
▁sneezing
▁Nonsmokers
Ric
gic
▁cryp
odiazep
eer
▁80%
Blin
48
biphas
=2.93;
80-1.
iologists
82.
trose
elective
71).
osag
▁papule
adenop
entered
ndid
▁jaundic
sulfameth
▁82)
▁theore
cetaminophen
randial
odal
6-
▁drilling
osam
▁drill
▁1.45-4.9
▁doubling
-11.9
▁cystic
▁NVAF
▁0.76-1.
▁Omnipa
▁hypoc
rements
▁Registry
dlers
▁polymyxin
cysteine
ocomprom
rograp
▁-4.
CBT
▁(45
-45
eic
▁nonproteinuric
▁1.62
azoles
▁13,
▁uncl
▁descri
eha
▁heteroph
▁17%.
accuracies
Confusion
5.4%
ctom
▁brisk
,5
▁136
rici
imentation
▁asymptomatic
aryn
fficiency
pidem
▁Antibiotic
9;
▁mirtaz
▁noncancer
ortab
thl
▁acutely
boovarian
inur
▁Severe
ukocyt
uliz
▁chlorprom
▁Interpret
argement
▁hypothal
HRT
ipidemia
▁0.5-
▁liga
xte
ominant
ultures
hile
▁(19%
▁smokel
▁(42.5%)
▁350
▁Evaluation
▁fulfilled
havioral
=1.3;
quor
vothyroxine
erlikows
aminosalicylic
94).
▁subgroup
▁preparations
▁manifested
udoephedrine
oxetine
▁lactulose
=480).
▁Viral
▁(7.2
▁1.1
▁61
▁1000
ouples
▁0.24-1.5
=20;
orty
PROCA
▁(3%)
hicle
acrine
▁antihyper
ionized
▁hyst
▁ovul
▁1022
erating
thros
beral
.08;
▁consen
traception
▁63.1,
fortable
▁polysaccharide
▁consens
PID
arred
.005
emiological
▁preinj
▁citalopram
▁proceeded
eclam
ostop
▁doxycycline
ufacture
2-
Ce
▁0.43-
epir
228
▁scars
▁77-97),
osion
▁hemo
▁33.
sgood
▁giard
▁0.0-0.
52.
▁PPIs
ulosis
▁paracervical
▁Inten
▁orre
4-2.99;
ylor
▁nondepress
ormi
▁malabs
telev
▁0.7-0.9
▁gonadotroph
▁18.3-42.
▁(25%-5
▁hirsutism
▁tuberc
OLVD
rinology
CVD
▁(-0.02).
▁Nutri
▁trimester
ynecological
heter
]=13.9;
6,1
▁(3%
▁hyperthyroidism
▁7.11).
▁distort
▁bacterial
▁classro
▁AFP
80;
-89%),
▁1.1/
▁styloid
riately
munications
5.2
iopl
ardiasis
astroes
yot
ostom
otrach
0%-4%)
lebograph
apidly
uberosity
5-0.
▁Vaginal
▁confirming
ideal
▁eig
▁Propioni
▁gentamic
▁0.07-1.47).
uloc
itriptyline
8);
▁incontin
▁inhalations
lw
olec
▁cys
▁menses
Suc
▁unp
▁RA
ausing
▁7.7
▁hydroly
uctural
-13
▁(4
depressants
▁Theore
bace
▁deoxy
athematic
ecdotally
▁82.6
edr
reven
▁Grover
idis
▁Behavioral
sartan
.007
▁HAM
▁disadvantage
▁Ral
▁revac
ictim
proteinuric
5.9
2/1
oxaz
.08
▁Notably
▁prescri
olyp
▁endp
udy
azin
ildenafil
▁vesicles
▁5.5
▁1.4-5.
iopathic
▁4.91-13
tib
▁1069
▁10
▁nasal
▁SOLVD
]=0.62;
▁sonnei
▁varice
45).
▁0.23-0.66;
90%
69
erlikowske
▁bism
.3%
parathyroid
▁Optimal
▁repres
▁0.5-1.6;
▁11-24).
mnip
pai
59
-2.8),
▁Ultras
▁432
cidence
haled
ripe
▁vitamin
▁cumbers
esop
▁fractures
Although
ewly
▁ARB
deri
oreal
/43
uprasp
akenings
acetic
▁anoth
hage
aner
orazep
▁substit
▁radiologists
78.
arouse
▁endotrach
14,3
cation
34%
lls
-10
▁1.04-1.40).
▁lipophil
actin
certainty
▁(15%)
▁addic
▁carcinoma
trophin
▁-0.28
eliefs
▁0.72/0.
▁gluten
▁cicl
▁mmol
▁transec
▁bioch
andag
plenic
mmetric
▁triathletes
eryth
▁purulence
▁donors
▁Pregab
manent
identify
renerg
▁0.22
icondylitis
olpidem
▁8.8.
mace
elano
pecac
iately
1%-69.6%
31)
▁0.19
oconstriction
reasts
▁asthma
muran
▁5-25)
▁0.89-1.15),
efac
7-7.8
=112
illec
]=3
▁lithium
▁chlorothiazide
▁0.22.
▁Enalapril
aryngitis
Tric
-0.71).
▁syp
▁Synv
ulair
orine
inorrhea
▁antifact
▁neuroleptic
10-0.2
▁unch
▁patella
▁corp
chondro
▁Impairment
9-0.
etere
omography
68%
▁Thirteen
▁digoxig
▁Inconclusive
▁trimethoprim
ryotoxic
ecific
▁seropositive
=125).
▁52%.
▁2/204
▁hairs
rosem
▁nonsign
etoprolol
.01;
ortance
▁44-8
▁0.63,
tigation
▁5.0-15.
]=57%
nurses
anin
▁longit
▁1.31-3.3
tec
▁26
▁lis
▁42.8%
▁adulthood
afe
-7.6),
0.3%
onfusion
uspar
▁74.
▁therapies
▁27%.
▁cumbersome
seud
vam
rease
1.9]),
idt
sar
istar
erap
=9.
▁dullness
▁drinkers
▁grise
rental
▁terat
ohyster
▁repor
▁brad
ylamine
▁6.9%
▁Bec
ripty
razole
▁incompletely
▁tobac
▁procalc
igra
kup
Nation
igm
▁nabumet
▁parathy
erif
▁neonatal
▁cra
▁sham
▁1239
trason
sychiat
tia
wers
)],
▁miscl
▁spas
0-3.
lomethasone
valuation
reas
aginal
depressive
▁1.15-1.9
aloxifene
elec
iopr
50),
arations
xh
tervi
33),
▁dropouts
▁palpable
/99)
iphenhydramine
▁129
=555);
▁criter
8%,
▁multicenter
EEP
-49%
▁ambulating
▁hose
yment
▁thres
▁1.11-1.90
▁uncer
▁Hos
trogens
▁bilateral
uciating
▁80.
olamine
▁suicidal
bance
SCU
osyno
erat
ophag
17,80
▁Ini
▁preeclampsia
▁sonoh
▁164.4).
▁46,
▁filmed
imited
acran
684
]=13
turned
henof
cessi
reatm
ceph
4%.
Wad
▁celecoxib
▁(167
enome
walking
▁17,256
sodium
▁peppermint
enoxic
0%-9
umetone
▁lowmol
amad
▁DSM
arious
wat
▁(78%
▁hs
▁combin
amilies
significantly
▁asplenic
▁spac
▁13%),
65
6-2.24)
ADCS
xacet
5.93
▁diclofenac
domy
emergent
xyt
nce
haped
sion
alysis
▁17
▁rales
thor
▁propranolol
Gin
ecre
▁hysterectomy
organic
esalamine
▁adhesives
▁hemochrom
▁2.26%
omnogr
sess
epla
rmy
akf
artate
pile
lassified
8.4%)
angl
actab
urves
▁1.2-14.
▁antire
5-0.79;
ermal
ortripty
rely
tigu
▁hemorrhoid
▁57,000
epend
▁borage
meter
aRing
▁prav
bab
ticosteroids
▁pigment
inoma
ognition
mentary
▁explosive
▁42)
ogre
▁donepezil
ulvov
▁subgroups
landin
minent
▁0.43-5)
Lowering
8-10.
6.6%,
STA
▁0.13-0.31;
olesterolemia
aminophen
valproex
.05).
▁plotting
▁Maximum
athic
▁sunscreen
imec
▁Ramipril
ifylline
onset
lamy
soci
oselective
▁Alarms
▁1.36-2.24)
=97%),
▁occurr
▁GAD
ucasians
▁1.2-1.
▁-20.
antoprazole
-0.23%
=2)
▁adher
23).
wheat
estis
▁0.0%
▁Murmurs
nerable
casein
32%
▁0.63-1.0
ramine
icitly
tomy
▁thems
▁lowering
▁Sulfasalazine
▁cytoch
uptly
5-7.
iscons
▁reit
onon
urv
efle
▁reser
▁-6
▁122
▁mIU
rolimus
▁neurolep
FeS
verf
▁fibromyalgia
phosphon
▁-2.
-7.6
▁prognostication
verification
▁Mesal
▁0.0%-33.0%).
▁autos
atell
▁hyperpar
▁94%
▁subjective
▁Iranian
remaster
▁131
numbered
▁reversing
▁scabbing
udoephed
▁1.84-13.16),
▁Interr
▁leukocyte
azepam
Midrin
▁cytochrome
▁(383
=9.1).
▁zalepl
▁discon
/367;
adder
otamine
▁isometheptene
poran
rofurant
uenti
amamel
▁Prevalence
inedion
erousre
-]=0.0
otas
rement
▁dermatologists
▁0.83-1.1
stem
eving
3.54).
=.09
▁memb
idable
30;
=2,
acro
lements
▁thyroidec
onad
lour
orbitol
▁symptomat
▁UTIs
▁unmetab
gestation
▁(61.
Mentax
▁-3.
ezil
-0.99
▁rhinovir
ternatives
,443
initiated
▁nontoxic
ddition
ogenic
▁CABG
-1.2
▁neomycin
intment
epressants
▁dysphoric
▁decreasing
▁postprandial
▁ablation
▁pn
92
ediat
=0.14
.06).
.000
▁empiric
stay
-90%,
▁0.2-0.5)
encaps
ipan
SOA
turb
ework
urth
▁0.36-0.62;
gnanc
82
=.047).
Ster
opopl
4;
enzac
▁0.62).
ophleb
ulab
▁hyperandrogen
entire
otassi
national
▁surro
terography
▁Sti
▁enro
7-1.4
▁5.5,
oliz
=19).
▁rath
=1.02;
▁426
5.2;
▁transvaginal
▁markedly
aused
34-6.07)
Cataflam
anoth
abumetone
-2).
▁30/70).
▁hypoth
▁35.8-74.
▁35-66)
keli
▁multinod
▁meticul
ucl
aturi
studies
40%
erosis
▁SCS
tiz
▁hemoch
▁vertig
▁constit
▁300-3600
▁5.0
▁McB
lative
dur
hion
▁nonsteroid
730
▁197
ocytes
epak
LISA
▁extensor
▁averaging
▁52.
nish
essive
eutics
DOR
choscopy
=1.32;
▁menorrh
=3.1
hosp
▁pyridox
▁64
▁Tonglulo
636
ndp
bj
14,300/
aried
▁6.3-4
▁(35%
1%-5
surgery
otent
▁278
▁lumbar
▁inhibitors
▁1.4-10
▁Gibbs
TN
▁ANC
ergen
ionuclide
Ca
▁0.72-1.0
▁neop
]=1.4
324)
-3.8
▁genitourinary
athermy
▁Implementation
.6%
▁2%.
edle
ozyg
tratter
weightbearing
▁1.13-1.63).
ramide
▁reinfection
▁rick
▁0.26%
cising
=18
Fren
-2.
oxac
8-1.5
rheal
▁Ebstein
▁diagnos
vigorating
▁Diagnostic
▁thyroiditis
roxypro
▁100%.
4)
injury
-2.91;
iodine
ephedrine
sules
trolled
ochromatosis
▁1980
irls
=135),
▁lisuride
=1.4
▁15,8
▁misc
Wa
,75
▁575
koc
ogly
izop
reval
anagement
▁salp
▁1.1-3.
=.929),
9.4-5
Eight
kets
valu
ressing
▁disimp
advent
=2.2;
▁Attributable
yroiditis
valence
▁8/1000
▁(15).
Effec
emale
▁DF
11-2
Bac
nited
▁gonorrh
NNT
▁premature
hana
orv
4%-9
anese
ylc
▁60.4%
▁heterogeneity
▁definitive
▁TC
▁levamisole
▁antiemetics
▁nonhormonal
▁(82%).
2,478
▁sulfox
4).8
=90
▁Doppl
▁undet
▁particl
▁pencicl
vast
▁calcitonin
▁1333
98),
▁phary
▁100,
henaz
▁Stro
oner
ephal
▁insid
tly
▁Symptom
▁NuvaRing
▁56%
5-0.77)
5;
▁bupropion
▁derm
interqu
▁tripl
-86%
▁93
▁insur
3.67
,25
▁industr
ocyc
arenting
▁herbal
▁IELT
▁70.2%
alainen
6%);
27.6
▁Functional
▁troublesome
trihex
▁21,
▁comorb
earance
▁tricyclics
▁leve
selec
epart
Nim
umor
▁Surg
zath
iatic
▁cetiriz
acteriz
▁indom
arrhy
azarotene
▁Sensi
▁Depres
upation
osalicyl
ticed
emal
andidates
rhon
umur
malonic
icially
idneys
▁Opin
eterm
▁graft
9.5),
▁phosph
atome
linting
izab
ticulosis
▁primrose
▁discontinu
▁tendon
▁Increased
▁196
Fine
▁beginn
▁ciclopirox
▁<3.0
▁imping
kelihood
=1.8
=2.23),
methylphenidate
9.5%
imod
▁pyraz
▁faulty
onth
▁intraven
▁cardiolog
siglitazone
▁extracorp
isole
8-
▁theoretically
adian
2%).
▁regain
▁200
▁199
ochrome
▁17.7
uor
inistered
▁592
entere
entration
▁restrain
andardized
lax
roidec
▁methylphenidate
ulth
▁hypom
▁reflecting
▁clopidogrel
▁glycosylated
▁antipyretics
aprosyn
ylpro
▁stok
=2558)
▁78.3
nacipran
venting
1-0.77;
=1.82.
▁Beres
▁spiromet
ilad
-0.38
▁gast
<.001)
▁(92%
▁40-
CRO
-1200
cicl
▁Magne
Mel
thalid
▁(1990
▁nitrit
thermal
▁tantrums
▁Serum
oligo
▁resou
30,000
paro
72
ynec
fluoride
▁deliveries
▁-1.0
▁calcit
=44,825),
sitiv
▁chemotherap
tivariate
otroph
3.21
ogniz
eavy
OPE
-]=0.02)
38)
88)
▁Higher
▁(300
bdom
▁Antise
▁Framingh
▁immunog
▁sedative
ertension
▁0.50-0.78
▁thia
▁satis
athop
▁McIs
▁50-72)
▁resour
mro
▁adenop
▁0.45-0.79;
1.1
▁radionuclide
▁1298
▁ticlopidine
etron
▁1.5)
▁scl
eftri
▁cac
▁mef
▁recom
alved
esearchers
emaf
bse
▁243
trok
▁thicken
-9.4)
▁gynecological
▁(35%-50%
▁specifying
▁Diets
-1.15),
▁margins
25)
chitecture
estionn
▁89
-5.1
▁12.1%
methotrexate
ypon
▁0.56-0.94).
▁retard
peri
▁231
cognitive
icul
<.005)
▁adip
iox
weren
7.3
emol
▁congenital
▁poten
▁glycosyl
▁MM
=3.5
inist
acrificing
iltr
istology
6.2%,
▁blistering
osel
▁questionnaire
yroxine
wax
=126),
ylcysteine
-14.58).
▁-95.93
▁4.93
etar
▁herpes
insulin
suming
▁0.93-1.67).
amomile
amins
gement
1-5.
yptorchid
▁hepatocell
igl
▁fourths
=0.99,
7-0.8
sou
rhoid
estant
fate
omiting
elanotic
-0.87)
▁12/1
eleb
▁0.00
▁betam
26.1
PaO
▁31
▁0.58-0.71).
lysis
adition
▁anemb
▁1%-
=3.0
-0.84
▁Gavis
83,
alog
1.00
▁aspiration
▁39,405
mokers
▁Oral
0.75
ecd
NES
▁0.02-0.2
▁physiotherap
▁(23%
azos
▁anovulation
▁quotients
7%)
▁1.3-4.5).
▁nonexper
olam
▁isome
8-1.29).
▁interfer
▁nitrites
41;
▁Cardiovascular
]=-3.65;
VCA
raphy
▁menop
▁mellitus
-4.9
retion
-0.20).
▁immunity
▁490
▁13.9
antif
itone
▁venlaf
onsistent
Fet
oriz
▁aPTT
astrop
▁(20/32
Tis
ropsych
=1200)
yoth
erver
ylitis
▁1.33-1.76)
uble
ompazine
▁initiate
enture
84).
▁prophylaxis
▁primip
ranes
trospective
▁Paren
▁50%,
etoc
]=0.9;
▁0.9-
achieve
▁unpl
rasp
▁Transbronchial
▁1668
▁researcher
▁duloxetine
▁breaths
=6379;
▁Prav
▁jeop
▁0.8%
erf
73)
▁doxycyc
parations
▁(20/
itoc
nj
idates
motic
thood
-15.
ophysiology
▁4.5%;
▁bedtime
Pent
▁infre
oital
otre
▁0.75-0.9
:3
▁delirium
upon
▁Intr
ependently
atterns
LHA
=9),
▁pertus
itig
ffin
identified
▁constellation
hydrates
epp
▁35%
▁daytime
.1,
inbur
laxant
ochemical
▁10,
=.021;
erone
odil
atex
-79
▁Asthm
▁8
▁abscess
nual
antamine
14)
orec
▁appointments
facture
▁obese
ysterec
rectly
reater
-1.88
▁rofecoxib
equate
▁verific
4.5
▁chemotherapy
▁isp
ephrop
tiati
alization
idab
editer
▁defi
odol
eon
=1250
-125
▁antifung
excluding
chondroitin
▁seque
rigid
▁Longer
59)
cinated
▁Breas
▁24,5
viewing
ractures
givers
exin
▁>40),
apent
▁ADA
=16.2;
rof
Celex
gestimate
62%
▁abnormality
esare
roglitazone
potential
▁urine
=0.72;
▁255
▁Escher
▁(15%
ewis
00),
astat
▁gentamicin
▁noncon
oncom
▁coni
▁(8
▁Lamis
0=
13
▁ALLHAT
llitus
▁97%,
▁Duct
▁unmed
5/108)
.04;
▁Lifestyle
HDR
thritis
▁angina
oquine
▁mebend
Cardura
eclampsia
▁anesth
▁Bric
▁Disease
▁relaxant
etrolat
▁OA
andat
4%-
imenopausal
▁(151
asotec
6.2;
ricul
3-1.1
▁64%-70%)
▁3.6
tiated
▁0.28-0.8
▁44-89).
],0.
okers
utralizing
▁bariatric
▁kep
▁23/1
=97%
lafax
=2.7;
6,22
ysterography
aemic
▁seborrheic
▁3.3-8
-0.96),
racon
psia
olig
ounger
naliz
ohnson
▁1989
pregnant
ulariti
▁0.29-0.96;
▁electrocautery
▁Grap
66).
etely
riam
invas
rtic
▁databases
otransferases
exia
▁dival
allop
oanti
acidosis
▁Petersburg
ytes
=.003)
▁awaken
▁Gord
▁implicated
▁CGIC
ynv
.09);
-1.01;
esive
▁1.9-4.
▁(140
gatives
2.5
▁bacit
onc
NIH
▁Subc
▁parity
▁regression
▁confi
▁EBVCA
lou
▁abstin
isodes
Hb
▁Fact
exCAPS
tiomet
▁variabl
yalg
onadism
▁28),
▁1.5
rickner
▁prela
ASA
▁8-
▁antecedent
▁communicability
▁cis
▁erythrocyte
7-1.6
nti
3.7
specif
tace
idebo
orvas
irte
ewise
=13.1
▁2.26-5.85).
ndividual
quent
▁950
▁supraclavicular
▁itr
ergo
41
▁retardation
▁etiolog
=7.9
▁Pravachol
ithou
▁modalities
▁vertebral
▁immed
7-
trum
▁1.25
▁serop
=1.80;
=.05
oxical
69%
ilization
6%.
▁lupus
▁immunosup
▁0.25-0.7
tissue
▁verapamil
edd
tene
tif
▁fasting
calci
opramide
▁2.0-3.
isit
▁anesthes
elst
Fre
retation
=1265)
▁triazol
▁SSRI
▁Secondary
ircul
▁specificities
=.03).
cem
▁1.4-1.
70
▁valsartan
6-0.9
]=5
tments
▁2.6;
estab
hyl
-2.4),
hydram
03).
▁nys
▁8.8%)
790
gid
gestog
ifampin
requent
enec
atog
▁Retrospective
icine
boph
▁616
endog
circumcised
▁allergy
sues
▁nonlact
▁4.7%
▁osteoporosis
onstriction
,23
▁coniz
▁Maddre
dul
oniazid
▁benzodiazepines
duce
Singulair
4-5
ribution
<2.
▁lea
cific
▁Cooperative
▁assa
▁pancreatitis
Sle
.10
oglit
▁ingestion
ilepsy
▁cetiri
urrences
▁ros
7/0.
▁practitioners
iabl
amom
▁gastrointestion
▁38%
]=1.8;
▁0.75-0.99;
reener
1-0.
elex
▁240.9;
kas
5,811
▁phenyl
thinn
icting
▁589
yroidism
CABG
▁neuror
assific
ourc
]=0.81;
4-1.6
lipidemia
lucom
glycem
alges
yograph
23),
actable
▁endocrinologic
▁urethritis
▁arter
-21.2
-20.
kotri
▁0.94
lating
▁sertr
▁Thre
▁basal
▁diastolic
▁50,
▁insti
-38%).
acchar
▁0.016
▁Prevention
▁lozenges
roidis
yyear
▁Waddell
▁0.52-1.30).
umab
▁2.6
▁avoidance
▁ceft
pful
ialty
atastro
,45
ticular
elodipine
▁diure
▁examining
▁1964
pretable
▁microbi
erestim
gesting
renat
▁uln
▁arteriosus
▁Intensive
▁Roch
=27).
105
-1.15
▁1.72-2.
▁682
iewing
oints
quartile
▁0.83-1.18),
▁5.2%
▁Orthov
8-1.34).
▁26.2%,
=24;
assif
berr
moking
▁20,2
95.
▁clinicians
▁1.0-2.
▁nonasthmatic
▁hypopig
otassium
edb
▁guidel
▁dysuria
▁79.6
displacement
▁2.9-
▁amnio
PLs
armacok
▁4.3
errane
olics
vestigation
▁capillary
▁132
▁malignancies
▁parental
▁Epidemiological
▁2742
discip
erch
▁Lif
▁questionnai
▁expulsion
interpretable
specialty
ifluc
9-2.
=3.4
=1.70;
duces
afloxacin
1-2
xyc
itain
▁toge
25).
▁560
▁electroly
▁0.2,
3-6.
=0.1
▁TPOAb
▁mononucleosis
69)
89;
4.4%
▁oti
4.9%
▁0.016-1.
▁>190
▁fulfillment
ulence
bute
▁LDL
▁(84%)
1-0.9
▁premenstrual
-2.76;
▁sprain
▁(24.
-24
AO
/10
▁141.
neezing
ransf
▁chaste
entoxify
oall
▁0.14
▁50,000
tocervical
▁cate
titudes
prog
fraction
▁Researchers
yclo
ropyr
opted
▁45.7%)
▁exter
iprat
mnipaque
Vistaril
.01).
▁nondepressed
▁(-0.0
▁11-
7.3%
▁standardization
angio
▁gou
hri
linding
omyc
erbil
dver
inim
▁revisions
5-5.
thromb
/1000
]=8).
▁progestin
cerin
▁reliab
derivation
ticoids
▁pituitary
-6.2).
▁Unf
tient
450
▁aura
▁eradicating
pletely
ilat
romatosis
lae
▁receptor
▁Luteal
/188)
▁selective
▁estimating
ypers
3-1.66).
▁cumulative
▁nonas
▁minocycline
eurysms
▁Chin
▁-12.34
=7.8%;
physicians
8.9
ffers
17,805
▁1.05-1.69).
clic
▁beneficiaries
viders
6-2.
calcem
odia
vaccinated
▁Whereas
cussing
▁1.63-4.
▁osteop
gG
gnancies
=1.21;
nity
▁dydrogesterone
roub
▁impaired
▁1.05-1.79).
1-0.8
tep
▁2.7-5.4)
▁montelukast
=24%
▁220
▁flutic
-96)
▁15.47
dial
bop
-2.20
▁tha
eases
▁0.98
allergenic
<0
▁anticon
▁glycop
▁2.82-14.5
▁Allerg
1,7
algias
▁outp
0.9%
lut
▁297
lre
ditional
azoline
▁ideation
▁Disord
▁becam
ffa
ucation
-50%).
▁dehydration
ritic
opharynge
▁osm
ctomy
COP
mia
▁Rochester
uelan
intestinal
uccess
gag
okine
▁corpuscular
parenter
▁resolving
ioly
▁poses
▁Unfortun
inalysis
7.26).
▁disting
46%
▁40,00
-8.
-6.
▁5646
▁(>10,000)
=0.25;
▁7.6
roa
▁postterm
eosp
▁resear
▁Closure
▁tinidazole
=33%
▁fatigued
9-
97;
▁hypertensive
28%
urem
scapular
▁17,25
▁infarctions
drox
▁postt
▁dres
▁bronchoconstr
Bis
▁4328
▁44
essarily
▁repa
ividual
IRR
▁0.29-0.9
riax
imv
▁occl
itec
emid
▁1.8-1
onventional
▁persistently
▁2002
▁atop
edipine
Demerol
nderg
velopment
-9.4
oppos
lebre
▁Antepartum
▁(1:1
▁(>14
-7.54)
71;
-0.8)
▁syphil
▁nyl
],17
67
itives
▁esophagitis
▁57
▁recruited
<.0001
▁cromoglycate
ercises
▁8116
blockers
▁(42/170
orsal
▁Lojander
eresf
Bere
mpression
▁zolpidem
▁granulomas
▁hyster
borns
▁1.11
▁plafond
▁valpro
3.7%
=.001
▁47,8
potassium
▁levonor
partum
▁Dival
▁newborn
70.5
<9
ticos
asalazine
pretation
▁Clos
▁kinases
apsulated
tioners
▁sulfonylureas
▁misuse
/170)
ortends
61.
▁intrauter
▁sumatript
ardiovascular
POAb
▁Vand
▁intracran
atisfaction
▁5.4-1
▁vulgaris
▁knead
1);
istere
5%,
▁5.4%)
yre
▁pentoxifylline
▁resuscitated
=.26
=.042),
▁neutrop
mmol
6.4
aroti
▁24)
ermatitis
Mur
▁colectomy
]=1.74;
inP
▁goiters
▁1.6%,
▁Stres
▁somnolence
thyl
▁innerc
bronchial
▁97%
ifetim
andidias
astroenter
ylp
▁2.8
hydrop
=90%
12-0.7
▁subse
itour
=10.44;
Vistar
▁prostatitis
comit
▁rash
onsillar
▁Bariatric
▁0.45-0.7
▁azathioprine
▁trigly
▁-4
▁mite
▁ThinP
▁MICRO
▁Sims
▁15%
enezuelan
▁1364
▁1.5-2.3;
▁2.03
.0).
▁subscap
ubc
▁-1.
vitamin
▁leukocytosis
-14.5
=9.0;
cises
rosyn
Fif
conver
▁11,
▁myalg
-1.86).
▁vasoconstr
ymptoms
▁0.01
▁nontreatment
rocy
enoma
ifical
▁suban
ingi
elive
▁overn
unm
=1.37;
ioniz
38,
▁neurol
▁cytologic
ABG
▁2.26-5.
▁4.0
▁suicid
troenter
avoid
econg
oftening
▁inqu
▁97.2-99.6%.
▁treadmill
▁51%,
loram
ycles
▁benzylamine
▁crutch
▁rearrest
agitis
▁pantoprazole
cestry
peptide
1.3.
▁1.57-7.8
▁endocrin
▁carbonate
oronary
▁2.10
▁41.
▁6.5%
78)
▁441
▁Significant
▁99.5%
tionists
VCs
rove
▁Rubber
gestive
▁0.20-23.2
teroidal
▁enox
rimes
creatitis
tivi
▁623
▁covert
▁informal
▁356,222
▁-1.21).
luoride
enolol
sA
▁43.8%
iometry
inavi
alap
▁angin
▁(3.12
raliz
Ele
resum
ghts
▁dipy
Vir
ranol
▁5.4-12.8)
▁Wah
▁7%,
3-0.88).
▁78%),
▁intoler
32;
▁neoplasia
▁0.17-0.44
atc
=8;
omagnesemia
▁dus
=2.7,
▁diatherm
▁Injury
▁0.57
▁nimes
oam
▁Likewise
acerbate
▁0.54-0.8
▁nonasthm
▁inception
%-
▁monitored
▁chorio
roscopy
▁breastfeeding
-40%
tenan
sity
▁2.5-
17;
tinate
▁analgesia
=1.24
▁4700
TABL
89),
ilirub
▁metast
▁nonpre
▁2.4%
▁(20%
4.7%
-0.9
teral
▁Statin
90,000
mentation
obac
OPS
ithe
isord
▁antihyperten
▁recordings
▁Neuroimaging
▁METS
▁acids
▁106.
ysti
▁mucos
verv
uminal
asoc
▁nonhyp
counseling
icyl
0-23.21)
▁DVTs
ikely
adia
▁manipulation
▁Elev
▁compartment
▁dumping
orking
▁subar
▁abd
bulatory
▁subg
oratory
▁longitudinal
ampicillin
▁Intervention
▁(820
96,
▁smo
foration
▁intracere
456
lodipine
▁gonorrheal
acists
lies
tients
]=0.59;
-1.30).
15;
ysuria
=1.05;
ocell
▁769
▁immunized
▁bioav
4.6,
chiz
▁ea
▁UT
▁3.4%
athological
▁formulation
97).
▁(278/43
▁heigh
▁outn
▁80-
▁thrombo
▁transformations
itely
=4.5
▁1.32-1.44).
▁nondis
▁hypertro
▁identi
ceal
ellbutrin
▁juices
=342).
uretic
eated
▁femoral
suc
-0.57).
ferrin
ethas
▁ectocervical
▁counterirritant
▁Biop
-0.8).
▁estrogens
▁13-
diagnosed
elecox
▁Prac
▁11.2
▁1.35-7.
izability
▁foc
▁emesis
▁Sleepiness
▁988
▁oxyqu
▁0.99
▁androgen
▁2134
rener
amole
Gail
▁pregnan
▁70
▁resul
undice
▁diffus
▁thi
57).
isks
ecati
▁Lef
▁97.2-99.6%
ublications
cised
▁Ninety
▁labialis
▁hepatoxicity
▁cardioemb
▁electros
otor
▁reproduc
7-1.47).
▁trended
▁intercourse
hyroid
eity
▁0.
▁hemorrhage
verticular
alosp
▁murmur
2.4
▁Exercis
paring
/110
0-0.9
▁etan
▁Ottawa
▁receptive
4-13.16
▁macroadenomas
▁predominant
▁weakly
▁donepez
biological
iolog
▁desmop
4060
omip
▁Apgar
andine
34)
▁584
-2.19)
/200
▁deca
osus
utcom
▁venlafaxine
ulted
=.52).
guably
▁>10,000
▁(97%)
=23),
vasi
icis
▁0.47-0.6
prising
▁Malignancy
ashimot
ducible
▁untreated
identif
▁(49%)
aminop
etast
▁LV
▁cla
▁ADAS
-90,
]=3.1
arret
cale
▁ppm
▁disord
▁pleural
orotic
=2.0-2.
▁responsive
2)
▁venous
▁(3.7%
▁<150/85
▁feather
▁5.7
▁7%
diabetic
]=5.0
=108)
78/
▁1.42-6.
▁sebace
-0.71,
▁fibroid
xamin
alifying
▁precord
241),
inl
llent
▁54
▁pts
▁furosemide
thr
▁3.1-10),
▁oxym
epa
▁3.3-6.
▁pretreat
45%
▁investigator
▁Detran
▁spirom
▁obstetric
inase
efine
ciitis
ndi
treatment
▁dyd
]=1.7
▁constipation
6.80)
arench
2]=57%;
3-0.79);
▁AFFIR
comf
▁cryogel
idating
vacc
zap
Tar
▁initiation
etran
▁5%.
armacological
-3.6
=.26).
▁nonacute
▁Coc
Benz
enon
▁cance
irf
lects
▁Comprehensive
ultic
icillin
ioch
▁metf
oppl
▁pulses
1.8%
oram
=88%
isual
▁wort
arotene
▁torsemide
=26
rue
▁prenatal
▁nebulizer
ithout
ogenous
▁insidious
Proz
▁IgA
▁arthralgias
ezafibrate
▁microhematuria
▁14,881
treated
=0.89;
▁macroaden
23
-54%.
▁Durad
=165)
▁fibroids
adly
besartan
▁focal
▁levam
ysp
▁25.3
▁7.3%
▁cortis
▁urin
▁Detrano
▁70%;
▁hexacetonide
00)
▁biweek
▁amenorrhea
16),
▁primro
eou
ceptiv
tyl
onstr
olisms
▁DMP
▁inta
etam
idn
▁studi
ondh
idazoleor
▁(40),
hap
edical
ermom
=1363)
▁jeopard
acorporeal
=4.8
43)
Ea
venox
▁regulating
chit
▁caregi
▁concomitant
-]=0.06).
90)
opper
▁GER
avir
teric
▁placenta
uric
natre
ypt
▁endor
▁0.15
-13.
▁>38.
osar
scop
00-2.
▁1.3-5.
feren
]=2
pore
▁phototherapy
▁progressed
▁hemorrhoids
7%),
▁ottorhea
▁angelic
6-1.88;
ignific
entil
▁defec
idespre
▁urog
-3.4
▁dran
oxif
▁incision
▁nevi
▁unusually
▁Prep
]=1.2
myocardial
▁wors
osteroids
6.9).
▁439
nei
aflox
▁Curettage
▁concomit
etim
▁contiguous
ibiting
illment
ystic
▁Scor
▁Neph
▁0.94,
AFASA
eud
ometrial
atad
aratriptan
rengthening
efl
isabl
▁genotype
cessively
7.7
▁lansoprazole
proate
AFP
erem
corbic
ipocyt
▁>36
▁pectin
▁nicotine
▁thiazide
▁45%-4
ilot
alon
▁appraisal
▁instit
▁GAB
▁fluorid
-1.23;
endec
▁disab
reng
▁126
ilab
▁curric
▁fenoterol
▁underwent
alsy
▁ascorbic
▁93%
ocardial
aphen
▁isolates
idoxine
▁11,000
=-1
▁immunoc
▁omeprazole
uscitated
4.8%
ROSP
▁clindamycin
opr
▁zal
▁administered
hydrated
sia
▁45%
▁SPL
▁Malign
▁4.32
▁83%,
▁elevation
▁(4.8%)
intermenstrual
▁47%,
▁18.3-4
eep
irr
umcised
elief
▁0.10-0.2
DVT
Pant
▁PPE
terl
ologic
▁6.65%
azolam
=7.8,
▁88%
6-1.
▁workups
-1%;
tagonist
=0%;
onents
fec
▁extrates
aline
acorp
▁34
▁vaccination
proved
▁antibod
95.9
▁converting
▁immunobl
▁activator
=24-3
▁Euf
analys
▁10.5-18.5).
toac
laim
plor
▁breakthrough
16%
7-1.0
]=2.8
▁Benzodiazepines
ABGs
▁PROSP
-0.79;
ittac
▁meb
▁87%,
dia
▁rasp
=-6.5
▁ana
=4091;
uas
immune
▁distal
▁endocrine
▁(5/110)
▁postcataract
3.3;
▁<15%
imbs
▁commercially
ffr
▁Thei
hro
.09;
▁polymy
proh
-3.1).
▁ultrason
ported
troviral
▁68.3
▁cured
▁3.7%,
arat
MW
▁piroxic
illi
cum
▁Mankopf
▁journals
▁polysomnography
50/
▁(80%
oscop
proach
▁lovastatin
▁bandages
abolized
▁unreport
olates
nalys
▁[9
redients
.003).
kgo
▁mainten
▁unb
anat
▁chloroth
pwor
▁56%;
▁meper
▁234
▁unv
▁quinolones
▁decayed
▁doubl
▁valac
grounds
▁thor
▁0.96%
▁duke
riginal
▁<100
▁cyclo
▁recurrenc
yti
▁75;
▁Tran
▁ottorh
140
uam
▁induc
pensi
▁12/
▁<2500
▁200-600
=.5
adjustment
▁80%-90%,
ulatory
8.5%
▁nadir
▁mortality
uervain
.8.
onadotropin
flamm
ochem
33.67,
▁-1.9
oat
elati
Dy
00-2.8)
8-1.
istor
entified
genital
troph
▁radic
arbox
xing
▁Seventy
PV
onfatal
sulfonylurea
▁precur
▁decad
predominantly
▁nontra
drug
=3.72;
▁sulbactam
=3.2).
POA
olos
▁curricul
▁alb
ureas
eci
-81
▁hered
enot
▁ovar
=0.15;
▁curretage
▁0.72
▁Prog
merg
▁enlarged
▁0.1
]=8.
▁epidemi
▁neutrophil
▁deoxyrib
ecurren
▁Tas
asonable
▁25%
▁unli
▁0.5,
▁cranberry
19)
▁0.04-0.13).
▁agon
-12.8)
Gor
ophila
Mun
▁INPH
eutic
▁LEEP
▁63
▁2.8%
pectedly
illn
esults
1.9%
9038
ingers
fir
▁subanalysis
689
▁angiotensin
▁thirds
ofloxacin
▁chos
▁Eleven
▁Tuberosity
abolism
ieves
etrol
etw
smoking
▁withdrawn
▁(8-1
ewor
-0.44
▁9473
vem
▁proce
plas
opidog
▁cachexia
cys
▁16.7%-8
▁Alendronate
1-1.0
omatic
▁chronically
laints
2-1
▁(14/
▁eros
luenced
natal
tion
▁intra
olac
zyme
ustry
▁bronchodilator
▁tizan
ENAAL
245).
muniti
ransec
nee
ilvad
yro
▁lisinopril
olytic
▁0.7;
▁6.6%
▁subcut
▁noc
Vet
▁0.19-0.67.
olectin
▁Ultrasonography
azepines
▁valu
▁algor
0%;
artile
▁>2000
isters
▁0.4%
▁spor
▁Terb
▁1.10
LGA
-0.94)
anual
▁identific
▁8.3
▁dizziness
cohort
▁Datab
▁maternal
▁Gonad
▁bony
▁66-70).
▁59%-7
▁confine
▁57-2
edist
▁0.59-0.82).
=4)
51/367;
ttage
▁(42/170)
▁cartilage
▁Phenytoin
sori
inyl
ystag
▁amput
▁macrosom
epam
ptococcal
▁(2.1%
9.42;
▁0.43-1.00),
▁683
aroten
esium
ulen
3-4
▁potent
atogenic
▁sof
▁corti
etirizine
xper
esol
<5
=3-61).
▁3280
▁abbreviated
▁controver
tali
▁metere
▁cardi
▁progression
▁membranes
▁Compre
▁43,738
▁(247
▁interventions
actors
10.9
ecreased
alH
FIR
▁evid
urid
dance
▁8.2-23.5).
iiti
▁(98%)
xin
▁Transbronch
9);.
▁cutaneous
▁(95
inish
▁concom
▁colonoscopy
entor
VAS
▁89)
▁Hg
▁multiorgan
▁parac
othyrox
▁Endoscopy
▁uninterpretable
▁bathing
-90%
fied
zati
thwe
81%
▁0.12-0.7
▁heterogene
-18.9).
otoxic
oeph
2-1.44).
▁reac
nda
tam
▁dehisc
4.6
qi
RAs
iates
▁1.5-1.9
▁tol
▁<10
3-1.6
8-0.87)
▁hypercalcemia
▁3.2%
▁212
▁Incision
▁hypera
79
WB
43.
▁22.3%
=60)
damine
perimental
▁cohorts
▁1708
ulfas
▁1.31-1.99),
▁ossicle
▁1.25-1.68)
▁Regist
enteroc
04
ispanic
▁calciton
▁histolog
hyp
SMD
versible
▁adiponectin
fib
▁19
▁99%).
floxacin
]=1
▁5892
ifesty
alos
propriate
pens
titr
eflex
atropium
44%;
oncl
sied
pne
ramingh
▁Oxim
cI
eroph
acla
-1.5)
veloped
-34
rosom
▁identically
▁1.1-1.5)
▁156
▁normotensive
verti
alor
anderbil
▁operative
onoscopy
▁Lorazepam
▁infec
▁gastroes
▁Respond
▁thresholds
troly
2.8)
mol
68)
alapril
hered
▁0.36-0.
▁cerv
▁recurrent
▁biopsies
▁0.82
▁(71.6%
▁16,
▁(94
opi
▁1.04-1.
daily
xes
thin
eet
verif
gestrel
imaging
▁57.
▁dela
menorrhea
ingl
eperidine
▁CAHT
eran
▁guaifen
usi
ergotamine
▁rosig
(7
ionic
Eigh
44
imms
iatric
lafaxine
antrum
40
▁2.5
acule
picil
leepin
▁42.
quite
trov
▁symptom
▁ong
▁Gynec
▁400
▁Increases
▁(10/
▁lumbosacral
=8
▁8.6
▁Candid
ussive
▁0.48-3.0
creas
50-0.
lacing
portant
ousn
ubse
▁hyperco
entic
roscopic
▁alcoholics
▁nonmil
endem
▁-12.
-=
▁0.38/0.8
▁possib
onsyst
PTT
▁characteriz
muscle
▁isc
esic
=1.30,
>0.80.
lical
▁1/30
▁metoprolol
=.001).
estinal
▁caloric
aturation
ichm
licting
oriation
▁uro
▁115
buterol
▁tripled
▁(400-800
▁constituted
odine
-7.86).
vac
▁Worsened
upraspinatus
=3715)
tbooks
anovulation
sibly
▁fibul
▁aerosol
nac
onou
earchers
▁(23
▁conduc
gred
▁55%;
▁scalpel
▁24%,
ortu
▁implying
▁(278/438;
▁carcinomas
▁anov
mediately
iad
▁1.2%
▁myoma
▁enceph
-5.3
4%-49%).
raconazole
2-1.30).
▁manipulative
▁carbohyd
▁0.79-5.
▁dihydro
▁shortened
▁PPV
▁lipoprotein
▁0.18-0.87)
erns
▁2.6-4.9
rojec
athoph
▁presentations
▁95%-9
1%-8
emas
=88%,
veloping
ertility
nionitis
▁scheduling
alac
actures
tolog
▁92.9%
▁hemorrh
ullae
▁6800
=10.
▁Hys
▁21.2
lipid
▁(15%),
etence
undic
4%)
arob
▁dipyr
▁circumf
ysterectomy
▁63-99;
▁(90%-100
▁respec
▁calorie
▁puncture
▁oxymetazoline
8-3.
7.1
▁myalgias
▁1985
▁panc
onale
▁guaifenesin
eduled
9/1
▁adnex
▁stimulation
02)
▁(40%
▁Tricyclic
▁57-2454;
ocl
▁(16.4).
itid
11).
▁matur
▁>32.
oxygen
Vene
▁(17.
omly
arameters
itati
ynovitis
▁discontinued
vices
ophen
▁mentions
▁hypothy
▁postinjection
urgitation
▁1445
.1,2
inj
-1.68)
▁Diphenhydramine
inergic
ecad
pici
erfici
▁461
(3
parous
Cro
9.9
▁10%,
▁premenopausal
3.21)
▁cara
▁blad
idw
hly
posit
igher
orectal
▁Hypogonadism
0.80.
oretically
LADA
▁Myocardial
-0.74).
tropen
toxic
idem
▁glyce
▁obstet
tiri
itial
rhag
yretic
alking
▁biopsied
imeth
▁thrombosis
▁diverticulitis
5%;
▁Suc
▁bromoc
▁14.4%
▁23/1000
▁0.44-0.98;
revent
zos
▁Antic
▁Obstet
00-
atistical
▁Excluding
anag
pointments
edule
▁Maxim
57
troduc
▁(0.9
-3.0
000/
ervous
▁LN
oidec
Effexor
onsored
▁exploratory
VV
iotic
▁80,
ylam
amou
apri
▁phosphate
urmurs
▁dropp
inatus
▁55.8%
▁0.47-0.61).
▁NCEP
parathy
▁blu
5])
3-2.7
▁inversely
▁granuloma
Silv
yx
▁coste
ibrom
utoantibodies
▁radiograph
▁erythro
▁introduc
▁2.5-5.
usation
oxycy
lates
-20%).
/34
▁masked
odilator
motor
Ig
-14.7)
▁strengthening
▁880
=50).
▁childh
▁yearly
uted
cerid
▁LR
=.02
5%).
▁958
▁(35%),
=7.4%-14.7%)
▁(39/188)
-2.8
ghage
ulg
▁immunocomp
iazide
ocin
▁10%
roxyzine
▁distur
▁35.
=.0008).
ecting
▁ow
onsequent
▁heelstick
ostin
erim
pact
▁microb
▁Highly
agonists
▁losartan
▁10-31;
▁Escherichia
ardation
osomal
2.2;
sutis
endation
ocys
▁transf
▁bronchosp
amicin
▁stepwise
▁triceps
▁Attack
▁Somatic
▁29.4-57.6).
inop
compliance
▁flunariz
▁Camer
]=0.60
▁clam
▁(6/10
poscop
=.002)
oben
=1.50;
▁endomet
▁neurop
▁5721
▁laxatives
▁multimod
▁pneum
▁Epidemiologic
▁Interpretation
▁uprigh
▁consecu
▁ultr
▁diath
Ta
ioth
▁wil
▁glimepiride
▁ribs
▁luteal
diagn
effects
onergic
atological
sensitivity
▁toxicity
▁unti
legiline
urses
▁0.013-0.
▁PCR
▁saphenof
RIs
▁11-8
▁chlorhexidine
▁6.
▁209
▁magnesia
isedronate
tla
oagulation
unli
tinues
▁hazards
▁orthop
stern
▁(32.1%
]=0.37;
inoline
3.16
aggerated
▁Neu
▁lem
=85%
▁77%.
▁measu
terus
itab
lea
lyb
Fol
▁admissions
▁6
▁ampicillin
matically
pworth
▁pyoderm
impro
▁PROS
urpos
▁syno
asein
▁doxazos
gredients
rents
arolin
▁261
▁hamilton
5,
▁arthros
5%-8
/2
lamine
7%,
tims
ilators
77;
emf
amphenic
▁Heal
urric
elet
▁57%.
=0.30
ithium
arted
atation
acqu
▁(67%)
▁Lamisil
▁9031
onitor
Bacitracin
▁discom
sic
inafine
Hypertension
▁ari
▁1970
▁disad
▁(92
irically
100.
8-20.
tihyp
▁pellets
▁=.00
▁adenoidectomy
▁chlorthalidone
hange
▁2.26
stitute
carotene
1.3%
▁0.88-1.5
▁glucose
8%-3
▁adenocarcinoma
avings
=.06).
▁optimistic
▁hyperbilirubin
=34
idoc
▁varicella
▁arous
ampaigns
survivors
opsi
cetic
▁4-
,000)
▁relaxants
▁9/
[9
ymmetric
▁Intranasal
lycer
gory
6-0.94).
▁struc
/30
▁NSA
▁techni
▁(69
lend
▁reactivity
sce
8-1.3
comprising
entually
▁homew
▁(45%).
,-1.
quine
asan
▁(49%
▁20,751
▁abus
▁1.12-1.8
▁7.2%
▁estrogen
ocla
zheimer
verap
▁colposcop
▁angi
yline
▁CHD
▁mam
tilation
▁pho
quiv
▁292
vegetable
onylure
ptim
=10,000
▁48.5%
arring
▁fluoroquinolone
=731)
▁triglycer
▁(545
eigned
ingf
Seven
bste
▁Combination
2.
▁therea
onephritis
▁8-1
sible
▁(66.4%
▁Nex
▁<105
▁paroxysmal
arro
5-0.8
▁nonpregnant
urements
fou
retest
4.8%)
▁differing
▁disim
▁(90%)
ffeine
gM
▁neutroph
▁embryotoxic
lly
▁recove
▁<3
▁penc
▁electroc
astrophic
ilitary
▁1.12-1.86).
▁prostatectomy
▁1:
24.
troam
tiometry
▁25,92
▁sativus
strat
▁medroxyprog
estril
▁clemastine
Gib
epti
struc
inm
▁2.66-10.
sychotic
lel
needle
▁examinations
▁vertigo
▁radiculopathy
▁192,478
venture
ongestant
=0.59)
ronch
effec
▁Aid
▁fertility
▁323
▁412
copical
▁myop
▁phle
LN
▁99.5%.
ective
-33%).
lod
▁60.6%
▁pregnanc
▁regurg
▁(46%
▁Oximetry
▁dietic
emiologic
▁<85,
▁Lipid
▁concordance
▁amou
▁(251/36
erest
▁mesalamine
epen
▁asthm
▁(43
▁estol
▁Calif
ranean
iminate
▁80%).
▁psittaci
▁28%-38%).
hisc
vasive
giti
▁breastf
▁603
▁derange
▁dyspep
LNG
Ure
▁glutamic
▁multim
ormly
pioid
uritic
▁unsweetened
ighly
▁rati
cepted
▁70-
▁Injection
▁44-
iniz
eam
▁endobronchial
▁1.3-4.
ootb
enzodiazep
cif
▁1600-
▁1096
terven
▁nonor
▁fum
iditi
▁18
ofulv
opal
▁giardiasis
3-0.4
▁cyt
empted
lyt
▁exis
ithrom
Va
]=1.16;
▁squamous
13),
=9%
▁monoth
pasm
ackles
75%
▁multis
▁usag
.0)
=1.06;
09).
▁84%-91%).
▁2570
utches
▁unrecognized
bos
atoid
ameter
endronate
▁1.38-3.
-3.6).
▁1.42-6.76)
elial
▁blockers
▁46.2
▁(74%
▁bey
levated
ificantly
sively
▁Elimin
▁audi
ternet
entoxifyll
argets
8-1.54)
▁0.54
.8%
▁75%
▁<45
▁(9%
▁1.1-3.8,
bef
Breas
▁cortic
significant
▁advan
oppler
▁(31%)
9.6%);
uat
▁6.97%
▁Screens
59%
▁phri
▁hypercoagul
10,000
tici
▁1686
▁68,297
▁coen
terone
▁0.71-1.0
vived
orsemide
idural
▁5.35
▁-20.70
/110)
▁55.06).
imilar
eneral
ocri
▁nonprotein
eek
-65
isner
trob
▁iden
▁nonm
lind
▁affinities
farin
▁AACAP
▁erythema
▁Inhaled
▁cravings
=8),
▁egoph
9%)
▁arthritis
▁Outcome
▁(76%)
103
▁prednis
ohumeral
▁augmenting
ffor
ecox
87.
-60
methyl
▁alleviating
▁0.4-0.8
▁CNBSS
▁serologically
/0.8
▁(700
tenatal
▁bicarbonate
▁susceptibility
Fran
▁parat
roxic
izanidine
▁noctur
roen
▁0.19-0.6
ausal
azil
▁<.001,
▁mainst
erly
▁dextrose
379;
lloc
inergics
rials
Hys
inetic
▁82.
DH
zine
ecid
glyceridemic
revention
gf
▁comorbidity
▁calor
▁1.15-3.1
▁29.4-57.
ainen
justed
rean
blind
=7.1).
0-50
0.10-0.5
▁343
5-0.97;
-0.93
ogon
enomas
▁0.28-0.
ttor
▁vulvovag
eat
edti
▁1.86).
apamil
▁223
=1.4;
▁ei
meth
9-1.5
arj
bron
▁18%,
▁supravent
▁1.51
sectional
▁psitt
sment
-90
antam
▁561
ositive
▁migrans
▁nasopharyn
=2.8;
=.023;
levation
orab
pati
▁hygiene
▁39%,
▁Artery
ersh
▁tib
▁Danazol
▁(5.1%)
▁appendectomies
▁stratification
▁itsel
▁somnol
ucind
anine
▁cavity
lycem
=0.185).
romoc
=.9
41).
ecations
▁Increas
9.1
tio
▁sampled
etiapine
idious
▁3234
etings
renia
ectr
meprazole
reac
etero
▁somewh
▁1.09-3.51).
pregn
▁amp
eers
68;
▁schizoph
flammatory
▁psychoph
▁MEDLINE
ypnea
ruri
▁cardiovascular
▁0.23-0.74).
loph
opathic
▁revas
irths
ortis
omal
-22
sence
ronically
agnit
▁fath
utive
▁headach
=1.18,
▁antif
emorrh
6%;
ostly
-2.41;
valen
irubinemia
rox
eru
▁hypertrop
▁clears
▁aspartate
imso
regularities
stracts
39
▁(3.4%
▁5.6,
Gastrointestinal
yuria
▁1.02-1.9
umetanide
▁48.
portance
▁AGA
▁poorer
heren
comitant
erated
▁dyslipidemic
▁bleeds
3-9
▁0.42
▁14%.
inemia
2.3;
<.01)
▁Schizophrenia
yclob
arcinoma
omnol
1%.
9.4
▁145
perat
▁overlapped
apalene
iphene
▁(47/34
unctioning
ifestations
ept
▁gyn
▁prospective
ertional
▁levothyroxine
▁0.0),
▁encephalopathy
mone
▁1.80
taz
▁antimicrobial
aggressive
sage
▁tympanos
hiz
orbidities
▁(1.58-5.1
stimulating
▁nonin
enograp
arrh
▁breakf
▁(1.58
WOSCOPS
umbar
=0.30;
ffron
▁protectant
▁(81%
hieved
▁placent
18),
▁abr
inati
33.
atification
8-1.58).
tute
isim
iterion
▁2.61-2
▁coworkers
▁iso
andi
iotrop
▁nondisabling
▁-9
0/
▁brevis
hypop
▁emboli
▁0.38/0.81,
▁hypercalciuria
ionuc
Tilade
▁(16.6%
ethylene
aised
=.0001).
NID
▁douch
▁logistic
weat
▁excor
▁hairy
ueb
▁0.93
Sporanox
▁disturbing
▁mice
▁bedro
▁sensi
0-23.2
ecological
45)
ALM
Soc
▁1555
▁0.74-0.9
]=4.
testion
▁ossicles
Ox
▁550
=480
curacy
7-5.9
onberry
▁homoc
letion
▁0.2%
chol
▁26.5
eterious
5%]
olun
ereb
▁bran
pirin
▁23.8%
misoprostol
▁youn
▁diuretic
ocusate
▁licorice
]=1.8).
▁RRR
radication
ainment
▁Rised
▁blin
▁androgenic
▁salivary
▁ValHeFT
ecal
24).
▁40%;
Ban
▁>7.5%
-]
omipramine
755
▁cereal
ratic
inog
oF
ellet
iclovir
artum
▁arres
▁9.2
▁replac
▁stopw
▁4.0%
antoin
oklet
tution
▁2.66
.0]
▁untreat
11%
▁refram
▁upt
esemia
▁ank
▁MMSE
enzyme
apid
orithm
▁0.65-1.02).
▁interleuk
rinted
▁135%
▁cromogly
▁carp
orre
ransb
sychotherapy
alaz
▁0.87-0.9
▁59%
▁86.
glycerin
ourages
tually
tine
eared
acto
▁28%;
▁postpartum
▁carbam
▁Obstetr
ronounced
-1.58
stetric
=0.64;
iatrogenic
4%-91%).
▁arth
euvers
▁0.17-0.
ABAs
▁0.63-1.01;
▁27.
-2.1)
▁194
tending
gus
8.1%
amphenicol
▁7.9%
▁saturated
▁intravenous
ects
.4%
terine
dosterone
▁Ventricular
rective
oic
munotherapy
▁dermatitis
clavul
tinoids
owor
onsi
▁215
ilob
ocalcem
conclusive
onors
▁75%-8
terview
).7
▁subtherapeutic
▁(63%)
80-
osu
▁183
idog
▁anticonvuls
urely
▁hypertension
urgical
▁solids
▁(94%
8.4%
▁hypern
adrin
▁CRP
titute
7.6
Nul
ophysical
fants
enad
▁1.18-4.20).
50
depress
lamydia
-5.7).
tizing
▁0.98-1.2
yograp
▁histologic
▁indeterm
▁concuss
▁progest
▁especi
▁aggre
anding
▁VV
▁Hypog
=.02)
mnipa
▁smear
.2%
mune
=6.96%
▁<2.3
▁crom
▁undetected
rimox
▁regulate
asian
fid
eason
▁(17.8%
▁mech
▁napro
▁Failure
▁Britis
▁82%
yph
=.042).
Buspar
50/85
▁allevi
▁2.47
▁78%)
▁weightb
urre
▁gels
aryl
ardy
tsd
monit
▁750
rebral
▁electrolyte
▁polycystic
▁glarg
7%;
brovascular
rganization
▁bruit
▁Statins
emop
alify
▁compart
rse
▁rela
fortified
-1.47).
-1.23),
▁neutropen
▁Hypocal
▁(4.
▁radion
9.8
euver
teris
gion
etoprotein
▁trig
ews
▁Secretory
irubin
▁(60%)
opsy
▁(478)
stro
ceb
aparos
esit
onsist
ticar
14.
nause
airment
amox
orks
▁3.79,
▁adenocar
cence
/100
ignan
nasal
▁elemental
▁Remaining
▁hypogon
▁perox
leur
▁1.31-1.9
athere
▁95%
=3.3;
▁suppositories
81,
▁magnit
righ
▁0.12-0.4
▁alan
ematic
=14
elvic
arged
inti
▁MRF
▁8.
▁antifr
<.071)
egard
▁50-7
icep
hone
yler
▁27,45
▁tricep
▁surgeons
▁inheren
▁Tsumura
▁0.22-0.88)
▁2.12-2.67),
▁0.83
▁cham
atedly
29
prednis
llat
▁otoacoustic
▁1115
fractions
▁discomfort
lucosamine
▁(75%)
tilage
▁Included
4]
=61%;
-2.92)
▁316
▁leakage
▁Chlam
ualization
ffexor
propan
estin
eal
etected
▁pla
▁(1127
emaining
▁Dri
▁correlating
▁migra
▁absorp
everal
roxine
▁Abst
▁Adipocytes
▁nond
▁transaminases
▁ECGs
edline
▁irritant
▁Impression
▁0.38
▁neurole
fam
reastf
zat
idazol
athem
=92%
).8
atib
osacral
-18.5).
aproxen
▁pate
▁angiotens
▁elb
▁1.19-2.
46
▁fluids
▁treata
proximately
centag
▁7.5%.
▁feigned
▁Steroid
opram
versi
inflammatory
▁functionally
teran
pation
▁interventional
▁simplex
=16).
dihyd
▁multivariate
resis
xys
liti
utery
▁ef
administration
idati
64.
onsystematic
bove
egree
▁immunof
▁vegetable
vati
▁2.4-17.10)].
icad
▁noninflammatory
=1.20;
0.0
onb
vertig
▁(38%
isuride
-7.1
73;
=5),
luconazole
curately
melan
=17),
tionto
▁retic
vie
▁decongestants
▁simplification
fusion
=44;
3.7)
▁paroxetine
245)
television
ipen
09
asu
tracorp
idst
▁Atarax
iazol
▁physiology
663;
▁Lact
▁Obst
fant
▁hemorrhag
reptococcus
opn
10-0.3
▁enhances
ophysi
improved
▁99%
-0.8])
ituit
inb
erand
niqu
▁defiant
rover
▁langu
oterol
eech
cination
▁71%
▁erythromycin
rogenism
▁(466
▁indur
▁pyuria
▁Staphy
▁scabb
▁superv
▁GADA
thov
▁42.1%-69.6%);
]=2.7
=94
directive
▁1.48
ifty
ceding
haviors
plen
▁0.60
Fir
4.5).
ralg
holic
▁124
riptyline
▁64%-7
▁0.55
alm
▁Fewer
▁orchitis
qued
sulated
gthening
gether
▁workup
▁supplements
onver
ibbs
▁1.05-1.2
poor
ibros
Fort
kowske
▁carcin
ein
oidal
sional
9);
▁Loj
▁fetuses
▁Hyd
tazole
▁saff
9).
TexCAPS
▁Subjects
opne
sive
▁plantar
breastfed
odular
▁6.7%.
▁PEF
SAID
▁0.88-1.11),
therap
Sod
xime
structed
asel
upational
▁COPD
ormed
▁17.1
▁(50.0%)
andf
▁sprin
/0.78,
leural
▁1.8-45.
=1.52;
▁sulfad
▁enzymes
▁unswe
▁ketor
▁concord
entou
iousness
ycological
▁carbamazep
▁117
▁Compared
rgan
xyp
▁28%
▁(26
▁Levothyroxine
▁8.3%
troc
▁acetylc
▁gastroint
agic
idias
▁Brev
▁970
onucleic
▁0.41
29.
Naf
73
▁isch
oxazole
ukin
▁disimpaction
nists
zar
umably
atella
tinomyc
▁1464
▁homeop
▁disor
hangh
▁264
▁0.5-0.
aiwanese
aution
▁Sched
▁restudied
▁amph
45;
▁congestion
mipramine
urf
▁pylori
▁cisapride
▁tracts
=1.8;
leepiness
▁abst
▁prol
▁(1.0
12-4.
▁thic
▁0.7
acids
fetoprotein
▁casein
.5%
▁birthing
▁aler
514
ricycl
amc
-1.07),
bitive
689,
▁Silvadene
▁stripping
-2.78).
▁tiotropium
alist
▁criti
ainly
▁Venezuelan
8.3-9
akote
▁threefold
▁detrus
publ
perature
individ
▁6.3
▁20,226
▁(1.3
44%
ucas
▁inherent
613),
▁hyperand
▁Eradication
duced
▁hypers
▁(1450
▁82%,
otient
▁Chlamydophila
▁vigor
arbohyd
onstrab
▁Obesity
▁0.27
▁GE
Dent
mph
▁Lut
arcer
laxants
lud
▁tolerated
=0.99;
▁VTE
▁0.04-0.
▁laparoscopy
inquency
ommendation
▁<0.1
▁65
▁42-7
▁20%-33%).
▁TVS
▁Reoperation
5);
itching
▁laparoscop
=.000
aprosy
ersen
cove
tary
ramad
▁instruc
elding
15),
.".
▁hypotension
Avandia
▁(33.2%
▁acknowledges
-70
▁198
▁40).
▁somn
conduc
etician
▁600
Rif
▁50-
fat
▁dihy
xation
▁compa
-1).
inh
reati
orol
biotic
asciitis
64)
▁116
▁lactobacilli
nion
▁problematic
▁obstetricians
▁ischemia
anid
volve
▁chal
▁Dut
▁endom
▁Troglitazone
50.
90.
▁(78%)
odality
▁corticosteroid
luor
carbo
▁verte
ticholinergic
▁0.28-0.60).
▁Hysterec
▁gynecology
1-
=2.5).
splenic
ubate
trat
athologic
44;
urtic
upirocin
56
▁(13%
etabl
▁selegiline
▁carob
▁rigorously
▁4.6
cillary
▁Fink
6-6.29).
▁propran
▁(98%
verages
acteria
-144;
▁nonresponders
5%-4
5%)
▁NNH
▁23.10
Pain
▁pneumoc
acycl
▁nause
ronchodil
▁protec
tox
nec
ousre
-0.73)
▁neutro
pium
Ram
redn
idec
agrap
pber
onent
veter
▁TSH
▁endarterec
▁troglitazone
=689
timal
,2
receptive
knowledges
-76%),
ewed
uin
▁zinc
▁nonorgan
▁echocardi
priately
▁17,
kows
obronch
▁541
ractic
ebo
bate
gat
imepir
uting
▁(90%
▁Factor
]=25;
cei
vigor
▁8.5
▁uncovered
19.4%
chom
▁167
▁24.6%,
▁expelled
carbohydrate
▁0.84-1.12),
issed
26%
01,
4-1
▁orchiop
▁(2.5
riminant
thallium
▁renal
▁relati
▁3.3-8.0
2-0.
▁underly
▁ibuprof
lacebo
oplasm
jec
▁0.34-0.73)
▁infarct
tiapine
venile
densed
ronoun
vate
riag
▁60-
▁metop
lier
igid
▁158
=1.41;
uped
valp
▁carri
PRAISE
▁2.12
epatorenal
asured
<4
struction
ecc
<0.001).
▁Varice
MCI
▁acetate
armacology
▁enhan
benefit
acheal
lash
▁acetonide
▁generalize
▁cephalosporins
▁psychopath
▁tretinoin
-0.60).
▁EGD
31
iopex
paration
udent
inic
volum
▁(1.
▁cann
1])
=4).
▁Mep
▁MH
-0.96
▁chemotherapeu
]=11).
ferase
uncture
▁72%
hyster
arati
80).
tate
amoxicillin
▁unop
erative
oniaz
OAE
▁0.11
▁7.1
▁onetim
othia
▁0.96%;
-98%
▁cosme
elded
axine
imethyl
hig
emis
stetr
eak
ormonal
▁sutures
hil
onep
▁intraepith
phin
▁psycho
eberry
ganization
▁midt
▁hypnotic
edding
=11).
armac
rex
talian
▁hemofil
▁generaliz
<.01
▁curet
▁Classen
roughout
riou
olem
▁toothp
henous
▁3.8;
agia
0.44;
▁prox
▁1.40-2.09);
▁pyod
=.25)
▁biph
steopor
▁withdra
iphen
▁Sevent
▁Raynaud
ipro
▁285
▁ethn
trav
=112).
▁phritis
▁obes
trom
▁18,816
6.9)
▁150,
glyceridemia
stinence
▁cylinder
ometri
▁RSA
▁meperidine
tihyper
verely
]=8
▁preeclamp
bivolol
▁fluorosis
5.1
Ls
ariatric
mitis
=80)
WEE
▁oxycodone
▁0.08
]=0.2
Lit
-1.8).
▁medroxyp
▁schiz
etrial
▁hir
▁1.57
ublesome
▁transient
rosomia
▁rehydr
EMG
inolog
iopsies
▁fumarate
embers
▁adne
▁ASCC
eteroph
-57).
tipated
▁metat
rotide
▁2.7-5.
▁1.46-7.54)
▁trichomoniasis
▁14.
6%).
.0;
nife
veral
=14).
oran
-36
sychos
ationships
▁revised
▁hyperc
olesc
▁1.05-1.6
8.8%
torchid
▁lorazepam
▁0.21).
thletes
▁nontraumatic
▁metopro
▁Staphylococcus
neph
Ru
andmark
▁subsets
▁tubes
erested
culos
lexa
8,
erob
romot
▁(1:1:
otri
bly
=6.
▁acn
ucoc
▁Validity
inotrans
▁thromboc
ropath
▁morb
▁dosage
▁-1
▁PSI
369)
▁pater
mum
roimaging
-2.9
ortriptyline
ricians
▁1.8-19
orpor
▁PSA
ectas
iteria
▁Combin
curred
▁hetero
erning
▁Caps
▁uric
▁lymp
ropathy
▁1.00-2.8)
▁-1.6
▁lavage
SRIs
409
irtaz
▁Cure
unblinded
<.03)
rk
▁(50%-9
ecl
▁20-45)
miz
=.00
▁(1/
▁Valsartan
▁birthwe
▁(0%
▁elimin
imitation
entrate
urett
▁0.81-1.0
▁sildenafil
▁entericcoated
reatest
enoh
ndex
▁0.23-0.4
unadjus
▁0.13-0.3
pharyngeal
437)
▁unsel
beros
jun
▁intravaginal
▁Fram
▁bup
▁14,
▁mobilization
=90)
azepine
9-1.
iasis
▁Testing
▁itching
▁cyc
onates
sophageal
dized
▁(5/1
hul
orou
▁menorrhagia
gulation
▁1723
therm
=93
▁0.67
▁definite
▁bivariate
-2.22
ternally
305
▁adherence
-10.36).
▁2.06-6.29).
▁gat
▁stres
utritional
estants
2000
albuminuria
▁anemic
▁atomoxetine
▁cleanliness
▁indicat
ranolol
ackage
▁nebivolol
sti
uox
▁methyld
riptine
▁10.4
▁2.3
▁uptake
▁NSAIDs
Crocus
strum
ormality
▁Litt
gressive
▁Recommend
cially
erad
2.3
05).
▁methad
]=0.42;
=3.7
4.6%
zop
invol
ilade
phal
▁0.3).
▁sild
▁vancomycin
/12
▁constipated
957
valuations
ystatin
▁hyperb
▁0.86-56.89),
atestic
▁2-
-8.0
78/438;
ichloral
maryl
▁0.04-0.20).
lexx
66-10.6
▁15%.
roids
▁5608
ortality
▁41
4),
▁dox
exer
00-12
▁unscreened
vative
▁2.21
aigh
▁beclomethasone
antibodies
abiliz
ardia
.00
297
accurac
odies
▁beha
▁consc
▁conception
▁DMAR
▁venography
▁fas
dds
▁PDSR
osartan
ifene
erving
umerous
42;
▁leas
ecif
tious
ovaginal
centered
aldosterone
cetamin
▁remis
sati
relaxation
▁70%
10-3.7
▁0.70;
8%.
oem
enati
▁exud
llular
ualiz
▁consis
▁ocular
-0.20
timulants
▁insoluble
utu
5.0%
▁(3.
bA
estim
ollec
idat
>4
=2.9%
▁0.6-1.
▁(>10,000
▁etretinate
01)
▁80%-9
astati
romi
▁(12
ndf
▁44%
-1.7
▁biweekly
=.26.
▁20.2%
etor
▁Adoles
lec
▁sai
emoph
]=3.11;
▁abortive
atified
ubitus
▁60%.
10-0.5
▁lipophilic
▁VTEs
lowing
creased
▁allylamines
uinal
▁Expressing
▁compu
:30
orbidity
akness
5]
anism
▁ketorol
sant
▁percenti
romes
etop
4.1),
urit
tigated
▁WHO
▁lengthin
lipidemic
▁0.78-1.58).9
lip
=136),
4-0.73)
2-9.
▁18,500
▁5010
-1.63)
▁endart
▁23/
Ri
endency
1).
▁serologic
▁-50.89
hibitive
▁cefi
went
ogas
ptive
2,684
▁(500-1200
-2.99;
sop
ducts
ilus
lactating
ndy
inidazole
▁dieticians
tinuing
▁Raloxifene
organisms
▁ranged
=637
anic
▁247
-98%),
▁triamcinolone
/68)
▁antiseizure
otonsillectomy
centage
▁fulminant
=1.30
▁ultrasound
▁18.
chlorpromazine
imot
93,
chann
gestational
▁hamil
▁1)
-2.54).
Hashim
▁Carolin
=4;
vealed
laying
-0.97;
3-4.5
▁benefici
-50%
opulation
acting
adiologists
hula
▁0.56);
-2.1).
inag
▁acet
▁Bayle
▁3300
406
odone
▁sulfis
isoprolol
weden
hydroergot
471
▁belts
▁0.03-0.
Bactro
▁0.67-5.
umbered
>.05)
]=0.06).
▁5-2
idities
▁biwe
▁evaluat
▁70%.
▁vulvovaginal
ultr
700
▁<8
ondyl
▁pneumococ
▁blot
▁misdi
yphen
00-8
quip
great
edin
ransient
▁ibuprofen
illar
ometheptene
resch
elic
attern
nition
ieving
▁miscarri
0%
▁96%,
onment
rised
▁kneel
enid
▁summ
=180
▁1.42-
002.
dural
xor
ELT
3-8
RCT
binate
5.8
stetrical
0)
ersensitivity
▁electrocon
mined
121
▁pyel
uish
▁1.02-1.2
Morbid
▁epst
fis
=2.0-2.85)
mastine
▁tread
▁1.35-1.78)
▁ovulation
▁herni
tutes
matory
enogr
ticoster
▁Genital
arenchy
▁88.
▁pree
bou
roate
ticle
otec
▁anesthesia
▁1250
ritin
▁0.23
▁nosocom
▁Adherence
▁contraception
inion
▁multin
idstage
-3.8,
hic
39%
opment
aminases
▁toi
▁cromoglyc
▁IU
▁aspart
▁(70
▁nodule
ffere
converting
▁6.2%
▁Eliminating
atency
isor
=0.85;
epten
rimazol
▁dementi
seizure
20
▁20,536
ISA
▁Thirty
aride
▁Synvisc
▁Treating
gnant
▁2.7%,
entax
▁1477)
=2.04;
acin
▁PMS
=83%,
▁24
Trim
=.031;
.5
▁assessors
▁psoriasis
▁(0.6
▁65.
strate
izure
roved
▁correlate
cleared
yocard
750
▁ejection
sill
rimental
▁dipyridamole
75)
lood
▁8.3%,
irations
▁capsa
▁>32,
ptiv
ificiti
lderly
▁2.41
74)
▁incar
glucomann
eliri
inuria
erpl
▁abnormal
▁35-6
▁Computed
resumed
▁hyperg
ayo
altep
▁(100
▁juvenile
▁triazolam
peci
▁crusted
sych
butrin
▁2.6-4.9]),
3.0
▁(20%).
erability
verw
Lut
▁unil
lve
▁statis
▁expir
iazolid
▁270
▁DCAs
otherapeu
-1.6;
▁medicines
▁0.57-0.93)
▁inpatients
▁Varico
▁backgrounds
▁0.6-1.9
▁29,
▁fluoroquin
otam
▁benefited
laq
aucasian
ths
▁Thir
▁terbinafine
bitis
oxacin
DCA
▁temperat
▁nebi
▁autoim
▁anticoagul
orting
3-1.40
▁33.3%
▁transcerv
phil
=.06
ocysteine
entation
▁(99%
22.
atiti
▁scro
oderm
trach
lant
timulation
▁ointment
▁Combined
▁2.5-4.8);
umarate
oit
Sin
quam
▁bronchospasm
8.1
▁noncompliant
-0.99)
addell
uprop
▁64-99%),
▁151
▁3.79.
51%
=0.05;
▁budesonide
▁5.6
▁lisin
26.17),
▁carriers
thmias
ulfox
1:
chang
stl
▁0.78-1.5
▁normaliz
-74.
entam
▁gums
NHAAP
8-1
▁adi
Pu
listat
=43).
interm
alb
opathologically
204
roat
▁fluvastatin
▁1.19
▁1.1-2.4),
timating
ationsh
▁luteinizing
▁overestimate
afety
▁(1.58-5.18)
▁<25),
riaxone
entar
▁pem
utoff
oiding
adac
▁wee
▁Nimodipine
odul
▁47%-49%.
ytim
onine
▁lact
▁14-3
▁14-
▁brus
=18.8;
▁1.4-101.6).
▁indo
▁-0.84).
tinuous
ultin
▁3.6%).
▁peanuts
▁Fam
▁numb
▁0.84-1.
▁gastric
▁overestimated
raphical
▁nonsel
oxid
▁6793
-15
roges
▁Bacit
▁tymp
erus
▁vesicle
carr
▁-5
▁(62
▁Ps
6%,
▁20%).
xtro
concl
▁Antiseiz
▁intub
ulcer
▁ketoacid
▁amplification
▁hydrop
▁Vanderbilt
74;
=2.09;
reatine
embol
▁0.97
-33.0%).
epw
▁saphenop
ipoc
▁deficiency
▁<23
▁63%,
▁antihist
operative
▁92%
▁1.56
▁Thes
▁340
▁intrau
▁-7.
tinuation
▁preceding
enosis
▁bupropri
569
opat
▁1.68
ostomy
-0.61).
▁transferrin
▁maneuvers
8.4).
27
operatively
49
asthmatic
odiaz
]=3).
▁Progesterone
edative
▁4.8-13.7),
▁solitary
vuloph
oos
itioning
▁arrhythmias
▁Intrapartum
.3-42.
▁unwant
astas
▁Myc
▁anticonvulsant
enation
▁Fractures
ticulous
lyce
▁1.02
=1.94;
▁25
1.3%).
=5)
▁1.95
echoc
▁indus
tranasal
▁12/1000
▁Swed
orenal
8.1%;
▁lumen
eant
ophary
ilure
▁24,
ofiltration
▁25.8
▁hydrochloride
merc
▁levod
arnett
▁alp
ritable
ibrozil
-1.12),
tensity
▁>16
▁0.14-0.52),
utoanti
edl
▁sulfasalazine
Ost
▁(5.1
▁9.
othiazide
▁cefaclor
▁2.21-14.5
ictims
▁(>9500/
▁nonsol
contain
-6.5
▁ofl
olg
▁scrotal
4.8
▁provid
aros
ymm
hically
,133
▁inflixim
▁incu
▁(114)
moderate
dotally
vations
GERD
ewb
▁2.5-8.
▁eith
avastatin
9%
▁DVT
▁(28%),
glycerid
▁aden
piratory
▁Antagonist
=0.65;
▁sensitizer
▁Adolescent
▁0.77/0.
ocervical
valent
asmoly
andomized
▁ferrous
efloqu
▁ecz
acental
▁sti
lH
▁-23.21
▁sometim
orta
81
▁antiseptic
URB
▁0.4-1.6
adual
nol
microb
▁Endomet
▁Prevent
=.0015).
estioned
▁digoxigenin
=14.
ulopathy
▁skinf
03
▁paroxysms
Nit
5-0.71;
109)
373)
▁vulvov
gestion
=0.5%)
oxify
ildren
▁0.04-0.7
▁HBs
7-9
=11.7;
romycin
posable
▁heterose
▁10.4%,
oglitazone
loro
▁ductus
▁Cheilitis
ympanos
▁scre
▁2.5%
▁38
/108)
▁NPV
rusor
rano
▁2.1-1
▁Bish
▁endos
oung
sthm
▁22%
▁counterir
▁(<
-0.4
▁enemas
▁0.43-1.
=5.1
▁predicting
▁corres
histamine
▁differenc
▁nedoc
▁19%
▁(0.55
▁cautery
▁237
▁430
▁elliptical
▁ABR
▁diabe
olger
ichom
▁prochlor
▁0.40).
foll
▁tremor
▁-0.28;
▁thromboembolic
]=13-17)
,790
oliti
▁Parental
roi
▁58%
horts
▁hypothetic
olick
siv
▁usefulness
▁antiox
opus
▁pharmacok
▁1861
▁1.15-3.
▁stokes
isad
Nip
3/0.
▁ruptured
=689,
▁17-23).
▁methotrexate
65).
atrial
▁nondiuretic
ocic
bility
indolol
▁copp
atisfact
=.0004;
sone
738
alar
▁0.44-0.9
centi
rG
▁47,1
▁enteric
arithromycin
exy
▁Mankop
96;
▁emul
anthosis
▁menis
excell
matur
gophony
▁79.
▁iat
yldopa
ermination
▁12
▁methodologies
▁diverg
-0.96;
ffected
▁13-2
8-0.7
ferases
89
▁Combining
▁sulfisoxazole
versally
uterized
brom
elstein
uresis
butamol
▁4.32-5
▁tricyclic
=3.43;
22,012
▁phos
ducer
kne
reness
ioplasty
]=-20.43
▁Inform
▁Acad
▁methadone
ulon
▁precis
63
87
tension
▁proteinuria
▁Screening
41)
▁presoak
▁neurorad
iag
orith
ymptomati
luence
9%-9
azapine
▁ori
mok
▁(-0.2
▁598
retage
▁adenopathy
actat
5%),
▁descriptive
-3.35)
ulia
▁exhibited
=20
antr
▁epididymitis
▁(10%),
▁0.05%
▁saibok
▁scann
thrombo
robial
64%
chemia
-92%
▁impai
sit
icco
SGR
▁0.30
9/10
tism
rounding
espite
viation
=96,1
▁30-
72;
▁overweight
▁trich
▁exposures
▁111).
ystitis
/109)
ardias
▁boxers
ffinities
▁16/207
▁Clinical
lingonberry
▁fec
thep
▁sedimentation
▁bees
▁Nyst
▁24.
▁Surve
ticulously
▁discharge
▁255.
▁Centers
▁paternal
ymphoc
tolic
rimester
nly
Wen
▁Barret
▁(34%-49%).
4.8)
achie
▁labial
reating
erapists
▁Melan
▁quintile
▁encomp
ardiz
Mor
pment
-52
zid
▁valproic
=60
▁<1.
96%
depressed
▁equivalently
▁lacked
▁<10.
sychi
▁adren
▁delin
cill
ximab
arri
2-5
yoc
onorgestrel
=.
phen
lied
itonsill
etable
amaging
ecretory
▁3.5-4.3)
▁synovi
ifican
6-1.30
29;
availability
▁dichloral
ifen
otransfer
hydrase
atoxic
eliver
novi
▁abbre
resti
Nin
,816
abdominal
▁isoniazid
onduc
tussive
ourteen
-89%
▁ASCU
uppression
thma
iplinary
▁digoxigen
]=0.39;
▁socioeconomic
adol
racin
upus
▁0.38-1.33).
=0.18
▁Instit
▁12.5
treat
=9.0
▁(56
22
2-1.2
bolism
traven
othp
▁chamomile
▁3.0-1
▁(38
enofibrate
▁1.80-5.37),
lerate
▁Tann
/0
12).
viron
ospor
=3.17;
vidence
microbial
▁endarterectomy
armacologic
lusive
ventric
▁indef
clavulanate
▁Pregnancies
▁MEDLIN
otrim
asot
-0.2
ichl
epth
usiti
erce
xical
▁2000.
<.
enzod
oplacental
udited
mpair
NHANES
▁hereditary
4.3%
▁hypoglycemic
Prozac
=52%.
▁0.95
▁(0
]=8),
▁scor
gues
▁protoc
55%
▁medically
▁(33%).
▁curret
aftin
▁fibrill
▁43%.
iotens
Dur
▁sequentially
▁3.34-6
urrently
8.5).
▁SMT
Rand
pom
4-0.74).
▁1358
metin
▁1.26
▁0.45-0.71;
▁offs
ucon
▁Likert
▁(42
elan
▁16
▁extratesticular
▁concentrations
Oth
anif
▁hypocalcemia
cataract
▁(<25).
▁Atlay
▁1210
▁Tenderness
▁Reduction
▁upd
edures
▁clarithromycin
▁autoantibodies
ercept
antity
ioav
▁fulf
▁20,5
uerv
153
terr
ulsive
▁Lon
▁68%-76%)
▁unsuitable
▁837
▁transcription
blocker
Spor
▁lisur
▁795
genism
olore
▁chan
redom
▁exclud
22%
tiap
▁nocturnal
afibrate
▁formo
epar
5),
ndro
=0.99
ller
Hos
bograp
ystos
onj
therlands
▁1.72
pout
▁bouts
▁modeled
ameters
▁abou
thosis
ephropathy
▁cysts
]=12.
▁prelab
orsening
liz
rth
▁acarbose
▁doxaz
rousal
6-1.30).
ussion
▁pois
▁pruritic
=52%
▁20%-3
romal
-]=0.
totreat
]=2.72;
▁diminished
▁remin
ynvisc
▁heterozyg
▁neith
arbose
▁popc
lome
earches
▁0.01-0.4
▁(4%)
rini
IUD
echan
▁irritable
▁nortriptyline
▁<70
▁oflox
ipec
▁0.65
elev
.5.
▁ques
erb
edications
ugent
6,
thes
▁hypoallergenic
▁40%.
▁Cryotherapy
confusion
▁0.12-0.9
1)-
enef
overall
ewest
valuate
ygen
▁Coch
1-14.
luding
▁(9
▁iatrogenic
ervational
-1.54)
▁polyeth
▁1.5-6.2).7
ukoc
70%
0.9)
imens
couragement
gasmic
agulable
=176;
pith
ecies
▁demise
iminary
Prin
cne
▁flexor
▁Psychiatry
82;
atistic
=1.44;
▁256
1-1.
=-57.
<.1
▁0.10-0.28).
onres
isone
lemental
▁RENAAL
▁breas
ephritis
opar
lows
alonic
yon
abial
lexed
▁hone
▁Egophony
respectively
▁tolm
utable
▁ketoacidosis
onac
4.3)
▁betameth
edis
enital
alazine
▁(4%
ropat
▁2.1-3.
tally
▁insertion
91%
▁HL
=13.7
usually
=.027).
tentially
▁TP
3.8%.
scha
etformin
kep
▁melan
1,
▁gua
064
▁multiv
stetricians
▁1.62-2.
tish
▁(122,
ypn
▁189
ovir
ademy
▁Pregabal
▁lactob
endron
=89%;
▁throu
▁ves
▁tabular
▁0.01-2.92)
]=0.54;
ecurrent
▁polysomn
luenti
▁endog
sychop
etal
▁3.9-10.
▁prescribing
2000.
▁saliv
ocyte
▁nonmilk
elsinki
=0.66;
36),
orpore
▁-0.7).
ruciating
vors
58).
▁17.8
9,405
ffair
LDL
▁Breslow
,00
▁perit
▁sprink
▁unex
▁aggressively
▁(42.
amethoxazole
Prinivil
biphasic
aflam
ueti
▁urticaria
▁Forty
edback
ophil
▁infrequently
▁cuff
▁nonri
▁=.0025.
amines
ethop
munog
ghout
atholog
▁prednisolone
curren
▁5.2),
45
tch
TEs
6.2%
▁evol
prohibitive
till
▁2.9%
▁illnesses
-=0.14
▁infrared
Hashimoto
▁yielding
▁0.7-0.9),
lafen
▁lutein
▁comple
▁modality
3-0.8
▁hypok
FEV
▁attainment
▁colleag
▁thrombotic
▁aerobic
▁779,600
1-2.76;
▁Ramip
]=1.4;
▁rheumatoid
ffairs
9-15.8)
]=1.6;
elayed
enox
enaz
orman
▁coagulation
▁neuropathic
▁increments
-18.
-1.09).
▁histamine
rong
▁tonsill
eigh
0.1
cts
,6
tigations
-1.2).
enom
ourish
estional
▁lymph
ranasal
24,
▁30).
▁(25%)
▁1.10-2.3
▁-5.27
9-3.
▁CALM
copic
▁adol
eady
excellent
4-0.99)
▁20.2%;
osom
▁Hyst
▁inade
Hyp
ediatric
valuat
84
▁podophyllin
▁countri
▁lipop
ipat
reatly
inu
18%
8]
▁immunocompet
▁EIB
medicated
▁Consequent
<.0001).
▁mL
▁pharmacy
.0025.
▁secretagogues
▁Wals
veal
-0.98;
luv
▁compla
-21.23).
▁6.7%
▁0.24,
▁(5%)
▁1.2-2.
▁saibo
▁12.4%;
xtr
▁stimulants
▁trichlor
5,8
Cen
esiz
▁docusate
ryop
llation
embolism
enstr
vents
26.
697
especi
▁arteri
esqu
▁postm
▁(500-12
▁0.06-1.2
idate
▁182
▁3.54
▁cauter
▁(77%
elical
terim
▁piog
▁glycemic
8-2
oxin
udates
-3.41);
▁conservatively
bonate
wes
▁cholest
▁77%,
Gh
▁exce
primarily
PROCAM
=7
opecia
iffus
amol
enro
▁salmeter
ruptly
ranber
5-0.94)
▁dexterity
itant
them
▁dysrhythmias
giline
▁0.48-0.94;
UPP
Mid
onstrates
▁-0.52
=92%,
idazole
▁(45%
▁deficit
▁Risedronate
818),
kinf
▁hydroch
▁20
▁bilat
1.3
=409
▁0.78-1.58).
▁buspirone
achman
lebrex
▁PID
▁abdomen
▁aml
▁attem
vascular
▁assoc
▁hydrocor
dwelling
=210
▁86%,
▁(3/
▁undere
cement
prox
]=4.5)
▁40%,
▁heavier
]=11),
▁adjus
2%,
▁characteris
▁(>
analyses
10).
▁22)
▁(77%)
plify
▁incarcerated
94),
▁tetracycline
▁2003
DSR
▁(35%-5
4-0.6
insertional
3.7),
tandard
▁1.12
▁87%)
▁regres
ecro
▁CRB
▁>10%
sens
stress
▁hypog
▁Limit
enign
enzy
▁tracked
3.4
nif
▁4.3%
fus
gents
▁diclof
▁61%
inam
oprostol
▁speeding
roch
▁ruptures
▁(12.6
▁murmurs
▁1.6%
uracy
opos
odest
inan
▁moth
efs
ocomial
▁confounding
▁CAL
-50%)
roac
PDs
▁scarred
odds
▁95%)
▁hypoxic
▁>30%
<15
oys
omethasone
litazone
INR
oriatic
gular
▁electroac
▁paradox
idality
▁levodopa
▁simplifying
waiting
▁psychosis
▁basing
▁imprac
elay
▁22;
▁morn
]=1.01;
▁21%;
Vasotec
-1.94).
▁Imipramine
arials
ightf
▁transth
6.6%
trospectively
rbesartan
▁8.28-20.6).
tum
ayers
▁cip
kwheat
disc
▁1501
inom
▁standardized
eck
gnosis
▁Haemophil
antit
apam
▁perioper
race
▁diast
▁plaqu
▁Subsequent
ariz
=1%;
enteritis
iclofenac
▁grouped
tiq
7.4
▁ure
▁whoops
ermint
bined
▁griseofulvin
]=8.4).
▁referrals
▁Stopp
▁5-
▁68.
▁intrauterine
▁pathology
▁Mediter
95.93
acerbation
cessful
2.8).
cob
rorrh
ismuth
▁earlies
▁91,561
perazine
ontr
idur
4.7)
▁Histologic
▁(7%)
ycolog
-78
ilirubin
▁benzo
emoth
tinop
ypoc
▁nonhyper
assic
-0.7).
▁nonspecific
aryngop
Nine
ipening
▁anembry
▁293
igrans
atric
estol
▁Depend
igmentation
▁3.5
▁>6
rhythmias
▁prescriptions
6.97).
▁Relative
imination
<.0007,
▁primiparous
▁teratogenic
=-5
ralf
=.94),
estre
BV
▁Gluc
obic
935
eced
3.6%
jective
▁transpl
▁investigat
ourag
▁cach
6)
▁postco
=50)
▁1429
-15.0%
▁disclosure
▁7046
▁ane
▁genitour
romat
▁streptococ
VAF
iflucan
flam
▁Newly
ernal
pital
ventil
▁coughing
ubles
.0,
reig
eber
triglycer
▁mycopl
acerbations
▁dihyd
another
▁Lachman
▁Melanoma
▁disadvant
elon
2.1)
charged
▁benzodiazep
▁anticoagulant
aucasians
loride
xu
▁Apnea
sychom
uscit
▁3.1-1
▁ae
otransferase
▁0.9;
90
▁690
orl
-224).
7%-
iure
▁>45%)
iteal
kid
▁ratios
ulfidine
teers
-1.44)
ygiene
9.3%
▁choleste
▁3%.
-5.37),
aight
amis
ulb
reduc
HN
▁hospitalization
Mort
▁cog
glyceride
▁0.4-0.
▁hypocal
▁umol
▁psyll
▁0.71-0.85).
▁stinging
tharidin
thical
▁11.9%
▁tenoxicam
▁Imple
eride
-2.38
oscler
=1.41).
ptine
losp
▁endem
orations
eut
onre
omnogram
eig
kew
]=1.23;
▁meniscal
lephone
▁0.3
▁(42/1
58
-3%
▁metabolism
andard
certain
rotal
astatin
▁10-3
andial
32,
apiti
▁cryog
igorating
=110),
ewing
▁0.41-0.77;
=110
▁Toddlers
▁urinalysis
onsum
=7;
▁0.23-0.43).
mpa
▁orthost
21).
▁90%,
▁Vag
74),
▁47,
acted
▁targ
▁(25%
armf
2-6.
▁specificity
adruple
esat
oscopic
epakote
▁Unus
▁300-3
▁>6.0
▁uncontrolled
ibrillation
Rus
▁nonoperative
induced
ropsy
=4.87),
▁1.66
erfen
efits
▁improv
▁acup
▁pharmacokinetic
▁Abdominal
orti
pecific
vein
vated
▁176
▁McIssac
ressive
▁disturban
Nep
athioprine
0%).
lasty
▁27.2%,
▁1999
▁ablative
achypnea
Mul
▁stent
arterec
erol
2-0.98)
erop
▁antiarr
).4
▁fluv
yrid
tication
ecac
▁(14/369)
▁76%
ternative
dayclinical
▁11-88
10.2%
tory
occur
▁inhal
asses
▁cramp
▁ionized
▁dissem
opre
▁incorp
FCA
tiation
256
▁UTI
▁anomaly
nesses
▁ODD
=-2.
-1%
tire
azod
▁miscar
rhe
]=19.
argest
ildh
3.2%).
OAP
▁104
sulfon
yclical
lliptical
=10,000/
▁sonograp
instead
directed
ingin
▁carcinomatosis
PDRS
=0.39;
18)
=7.6
eteen
aturated
▁subj
=1.38;
▁ripening
▁inducing
=2.6;
5.1),
▁9.0
quid
▁5.2-8.4).
▁histam
▁oxyc
Gon
▁cyst
▁Cream
35)
yroiditi
ormin
▁(16%
oxet
▁0.04-0.16;
9.4%
▁influenzae
ativus
itoring
▁Institutes
▁specifics
ganic
5.8)
▁0.70
▁21
▁lactation
rogesterone
▁fasci
thw
cessive
▁nonblinded
elih
81.
within
Motr
▁(36.5
▁microen
▁antith
otons
▁inadequ
tisite
ndere
loth
opalatoplasty
opathological
-0.8
7;
▁444
▁postnatally
onococcal
▁pathophys
▁(50%)
ircum
▁414
▁dau
▁38%;
▁unk
▁autoimmune
lator
▁radiograp
resectoscopic
▁medit
▁practiced
▁inhibitory
olerance
bog
▁antiretroviral
▁stenosis
▁Americ
▁Twel
itidine
somn
▁temaf
oac
▁fung
▁Preven
▁9.7
oub
▁chills
▁Coza
▁(2.9%)
0.70
ods
▁microwa
olit
efol
lid
ectional
]=2.
▁neuropathy
▁Manipulative
▁microvascular
]=7
onuc
▁0.63
▁underes
▁unrec
▁bisoprolol
▁2763
▁obesity
-5.3).
hinP
▁granul
▁Statistic
-2454;
lamines
-1.95)
<.0001),
ROCA
reaks
ipram
biotics
icell
iagn
▁pentox
=11.
osoc
▁>8
▁0.76-1.30).
elecoxib
hasized
orres
ransv
6,790
▁Adip
thod
ilden
dly
onyl
900
▁twof
reates
osures
Ep
▁1983
▁66;
▁0.40
▁Cough
oplasty
▁824
2.1
thad
antib
PCR
▁Petersb
▁obstetr
▁1.01-2.7
▁1.63
▁0.36-10.
▁alw
igric
invasive
opnea
vide
tivities
▁0.19-2.3
▁<60%
▁nef
uret
▁atyp
ogl
riath
rater
ewer
olor
atec
stres
-14
▁contracep
lavic
▁traction
=.04)
6.1%
obin
tensi
▁metastatic
▁11,42
▁venti
▁0.013-0.063;
1,561
▁10%-50%).
▁postoperatively
▁rehabil
▁Paragraph
udg
ocused
▁(24%
sponsored
▁Drawer
▁antec
▁quin
▁stratif
intens
laint
▁Patient
udinal
▁informational
,880
▁insol
>7
▁preter
lthough
▁48
▁1996
▁(1.4
opharm
/6
tazol
22,0
66-10.
▁3%
proced
▁twent
▁39.6%
▁Antimal
]=0.5
voc
▁pancre
hydro
▁colicky
olycystic
▁pretest
odipine
7-5.
ceous
▁testis
▁saphen
tices
▁excre
ogies
▁poin
hypopnea
ectant
▁0.36-0.6
▁84%
752
▁273
deriv
▁0.99-1.34).
ulitis
▁preser
weightb
▁Adh
▁noninf
▁1.48-2.05).
ected
finding
▁42;
astoid
etamine
macule
▁hyperm
olicy
endoscop
▁20%
ilies
rofloxacin
01.
oiditi
methot
▁Factors
▁(278/
▁<150
cand
▁supra
Celeb
-3.1
kotriene
▁smears
jalain
▁antic
▁cephalexin
=1.87;
urologic
izan
▁inflammation
▁Trials
wth
uspir
▁triglycerid
dL
▁predic
benef
luc
accin
-3.3
▁embryop
▁295
ungal
=937
▁spanned
▁8.4%
90).
=2.16;
▁96%;
=274)
▁0.12-4.16)
▁kits
osalic
3.9;
▁ceph
chlatter
.4;
=.09).
=4.8),
yrib
▁nonsk
utein
=18,24
▁580
▁86%)
-85%
lamm
▁(55.7%
▁contradictory
09)
axim
IgM
▁(1494
mec
▁2.9-1
19%
▁amenorrheic
hyperten
▁flawed
<7
,22
▁roughage
=0.47;
▁epidem
esu
bral
▁alcoholic
▁(74%-93%
▁acti
-0.92;
urul
▁sulfonyl
ipidemic
abep
▁hypertri
▁restric
iseof
07
sitive
9]
omplete
▁airflow
▁164.
jury
arjalainen
entilation
gitis
▁preventive
▁53%
stit
=5).
▁969
oloft
▁(85%;
▁zaleplon
past
▁secreto
azep
cervical
▁modifying
cessib
oxi
pecies
▁28%-3
6-7.5
fici
Sporan
▁apar
▁expensi
▁Blin
roscopically
▁intestinal
ndones
cause
▁galantamine
.09)
reened
9-2.3
▁allergies
▁(85.
aintain
ounc
▁reiter
▁29
bating
▁theo
Ral
▁1.19-7.
▁accessibility
▁CBT
▁surrog
masteric
tional
generation
timat
▁25.84).
▁indefinite
▁synthesized
▁Alar
onu
▁diar
▁rehabilitation
▁bandaging
ethoxazole
▁surgically
topril
]=1.71;
▁midstage
lter
ucasian
▁interc
▁peroxide
▁-5.2
ocalcemia
▁salbutamol
▁portends
▁enuresis
▁800
▁0.4-24.3).
▁0.23-0.79);
ocyst
ogm
5.96;
intensity
▁0.70-1.09);.
▁misopro
▁cryptor
ividu
▁-0.5).
edent
inovir
▁voluntary
▁costeffec
xameth
immun
▁nonsmokers
▁TRIPOD
actob
eature
bosis
▁pean
▁retested
▁shaf
ectos
▁splen
<.14).
▁metform
ceride
5)
nias
henytoin
▁0.49
793
-3.03)
▁establ
▁699)
utoantib
-0.34)
definite
vera
▁reversed
▁abstinence
▁(<2
=46
=0.
▁inflate
ihyd
▁insul
▁midwife
▁forceful
adren
ibromy
▁Pneum
sver
vestigated
▁0.70-3.35)
retag
58)
<.0001;
utn
sac
timation
▁gastroenteritis
gests
▁0.98-1.54).
▁458
▁162
xact
▁procal
▁expens
▁ciprof
▁283
▁1.07-1.8
-14.9%
1,567
5-1.02).1
-0.5)
5-1.9
-1.90
roxys
vox
=0.60;
unded
▁congen
▁Osgood
▁4)
spectrum
3-1
yog
▁97.
pir
acute
▁ventricular
eab
▁budes
83
]=0.3;
=1.77;
▁ethnicity
ewh
<.001);
▁3.34-6.07)
▁419
▁menopause
▁enterocolitis
errit
crip
ocaine
counsel
▁eccent
▁comprised
ransform
300
▁clot
▁injec
71%
ycop
ovas
igorously
▁xylitol
▁cli
usag
anent
eem
xam
▁Infants
2.1%
wel
▁infli
▁thiaz
39)
31%
aminers
▁predn
arrest
umentation
]=0.22;
▁prednisone
▁benzyd
▁drip
▁-2.95
▁thrombophleb
=1
▁SMR
▁incontinent
entral
▁0.10-0.3
lith
▁glimepir
viou
▁3
=64.3%
▁evacuation
▁1750
whey
▁betwe
25,
xat
▁interp
▁Shorter
▁survi
tinguish
izoph
▁lith
umption
ocytopenia
relaxing
TSH
▁milder
Lax
▁Endometrial
▁pai
energ
▁3.9
▁1.40-2.0
yocardial
avach
ergency
umati
▁(32,
▁polyp
▁irrigation
ividuals
reatin
▁274
ublished
wk
agulation
alox
rul
faction
ternating
▁acar
▁tenos
ibro
28;
idesp
ocat
=5.5).
terp
xo
▁exacerbate
ripp
▁2007
pidemi
oracic
▁benzoyl
▁rhabdomy
▁irregularities
ticul
▁0.2-1.2).
uft
▁1.2-3.7;
omanic
▁sonne
▁14.5.
▁Nit
onance
=18).
,608
endence
▁inflamm
etazol
▁(36%
oxyrib
62
▁47,150
ampl
=27.
Eig
urmur
▁manifestations
▁molecule
ciuria
▁examiners
weighted
▁Infection
icare
ormaliz
ptococ
-41.8)
▁0.97-2.3
=68
istency
▁0.75
romaz
Lact
▁89%;
0;
ean
llet
retro
ossa
romb
glucosidase
]=0.82;
▁electrosurgery
▁incubate
▁hepatitis
aramycin
onucleosis
nowl
▁unscreen
23;
iewed
▁thromboses
▁wi
Ds
Pravach
▁Aler
longs
▁malaise
=3.77;
5.1%
teron
▁Cyc
econazole
▁0.4-1.6),
=2-3
▁0.57-0.82).
▁(41%
iscal
cus
ommun
Wis
▁chemoth
ropyridine
99.
▁pathologic
itively
▁neurogen
compr
aryngopal
confir
▁Osteoporosis
▁neurobiological
▁antiseptics
ferr
lococ
▁0.70-1.23),
othyroxine
1)
▁popcorn
▁atropine
▁<30
▁montel
▁>3.
▁phenylpro
▁IB
siti
xen
oed
otland
▁SSRIs
▁77
lyte
IDD
expressed
oniasis
▁1213
▁awakenings
esw
onverted
▁0.45-2.
▁(97%
▁lactobac
▁0.70/0.95,
bod
▁0.60-0.8
rogression
chiop
▁Tender
▁2.9-6.7).
▁methodologic
▁221
▁Cogn
▁(7%
▁digox
▁socio
▁coenzyme
▁cervical
erange
7.5
▁retention
▁235
5.1%)
2-1.0
acuation
005
abetic
oce
<.010).
▁colorectal
ellation
arting
elu
▁isometh
=2.32,
bulation
▁crosssection
▁stricter
▁tog
▁eti
-65,
estan
erapeu
▁sucr
▁rhab
urosemide
▁testoster
citalopram
2,0
=93.
▁alcoh
▁antid
rinologic
,7
umented
ereal
0.9;
▁0%;
SMR
lorth
=7.9,
▁deri
▁0.4-0.9),
eatoma
▁testosterone
▁LD
iol
0%),
▁CG
omat
50%
]=0.23;
▁0.05%.
stric
atastrophic
xers
8).9
▁cital
▁Chlamyd
▁spirometry
▁dipyridam
▁ACI
23.
umura
▁identic
ymp
-23
▁3.
<.01),
phor
asur
▁Asi
llowed
=12.8).
alicyl
-35;
▁nephropathy
▁99
niver
ulou
▁0.66-0.9
33,
onucle
engo
particularly
▁Hamamel
▁32.7
rans
▁Smoking
andatory
isterone
▁Metoprolol
▁underestimated
▁antipy
5%-9
▁3.0-19.
ysician
doster
▁Subjec
=.045;
▁(43.2%).
▁postin
▁1.36-2.2
▁2.25)
seiz
52.66
sicle
atty
udies
82%,
inediones
abolic
▁prognos
▁amiloride
ommend
convention
ospitaliz
cesses
5691
cyt
4-
paz
bose
urea
joene
▁targeting
1-1
▁1.38
58-5.18)
▁344
▁25%;
ertil
4-8
boov
8-0.8
3.3).
▁sterc
hydropyridine
▁coitus
42
istory
hod
6%),
9/188)
370
-0
aic
Gy
-2.74),
▁nonblind
▁SABAs
veni
▁31%;
▁ergot
▁newb
▁16.1%
igaret
itamins
▁ack
3-0.2
omnography
eswax
▁nonsurgical
▁11%
▁4;
inuri
=8.3)
▁suppositor
▁(9%)
67%
▁Insoluble
▁-12
▁(>14,300/
▁argu
▁socioec
>5%
ylm
ronchoscopy
▁1.2-14.7)],
emin
aternal
-245
12),
▁atopic
▁nimesulide
25.
▁1.29
.0-
lammation
olat
tribut
ertus
mpicillin
▁lozen
▁longus
<0.05)
▁1.5-4.
inoc
▁90%.
▁practi
agulant
▁nonsur
▁preinjury
ressin
90%,
-93%)
▁1.52-9.
letes
▁communic
▁pillows
▁internists
Altace
▁gastroenter
eos
▁effec
▁13-20
▁fractions
specificity
3.6
▁taper
venou
ariates
xet
▁Depression
▁beats
pharm
▁linearly
/0.89
apering
ecture
▁179
6,80
▁births
▁ons
opri
yses
▁respiratory
<.0001)
▁medrox
-3.5
-97),
dic
-2.36;
fet
=2.08;
▁rigorous
throm
▁econazole
4.6).
54).
▁144
▁(33%
▁uv
▁coor
▁endoc
▁recommends
anu
revi
ourth
-54%;
FIRM
▁1.38-3.98)
cere
otonsill
anaz
lebographic
pog
Ai
thri
hospital
positor
quen
hyll
atars
tratified
ectin
oconstr
hyd
▁ultras
NNH
=3.
▁0.71
=24%;
7.0
▁0.2-2.3).
Morbidity
▁spasmodic
▁(80%;
=0.71;
.0-2.
▁morbidities
▁diets
regn
▁endogen
▁neurologic
▁Butenafine
=63).
▁6.3-41.4).
▁sprue
▁3.0-19.5])
tural
▁(14/36
Tolectin
▁warr
=13.
feron
84%
mated
3-0.19)
atati
erably
▁vitamins
tatis
9%-4
▁glucocorticoid
▁2.03-2.7
aminations
▁aspec
=1200
studied
▁chorioam
2,47
-0.5
mpro
▁antibio
▁Incis
Hig
▁ned
=3.3
quival
tist
uretics
4-0.5
▁testicular
▁aripip
4-0.54).
▁Penh
brel
azaro
4.2
isapride
]=2.85,
upi
rhea
▁toil
▁erythem
mall
ublication
▁microorgan
▁0.013-0.0
zaf
eati
ulomas
uthyroid
▁impulsive
onp
▁malab
ainag
=10),
▁1078
▁Aerob
murs
prothrombin
osynovi
oches
Lam
]=25.9
roalbuminuria
uaifenesin
onh
ircu
▁influenti
ritish
(2
Risk
=44
▁bradycard
teroscopy
▁0.43-2.1)
arental
tinopathy
borrheic
continu
▁-0.5
▁biop
03%
▁obstr
Ton
Bow
erog
tician
▁orgasm
=2.7
▁multid
▁dilat
,52
owering
respec
▁excluding
▁Terbinafine
17%,
98
▁52-1
hild
tioned
▁50
▁62
▁prolongs
▁Depending
▁Likelihood
oxap
ucer
ylureas
▁Subjective
▁sensitivities
idr
metazoline
▁adhes
ofib
▁1977;
▁tantrum
kth
3.
dence
▁MCV
▁(58%)
trates
80)
=1250);
ightn
itou
▁correlates
=3).
▁VALUE
cIs
ainst
erbal
=1.5;
permint
-88
▁chlorhex
▁endogenous
intestional
catar
,92
▁2.1-3.7).
▁68%-7
1-2.9
epezil
vels
427
opausal
illus
icens
▁surp
▁hea
66;
pou
reu
22;
cisely
▁transmitted
▁(12.5
▁colonization
ransth
owl
leuk
▁sucralfate
▁brainstem
reathing
▁Resol
▁progestogens
▁threef
▁psychom
iltration
▁imple
▁expectantly
▁induction
▁infections
ollic
▁20-57).
▁42,44
▁calcification
▁DEE
▁(2.9%
Veter
NSAIDs
▁0.86;
▁37%.
ischemic
▁nosocomial
=5.7
▁ASCUS
▁Toler
▁15.
▁posttussive
▁pyrazinamide
-0.81)
▁(=
▁posttreatment
sistent
▁indome
▁nebivol
▁perimenopausal
▁Fir
▁Fet
tact
tite
=125)
▁rGH
apled
=93.8%.
enectomy
chidism
▁16%,
▁749
▁65%;
▁Pregn
inkel
osteroid
choth
]=1.37;
cce
iopath
mogr
omain
▁Surgery
resect
zhe
toch
▁fumar
01;
▁inhibit
▁46%;
▁Overf
-1.09)
▁ancestry
▁56,
assro
▁glim
trog
disciplinary
arbohydrate
Dut
classified
▁indomethacin
noth
000.
iating
etopro
=116
▁Alert
7.8,
inities
ooling
▁trichloroace
▁splin
▁sterculia
▁99.2%
ypas
vuls
▁5.
thalidone
=2.0
▁muscul
atical
▁hin
opidogrel
Remicade
Dif
tro
emicals
mput
Fro
zuelan
85;
▁1731
CAPS
Hep
2-41.
▁Metformin
86.
onstrate
behavioral
entive
41.
thysterectomy
ogic
▁Chronic
▁152
vulsant
heral
▁>19.
▁(500-1000
aP
▁71%-86%).
▁1991
rogest
ripping
gab
▁streptococcal
▁500,
▁persists
▁Resolution
5.8;
▁leukocy
237
]=-3.
▁HDL
▁111
▁Unusual
▁Targets
▁52.9
artm
arder
▁81%
errant
3-19
▁78.
▁fla
/324)
▁40,233
▁Douching
Gastro
0%.
LSIL
▁ECMT
▁hypermen
▁appendec
▁48%.
▁(5.7%)
tav
6.2).
thick
amined
roxyp
ftin
othal
▁-0.7
ocalization
▁reflux
6,064
-4.20).
▁serone
▁interrater
▁Enal
▁thyroidectomy
uising
▁-4.5
ailu
▁interle
inod
oan
alc
▁Blinding
78
▁ketorolac
91;
acervical
▁0.07
.0%
▁0.49-0.
athyroidism
endons
utom
▁indi
gA
▁200-
▁4.8-13.
upture
▁cisap
▁5097
▁anh
aintained
▁cotrim
▁Iberog
▁1.31-3.32).
rillation
▁64-9
▁aq
vestigat
urettage
▁splenomegaly
eric
accharide
▁165
▁(1408
6-2.2
▁Calc
ticulocytosis
▁chewed
acou
▁dul
Lymp
▁(75
rast
.09
reases
▁Gav
▁ventilator
▁5%;
anov
]=5.3
inkg
0-
inatal
▁0.29
▁sacrificing
▁montg
convulsive
mur
▁ove
▁netw
ults
▁detectable
▁10.
awback
▁infliximab
▁exacerbating
6-1.2
atly
▁-0.3
tenc
Sti
swe
ercis
7]),
▁Bisphosphon
▁2.4
▁jum
▁embolus
▁confirmatory
▁Nystag
tensives
▁fatigu
ohns
83%
▁shor
▁1.18
,536
ocycline
prehensive
▁postscreening
hia
▁hypercalci
▁infan
sth
▁stap
▁multinodular
olot
-14.56)
tran
ervative
▁interac
▁60%
▁urea
gely
cB
3-0.
)...."
▁(64%-81%).
▁hemog
=75)
tT
▁macrocytosis
enteric
08)
805
▁atti
iopexy
perin
▁ciclop
ectious
-3%;
6-0.7
-2.3;
56.
▁favored
uprof
erived
esterone
▁-7
nose
▁microw
24%
5-1.2
3-1.0
▁fatig
▁quinacrine
▁abstr
illary
▁metic
solving
PST
glitazone
▁expectant
9.96,
▁inaccuracies
▁0.02
▁anteced
▁(10/120
▁(86%
▁Fibromyalgia
▁Exac
toacous
mpic
iap
positive
illow
andinavian
7.09).
▁51.
thn
yzine
▁underac
asonale
▁fluor
enol
▁incomplete
atigue
ligh
▁5.11
visual
▁statew
▁atrop
oxers
ometritis
▁nonorganic
renc
▁(2.1%)
▁12%
▁0.23-1.76)
▁circumcision
▁bradycardia
LH
▁aro
▁88.1%;
cetonide
strab
veri
▁carvedilol
/8
ystere
▁fortyyear
inkl
NHAN
/2000.
]=5)..
▁phleb
5-1.
=31).
ndag
ositi
=37
▁mesal
▁Rare
rivastine
50).
elogram
8.3;
ophageal
ociation
ENA
siven
▁dexameth
ubs
orption
▁purp
ibs
▁Clofibrate
-11.
=.043
▁microwaves
3.1).
asten
iuri
▁pyelography
iloride
ecomm
ackl
acturing
anide
opoplite
▁ptsd
imab
4%-14.
.001
lob
▁112
▁EST
-5.6),
▁1.15-1.98),
▁tendonopathy
2-4
ffecting
▁28%,
▁1.08
pab
-57.6).
▁terb
asop
▁indications
ipit
rre
▁2.9-6.
nter
▁adolesc
▁minus
Tapazole
tentionto
odip
.005)
▁(24
-6.59
80
unus
▁hysterectom
erfenadine
16-1.
▁pulsed
▁1720
opathology
-16
97%
▁biopsych
aind
▁5.4-12.
lific
▁placebo
=9443).
▁mononucle
vile
injection
>0.
▁1.4-1.6.
▁chloramphen
▁Premature
rill
=135
▁physioth
osened
<.005
ifestyle
1-137.2
▁demonstrates
cet
alic
utinely
ollicle
▁systolic
oxicillin
rologic
405
verall
leas
30-1.
arid
ffec
▁(158
▁46,80
▁adnexal
▁0.82-0.98)
6.7
cephalic
unable
ansoprazole
calating
5-0.79)
▁subc
▁metformin
Tricor
atosis
▁subarachnoid
asound
▁metoclopram
▁superiority
▁surrogate
erythro
]=0.56;
ancomycin
hinPrep
chl
iotherapy
▁unplanned
07;
▁agglut
31,
=1663;
▁necrotizing
emain
▁abdom
▁soy
▁2611
▁sprinkles
-1.44).
▁Bacter
adily
▁lef
gine
▁forc
xual
sychoph
▁fertile
PDR
eresting
▁aberrant
vic
▁Levels
ickness
▁thrush
vitis
▁sple
▁edem
erred
▁swabs
trial
▁techniqu
▁3.3,
,-1.3
▁resus
CNBS
bohydr
▁transfusion
ibroz
timi
▁urologic
▁volum
Morb
lained
▁TCA
reastfed
innish
▁146
▁Austr
▁(63%
▁refle
▁antithrom
atitis
▁46%
▁Carotid
▁29,13
RAISE
utic
▁0.87-1.20).
▁miti
ysteroscop
ipants
▁medicin
▁Pn
▁pregestational
▁bicarb
-3.32).
Actos
oephed
▁quantit
▁purpos
ylene
▁cytology
▁9.9
8.9%)
▁norethisterone
▁sequelae
▁uncircumcised
▁Corticosteroid
eoper
▁orally
▁hyperch
▁cartil
omycin
0.67;
▁becl
▁-20.0
-0.97),
0.6
▁2.7
▁textbook
24)
romo
▁bioavailability
▁27.5%
.0]),
3.7%)
pap
ozy
reted
itnesses
trattera
orion
Thor
▁thrombocyt
7-1.8
acid
▁febri
=7.3%
iners
iog
▁aggression
]=5.2;
relate
▁weighed
=1.3-1.9
EET
Compazine
phosp
icycl
▁Tong
oure
▁Fren
▁outpati
.5).
▁hyperthyroid
▁Mycological
thp
▁2.1-11.9
mE
▁nip
▁71.
ubo
abit
8/0.81,
▁(54
Od
▁uni
▁27%
▁Bowel
▁epicondylitis
enor
▁18%.
▁137
▁147
acros
.50
▁microorganisms
6-56.89),
inser
43%
iovas
▁9086
radiol
dihydropyridine
tiqued
▁chlorth
elative
1%-
▁agonists
erestimated
▁confir
essation
▁240.
nin
stin
xtensive
▁topically
▁0%
osmol
9.5%.
=1.70
ulom
ranulomas
nre
▁0.51-0.89),
▁infar
▁exceeded
odiazepine
aridin
tral
▁prodrom
▁Improved
4.7%)
buliz
▁Effic
▁hemorrhages
▁840
▁0.13-0.65;
62;
henid
idyl
28).
omogr
ommending
lora
ilator
▁0.86-56.89
omial
cessibility
8.7
-5)
anaf
1.8)
,001
.9%)
mation
▁bucind
▁Vene
59).
06).
rofur
athyroid
yphil
▁citations
threat
8-1.33).
organism
▁LIP
wanese
cified
▁0.34-0.54).
▁preso
-33%
mep
efec
cinolone
▁hydroxyzine
=4
▁quas
▁ather
ossi
ranuloma
anan
▁clinics
▁40,000
yz
▁40.4%
58%
cycline
ecology
ypically
▁preparticip
▁neurotrans
▁(1.5
▁43).
gree
atifies
▁tach
troent
onable
▁glybur
42.
terac
isur
▁markers
-3.51).
ophle
0.8),
▁dysplasia
▁compositions
▁2.8-10.9).
ripip
▁(<15
▁detrusor
▁63.
surgical
=3057,
traction
▁wit
▁ibup
▁capsules
▁substanti
▁nondiar
▁sediment
▁variability
=0.33,
idely
▁flaws
▁prolactin
▁mebendazole
▁psychosocial
▁Farnett
acerb
orh
<.07
rolatum
hepatitis
excep
troll
=0.0
▁1.5-6.
ironmental
strogen
reast
▁suprac
▁pharmacologic
▁Manip
definitely
▁(21%
▁contamin
ulm
2/0.
agnos
anderbilt
▁simvastatin
▁113
▁99.9
ecreases
fax
▁0.016-1.7;
▁6935
▁4907
▁nonlactating
9.12),
eview
entag
▁(3/1
vely
drome
▁(49.
amelis
▁microin
▁pregnancies
roce
ractical
600
epin
eriti
alcem
chond
▁damaging
AFA
▁regained
▁insufficient
▁outbreaks
▁1000,
▁0.25-0.77)
▁nonoper
ooxy
▁0.12-0.77;
ioxx
ifenesin
▁chloramphenicol
efib
orrhea
eces
▁dias
9-1.3
Ly
▁shou
▁dipyrid
▁Omnipaque
▁0.9-1.
▁keto
▁Belc
70).
▁1.4-1
▁0.2-2.
▁47%-49%
anl
-17)
dere
elp
▁assays
ethoprim
▁traumatic
ecam
▁bac
oided
ALTS
reec
▁1.61
irsu
▁ionizers
enr
tive
▁uterus
ingdom
luen
▁lipids
▁779,
ixim
10-3.
▁fibrom
typically
▁777
enges
▁mI
4-0.
revoxyl
tiou
jum
pable
▁chas
▁stool
▁0.89
▁(60%-7
gated
ecologists
▁colore
munication
=23,
iton
0.43
10),
▁alum
21
▁eighth
▁Progression
-7.0
▁LRs
▁intracerebral
▁anomal
oclavic
mild
ightly
thic
▁endeav
oing
▁Milk
▁-2.78).
▁-0.8
]=0.3
measured
positives
abd
bati
▁glen
onit
▁favo
▁creatine
▁antidepressants
▁vigorous
▁0.77-1.1).
▁diverticulosis
arac
▁electrod
▁inqui
ulable
▁PTS
02
yearly
▁cephalex
▁encopresis
Ey
▁356,
cough
▁(60%-70%),
▁Isch
▁0.23-0.6
▁1140
opidine
Fam
teras
▁Cochrane
▁contraceptive
▁476
▁Absolute
▁adjusting
=.042
▁Dent
7-2.3
▁190%
-1.7).
▁0.2-1.
1000
=1.11;
loqu
acyclovir
▁chast
inp
terq
]=2)
▁6.5%.
▁Stress
idox
▁jeopardy
odiazepines
cancer
▁acyclovir
glucom
▁concealment
▁(<150
1/367;
▁Silv
▁52%,
▁anhy
=1.7
▁adapalene
icam
▁Inves
▁congestive
ronate
isol
▁19%.
nique
ditioning
zation
▁1.38-3.41)
-4.94).
erotic
rinivil
ryotherapy
xants
▁noncep
terase
▁tic
=0.80;
3-2
onorgest
=.92
▁headaches
▁5.11-21.23).
▁10%-20%
glit
▁multination
▁smok
▁valacyclovir
erception
:1)
▁43%
▁383
▁1.29-1.5
▁ipecac
▁Finkelstein
cler
▁dum
achnoid
▁Brazilian
▁echocard
▁Revaccination
▁enroll
▁orresp
▁Tiotrop
Sul
▁51.7%
,300
▁breastfed
▁atrophy
▁(0.9%
itecture
▁32
afti
▁decreas
▁105
▁Arter
arket
inki
axone
53).
▁anxiolytic
eterol
emetic
ionally
▁enoxaparin
thickness
▁3.1
=12;
▁816
▁1.75
prothrom
34.
epine
mpty
cital
▁postdi
erth
▁vaginal
6.89
▁5.4-
roduc
MARD
adings
etion
HB
▁rised
▁16/
=9%;
Tol
▁angioplasty
▁glomerular
▁1.17-1.9
arated
▁canc
5.2).
▁hysteroscop
=98)
7-1.1).
berosity
▁12,
▁critiqu
enser
cellular
=0.59);
6.89),
kwhe
▁577
]=12;
▁mycoplasma
=-0.
ectable
=10
iology
-0.62;
▁impairs
.03)
=80
tivat
▁(1.6
Seasonale
-0.8]
▁hypothalamic
▁>300
▁painf
gul
▁(1/1
Foll
acupuncture
irthing
▁98%,
▁bever
▁exams
rays
▁papular
infection
▁surveyed
WTM
nology
-0.75;
minant
▁>14
▁1.35-7.41;
▁approp
iplin
▁65%,
▁ivy
ryonic
ABA
upro
▁hepatocellular
▁25.
▁1.45
-1.21
▁corticosteroids
actu
xyl
2.9%
mentar
aths
IH
▁heel
▁257
retrospective
tut
▁0.0
▁scabies
▁whos
,)
▁Pertussis
Pravachol
▁duoden
▁OC
=17
retory
▁Fibrillation
ecome
109
▁diap
sib
▁mann
-13.16),
▁inguinal
theroscler
akage
sychosis
▁bumet
▁methylphen
tracep
ysicians
▁Limitations
Cas
▁nonskeletal
▁Helical
rame
ainf
Strattera
unad
▁Coronary
atien
=18.
ocardi
ticulocyte
inat
thyroidism
=1.47).
▁(3.2%
-7.0).
▁0.45-2.20).
▁sclerotherapy
▁0.06-1.23;
▁Incon
ecdot
▁whey
▁Aml
<.002)
ucose
▁88
▁Wound
▁formulations
▁drawback
816
yod
oneal
oxicam
Lopid
=605)
=2).
▁obstructions
▁(67%
▁Manu
▁Across
▁metastases
322
=4.92;
▁percus
19).
▁0.93-1.
▁publ
istamin
▁rebound
▁desaturation
▁quinac
valuates
araz
▁inflam
▁whee
▁Physicians
▁conte
1,5
▁enz
▁themsel
▁metatar
▁(72%
▁100,000
▁0.93-1.6
leared
▁noncan
▁<90
comyc
▁critically
LVD
tric
arginal
arked
=27
▁<5
▁1.4%.
▁bip
acerv
stratified
ipheral
ongit
▁1.3-3.7)
reaten
tard
pti
calcitonin
linded
Ho
▁85%-95%).
athroom
▁rupture
RIPO
▁Simvastatin
isab
▁stercul
▁immunosorbent
2-2.
▁restud
vestig
▁Survival
▁trazodone
=1.8).
uished
7-2.91;
rawal
alphen
▁heterosexual
istamine
isn
tivitis
4-0.8
▁Comorbid
pharyn
▁developmental
aig
▁inste
▁adequately
ulose
ystematic
73).
imesul
▁buc
▁curettage
▁170.15;
tent
▁shave
▁170
▁excised
NSAID
▁30%;
eteran
tency
-7%
▁immunofl
▁0.58-0.98).
▁18,8
=100)
ofl
resl
52
ditions
40),
troin
oxib
ellets
▁antisecretory
uban
onvul
breaks
adach
estry
ectoscopic
ioids
,000.
dihydrop
▁10,001
quit
rofession
athyroidectomy
onl
▁dih
fficiently
isom
]=142
▁polyc
rogram
8,75
54
kert
apamide
irocin
▁2.9-16.0]).
▁thyroid
-0.44).
.1;
racla
ribonucle
]=13.
▁incis
rimoxazole
=0.5%).
▁63%
▁transects
0.4
▁resonance
▁antigliadin
▁emes
▁Beta
coagul
▁>70.5
ecu
▁soiling
▁demonstrab
▁85%.
ecar
▁thiazolid
tivari
▁etiologies
-2.54
ipr
▁menopausal
▁102
▁177
veget
▁Topical
▁64.
▁15,880
▁coit
▁Neospor
41%
edules
▁(30
▁manag
ifferen
unf
5.7%)
agl
50-0.7
▁2990
-1.33).
ternational
nogr
▁antibody
▁0.70/0.9
▁seronegative
,24
enough
leven
utin
edg
6-5
▁consti
Lipitor
=.004
▁nonanti
adrup
▁Hypertension
ithro
▁cephalosporin
▁dentures
=0.50
▁(8.
actam
mittent
longed
▁bronchitis
ints
otyp
▁(1/19)
conducted
▁Respiratory
OSC
thesize
2).7
onas
88%
▁1.47-2.9
verific
onide
ubgroup
▁verbal
▁thrombus
4-0.97).
9.6%
▁awak
▁counseling
▁carbohydrates
▁ston
▁preoper
▁gonadotropin
Priniv
▁alopecia
▁reproducible
▁andro
veg
▁cremaster
enography
▁<9
geable
Relafen
▁kidneys
▁urography
tyyear
Hashimot
000
icella
sulfonylure
BRCA
▁refract
▁bumetan
▁derangement
▁pulmonary
▁analges
tho
tates
osid
7-2
<.01,
▁estro
▁standardiz
2.6;
▁Concent
▁POC
▁0.44
vascularization
sient
pri
ropou
lun
▁945
▁Varicoceles
getable
wis
▁unco
lerotherapy
5.14
upri
urrenc
yop
orphine
▁0.4
plif
▁endoscopies
henic
6,7
eartb
knowled
▁(88%).
.09).
10-3.77).
=3]
,88
opress
▁spann
dary
iatro
ilin
61;
itiated
adenomas
domen
opharyn
aspin
timates
▁sprains
bilirubinemia
rising
orrec
acral
▁ral
3%;
PDS
]=1.14;
▁salpingitis
▁evaluating
▁39%
tained
8/0.8
6).
▁biofeedback
▁homogeneity
012
▁revaccinated
=.024).
ergic
▁amphetamine
▁<25
32.
vior
▁52%
ALU
erbations
▁(400
iologic
2%;
▁alarms
▁Committe
▁differen
ndet
▁1.04-3.3
enoterol
-25
eath
edema
fficient
▁occupational
ycardia
27),
urol
orming
ceton
▁281
▁aerob
32).
fice
▁assessed
▁(41.
=.03),
▁1.45-4.98).
▁38.0
]=50).
▁reco
=12.3;
ulliparous
verbal
ometers
riniv
eplacement
▁unmetabolized
alding
statitis
▁Doppler
/90
▁2.72-41.8)
lafond
neumococ
ularity
wif
▁Clinic
▁-1%
hrop
▁Hb
radi
tillate
azard
▁scans
traline
▁1153
▁Antibiotics
▁9%
,233
▁333
▁alop
▁<85
▁oxygenation
▁carti
34-6
epsis
ainten
▁seafood
1.23).
ulgar
romocript
esonide
▁exercising
▁syndrom
ycard
▁1030
aple
▁Dysfunction
▁0.24-0.99).
trasonography
reported
▁-0.6);
▁0.7-0.
▁postc
reactivity
▁Duradrin
sufficient
itrof
ainage
▁colec
5.5
▁0.81-2.
elste
titi
▁tympanometry
▁Bri
ucr
atew
enan
▁adrenal
▁excret
orrhagia
▁1.61-5.34;
4-0.53;
tering
▁quantified
▁percentages
3.1
eticians
6-4.
absor
▁0.87-1.
otranscobalamin
reakth
▁Spl
hensive
9%;
▁4.5
▁rhinitis
▁NESTOR
llb
6-56.89
▁unaffected
oC
arboxylase
3057,
▁articular
=0.76;
arved
95%
▁stepp
▁persisted
yel
parathyroidism
▁multior
=0.13;
▁atten
etiri
▁41.8
▁oin
▁MIs
ergon
▁immunocom
=5.6
-25)
▁Invent
MRA
▁physi
presumed
▁710
olecule
inute
rut
urrent
▁(12-18
▁Moreo
▁modific
otherapeutics
44,825),
icits
80%
▁adipocytes
otensive
▁unfraction
▁divalproex
esquam
▁eczema
=1265).
▁splenic
axative
▁>0.8
-1.08).
-0.98)
▁Corp
estrel
=47.
antages
nalapril
▁esophagus
omor
hythmic
▁nonop
▁0.71-0.91).
-1.07).
hemo
raspinatus
arrhythmic
▁zoster
gations
panolamine
▁caregivers
eine
thre
▁0.06
eptene
wic
▁2.5-4.
▁episod
▁14-35;
clus
0.65%
▁comorbidities
▁AOM
▁Hamil
drom
▁21.
▁42.1%
▁8.3-9.4
ipid
BVCA
▁1.0-12.2).
,8
▁interestingly
▁propion
etin
concent
amip
34).
▁reviewer
uride
=78.
=8.3;
eliac
-3.41)
tingu
promised
▁33-
▁6.8%
merci
▁nondiab
unres
▁14.8
▁phenot
henhy
ylure
icyclic
amycin
opul
iterat
ondroit
79,
▁unnecessarily
▁americ
▁686
▁hypoventilation
igare
.3.
quisition
bial
ordial
-20.70
=.002
▁16.7%-83.3%).
21)
saicin
▁IVCF
▁psittac
▁Cumulative
▁Azasan
rela
=73
ndian
▁171
atally
avors
cqu
▁0.35-0.57).
tise
▁(2),
▁readiness
▁antich
avage
gnancy
(>
▁deh
▁91
releas
▁dextroam
elanom
▁23,1
▁(34%-4
▁Insol
▁supplemented
omprom
9.
▁montgomery
93;
3-0.74).
9),
▁0.51
Nor
orad
-2.7).
▁clonidine
bri
NSA
atum
▁DV
brile
66
▁heterozygous
ingonberry
]=1.1;
▁insomn
nisolone
atient
sparing
acitracin
circum
▁>1
endix
▁gout
nq
▁-5.
▁experien
obacill
uniz
▁Lumb
adene
▁textbooks
Aer
timalarials
▁abnormally
isus
tinu
olyc
inester
lamp
▁ankle
▁4.2%
noid
leosis
ivary
▁ingu
▁buprop
▁Eb
▁26.
ginate
=15.
myx
▁Fluc
astine
8%-7
▁13
▁(0.
▁>1-4
448
unos
xud
roxen
▁(44
▁anticoag
▁(53%
▁nipple
▁pyr
▁doubled
efinite
=824
796
▁esoph
usu
udit
>9
▁formulating
▁amnestic
-3.
vulsants
osm
▁glenohumeral
▁4-5
▁noncontr
▁3.1-10
▁grains
acipran
ycol
Nati
▁cardioembolic
lamin
bonic
apro
▁vulv
lol
rofen
▁<25%.
▁acyc
-2.58-
ifed
46).
▁comprising
=.36).
▁(16%),
▁cyclobenz
▁Individually
▁1.33
▁noninvas
inety
ondy
adycardia
▁4.91-137.26).
ocytop
▁pollic
▁fluoro
▁Hear
▁1993-1995
lytic
▁lidoca
alamin
ucat
8-7
8-1.2
asked
▁1.48-2.0
▁308,
tic
▁Postp
▁maneu
ymal
▁(101
osition
▁Nul
▁Bef
▁chlorthalid
cystic
▁Postpartum
▁methion
▁pseudoephed
eco
cutaneous
unl
terized
▁1.1-2.7
lya
HIT
ecrolimus
cious
12.
-1.6)
STOR
▁56
▁asth
sart
amam
▁undergoing
6.7),
▁anoxic
0%-100
asou
▁dimethyl
tially
▁78%
▁99.
▁danazol
▁PV
onsillectomy
▁preex
gim
▁magne
▁judged
▁1.61;
▁residual
lline
▁irritation
istat
▁Omnip
13-0.
97-0.9
delaying
▁39.
ocrin
▁2
=.043),
resistant
▁Mast
ardura
ytocin
▁FDA
▁horiz
▁veins
▁suscepti
roxicam
▁Aspirin
▁1.8-4
creatinine
▁0.25.
HF
▁Dried
cents
=10,828).
imenop
<0.00
▁566
glycop
▁extrap
irre
▁augmentation
/0.89,
-1.1).
udati
▁(76
ritis
arean
222
▁500
]=1.1
unop
omograp
▁hydroc
▁noncephalic
ommended
▁ferrit
ucral
5.7
.0-3.
▁OAE
ysuri
▁smokeless
▁montgom
▁buproprion
▁banan
▁50%
▁obstruction
▁titration
0%-33.
glucomannan
identi
istered
rimaz
▁(0.92;
ifte
tors
▁1.38-3.9
3.0%
unctionally
=0.56;
▁invasiven
11),
CDC
▁spuri
428)
oniz
iatry
thoracic
▁40,
scap
viating
lum
▁6%
oling
▁2.0-3.5).
munob
sod
▁Lescol
▁Osten
▁instrum
oriasis
IPOD
ogast
Rim
clin
versely
kine
▁caref
▁4.32-526.
▁bilirub
▁(89%
PGA
▁reliability
▁1833
▁neutralizing
parative
riment
▁povid
▁(3),
▁micros
▁(34%
esth
133
allenges
▁Taiw
001).
▁2.0
usual
esul
7.10)]
61).
▁<.00
▁comparisons
ranial
anem
otional
▁topical
▁plasm
▁melanoma
▁8%
▁1.17
lide
▁stratify
-0.89
uconazole
▁relied
▁anecdot
oer
ocioec
▁58.0
▁12.5.
calorie
▁anticoagulation
5-0.99;
=6.0
,828).
▁Achie
▁4.76
804
▁63-9
probable
zard
▁tes
▁Attribut
]=1428);
aising
10-0.52;
oDerm
ranspl
▁1.1-2.7]),
ucial
▁amoun
xaz
racyc
3.1,
onidine
ymitis
▁nonsystematic
omeop
ypass
▁venla
▁EI
yed
racycline
ularities
ransbronchial
▁tho
2]=
=15
▁nitro
ericans
▁660
▁88%-95%).
aO
ymphad
▁anat
▁4.32-526.17),
atry
lamyd
ACA
resenting
▁insu
605)
rolin
▁AFFIRM
9)
7-0.9
3-4.
▁0.497-0.97)
andina
▁sorbitol
▁19,25
▁shampoo
thrography
leed
geons
infor
▁ach
donal
▁hypermenorrhea
ticoid
allowing
/0.96,
thion
▁Caucasians
inases
▁antim
▁33
ergy
26),
▁Lymph
=1.24,
▁0.55-1.38),
apaz
▁bowel
▁hypomagn
▁rhinovirus
▁areata
25;
inister
erni
orrheic
0.14
],0.10-0.52;
3-6
EDL
▁dicl
▁flunarazine
11-21.2
▁insufficiently
istol
inut
▁cohos
08),
tisit
=4060
gestogens
▁myocard
▁yi
iwe
essm
Fu
tinent
▁0.25
▁wk
▁1.3-3.
▁holid
ripl
▁Symp
▁superfici
mpt
▁1.61-5.3
▁polyethyl
papulopust
reto
▁nodul
alteparin
strac
▁reproductive
▁21,752
▁Preventive
intest
▁24.7
uetiapine
elstic
▁1500
▁108
▁=.002
alked
olof
▁correlated
▁(10/12
▁sic
-0.60
▁1.2-8.0]),
▁ambulatory
▁antispasmodic
▁nex
ertion
,15
▁1.09-1.5
oful
8.8;
▁elimination
▁Thy
nop
3.2).
iride
ictory
▁specialty
eluk
-32.
4-0.20).
-1.40).
▁supple
<.001).
00-800
100
▁(-0.23%
9-0.8
-1.9
▁PCOS
▁Nutrition
▁2.43
▁slowing
=0.3
=5.67;
ocar
▁0.80
▁811
▁headache
▁(10/1208),
occurring
▁0.98-1.5
biph
▁worsen
minist
rj
2.7;
▁choles
▁hypercoagulable
exce
800
vedilol
20,000
pidemiologic
tiar
acip
▁Identified
thirds
16)
▁presumed
170
trib
25
NPH
▁Streptococcus
tepartum
raclavic
ypne
asmic
obacilli
]=0.63,
athology
eterogene
4-1.7
▁seri
arction
▁ani
▁contraceptiv
▁serological
995
=96,
niques
▁interm
ibb
▁0.06-0.29).
▁277
▁451
=6.41;
▁serol
▁0.48
▁Opioid
93%
atients
▁40
▁0=
orated
▁mitigated
openia
lycop
ctionally
vul
ictable
ithelial
bearing
viding
hoth
oep
▁Hib
inantly
poin
▁intrace
▁profil
tioning
▁paren
92)
▁1.9-4.1),
▁(2.6%
▁>3
▁37
oconstrictive
scarr
▁qualitatively
tancy
▁>10
▁genot
▁hyperl
▁1.1-2.
▁Munster
responding
kast
omiphene
▁67%,
▁psor
66-10.67)
scherichia
osocial
▁variously
ansi
jur
▁0.19.
▁2995
▁decreases
▁181
▁Aerobic
▁-2
3),
▁65%)
erq
adic
reports
3.3%
porting
▁448
▁impot
▁ipratrop
▁underg
▁acquiring
mpl
▁heartburn
▁bananas
vail
effectiveness
onvuls
▁caries
▁excretion
▁perone
▁semen
2.4;
yq
▁75-
4.5)
chitis
Dos
fad
▁singl
quar
afle
▁296
▁lidocaine
adiaz
ricor
linic
chizoph
weighing
▁commerc
hag
▁confl
ectom
▁prophylac
fro
▁0.79-0.97),
tend
-10.7).
▁(15
electas
▁intere
=0.44;
3]
alian
93
eroids
atadine
xal
erid
RSA
.8
▁3.22
▁meningococcal
quently
▁395
150
▁Amlodipine
coronary
=7).
ucralfate
onomic
5-4.9
xist
▁LNG
▁percentag
▁0.9
-3.7).
▁2.61
69.
Ae
erbation
▁enrol
▁stran
▁glomer
▁antenatal
estrogenic
▁intracranial
▁balanc
ovisc
19
-1.94).8
ostd
2-10.
=.02),
dant
▁nondi
▁Responders
▁inspiratory
epr
▁suctioning
▁Lymp
▁remission
trocon
dominal
▁Esch
hemolytic
ymptom
iliz
▁(1
▁McBride
▁ovaries
▁Practi
▁cutoff
1.4).
-0.82).
▁polye
ucate
Eb
tiol
rinolog
▁quetiapine
▁hyponatremia
dens
▁glenohum
▁tubercle
▁absorptiometry
▁465
▁0.93-1.00).
1.2%
-4.
7.6).
▁Simms
ulting
=78%
▁styl
▁trichom
ostil
60%
izine
ternalizing
tropium
400
▁0.93.15
compli
enac
.07;
grou
▁1.04-3.34)
bations
ylase
efin
=5
bstein
ilify
eref
▁0.04-0.1
thlete
▁40%
27).
▁succin
▁irreg
SOLVD
eilitis
▁1.46
renting
vulation
ounding
Wou
▁overt
▁lipoph
elogr
-1.3
unctional
ynecologists
.01
▁nonsurg
proic
ropium
▁INH
▁Evidence
variate
▁0.34;
=-6.59
▁alendronate
▁16.1
copres
=2.0-3
olal
▁nitrofur
▁(64%-8
rotec
iddie
tinoid
ifes
▁polysac
correc
▁immunoflou
▁dye
▁antagonists
-0.70
▁relaps
▁naratriptan
▁Mesalamine
ADA
guing
solute
4-0.1
▁3952
▁Colposcopy
▁sput
ysterectomized
▁(52%
▁7.0%
▁cancers
▁-3
▁schedules
▁>2.0
▁methionine
▁1.53
443).
▁decub
estation
acteris
▁bioavail
▁(32,684
30%
eractivity
ithi
enterocol
▁nonf
▁plasmace
courages
▁1.16-7.0).
increased
▁1.44
▁expen
jected
tig
=44)
▁calculi
▁(25.5%).
isod
adjus
▁nonmelan
▁radicular
coat
-7.1])
lude
▁36.4%
tifine
▁epilepsy
▁20%.
▁epidemiologic
inid
5-2.
▁dors
▁17-
▁(4.0
▁0.69)
inusitis
▁Reas
ndivid
▁(43.
3.2%
=25.
effic
ognized
idone
▁psychi
orkup
ysmal
▁lumbosac
9/
▁Gonen
ungus
▁nabumetone
atolog
▁Investig
asteric
cardiogram
aso
alanc
anomet
enters
▁retinal
onti
▁effus
▁indometh
▁1154
highest
▁fibri
53;
▁59
-5.9
>0.8
▁MRFIT
icter
▁liquor
nus
808
26-
▁hyperlipid
▁progestogenic
▁43,
▁enal
ctos
▁SGR
▁Exercise
▁-1.64
guinal
esia
▁requir
▁0.77
ilic
(4
vertent
ocuses
hers
▁vein
-56.89
▁sunl
thost
▁prognosis
arice
scheduled
deficient
3.5%
▁68.4%)
=16%
53%
idic
▁ispaghula
7,000
▁clomiphene
ertensive
63;
sibility
▁40,000.
▁accid
fuss
▁dysf
releasing
phosphonates
ystat
acor
▁NuvaR
▁oto
blinded
zyd
ceti
▁29.
▁infusion
]=0.66;
).1
46;
nalap
eccent
Lac
▁vitro
orazepam
▁0.36-1
-20%
9.6
▁ranitidine
CHD
sitt
duci
▁(64%-81%
▁adenomas
7-0.91),
-4.5).
erally
▁apnea
▁(50%
abeprazole
▁Risk
▁Referral
isap
▁47,88
thac
-83.
▁Stopping
▁352
eSO
frequ
seled
olpos
▁hepatot
itam
]=6).
anati
leph
▁Gonadotropin
-5.8
▁Pravastatin
represent
▁5-33).
Cylert
▁alar
2.4)
artic
▁electrocard
▁Nephropathy
▁itraconazole
▁qualitative
3.9.
91
reslow
▁9610
▁sequenced
=.50).
SRI
arou
▁adenoid
edrine
<0.
olol
▁lengthiness
125;
▁tenderness
ABL
reatinine
▁stenting
.3-42.4)
▁3.5,
▁hypoven
inistration
essar
unin
▁undiagnosed
▁1.5;
▁10%-2
▁triad
▁appendix
▁albuminuria
▁472
vervi
ffus
▁servic
2-0.8
cyst
onmental
0-2
▁itch
,805
atosus
▁deleterious
▁appropriately
fatal
=-57.93
▁55.
]=0.72;
ognize
ucos
▁esophageal
0.0%
=2.9%).
▁voiding
30-
ocolitis
7.10)].
aprox
▁cruris
▁empirically
=.007).
osclerotic
ppro
oreign
geab
▁239)
▁rupt
▁(83%
atorvastatin
-97
henop
4-31).
-1.57;
▁0.12
▁980
lementation
lamydoph
erp
0-2.3
amnionitis
itrofurantoin
▁0.75-1.05).
▁90
▁bacteremia
Enbrel
apac
▁50-79
]=2).
Fou
tin
▁unif
LU
3%,
▁(95%
ejection
greater
ypertension
▁durations
▁depres
irw
terogr
▁rur
adrenergic
▁pertussis
ominantly
▁128
igricans
▁anhydrase
rimethop
yogr
40-2.0
ermy
cobalamin
=166
▁19,257
▁macrosomia
▁postdiagnosis
▁(1.2
▁clues
rigly
phenazone
=0.53;
▁91%
▁48.9%;
remasteric
tical
▁42%).
-6.0
▁29.4
▁4.8)
▁preoperative
▁HRT
4-0.98;
▁spurious
obronchial
▁conductance
▁AFFI
-0.86).
=2.0-3.0
apartum
otom
amazep
▁thyroxine
▁nonan
ixteen
▁shoc
arynx
▁1.24
oronto
▁1.6-
acil
▁Copenhag
<1.
,0.
ranscer
▁ketoconazole
enoc
▁(50.
hilis
▁acromi
▁39
▁datab
▁predisposition
0.9).
▁Criter
353
=2.26
-1)
▁cyclobenzaprine
▁nonins
▁chasteberry
▁administ
icat
▁inaccurac
▁outweighed
▁4.
-1.
-5
▁0.63-1.07).
▁secretagog
▁detr
▁1%
▁mcg
ivilian
▁premise
10-
▁135/85
=5.8;
=.026),
▁EB
quences
verestim
ehold
=22
▁15
▁SPLs
▁Outcomes
▁dermatoses
▁192,47
▁83
kage
osphate
▁antimicrob
mega
llow
irms
▁(26%
▁1.33-1.
▁cardioem
4.
=.005)
▁95
▁Autoantib
▁68,
positories
▁spon
eedback
achex
▁0.12-4.1
Pn
otl
▁quitter
▁pea
81)
tial
▁divertic
hlam
▁neuroim
alidone
orical
bth
ventional
tomati
▁3.0-19.5
▁252
▁polysomnograph
▁musculoskeletal
▁biv
▁metered
▁splenectomy
menstrual
xia
▁cholesteatoma
▁1.89
],1
flox
▁-7.9
▁insignificant
▁trac
arboxyl
▁5.6%;
▁multinational
-23.
▁<0.75
actul
oidectomy
▁acromioc
▁0.40-0.97;
094
lina
mpact
pH
9-0.6
bograph
mpac
bic
61%
yspl
▁Antidepressants
lent
dered
reptococcal
armful
stag
rimro
010
▁1986.
pasmodic
otb
▁Autoantibodies
▁1.66-1.88;
Bactroban
-5.
epending
▁adenoc
arriage
5-1.7
rch
▁Thi
▁receptors
imus
▁coadminist
hort
timul
eremia
40)
1.7%
▁enrollees
=.01
▁hypokalemia
▁osteo
▁volun
▁dermat
▁contraction
reath
▁radiologic
versing
calcemia
rochlor
anox
▁duvet
▁desat
▁Ib
]=3.
sely
▁protr
ribon
aliz
odific
▁fulfilling
▁neuroimaging
▁2.21-14.56)
clavulan
apulopust
onven
▁glucocortic
▁1.1-
upu
opustular
▁89%,
bies
tment
▁3,
vial
DHE
▁identif
Abilify
revious
8-1.11),
ffici
=2.29).
tebral
▁Leu
iatrogen
leptic
▁serum
intensive
zinc
vente
alies
idoca
▁transverse
1.5
▁monotherapy
▁estrad
Wellbutrin
▁ipratropium
vian
Sid
▁[95%
▁1141
cros
-0.77;
▁Measure
▁statistically
ormations
▁retinoids
toms
▁concussions
=12.
▁monit
vides
▁concurren
▁0.72-1.
=96,19
alati
26.5
ralgias
▁pharmacokine
▁torsion
▁quoti
▁RCTs
<.001
▁Pooled
breast
▁preexisting
-2.0
ameron
▁resection
▁aids
▁achieves
▁0.4-0.8])
▁suggestive
▁schizophrenia
▁perioperative
1,75
throg
-17.
▁TS
▁<10-
umans
▁jus
-13.9
pac
eroth
▁earl
▁McIss
▁malar
medy
4).
ramadol
▁deform
▁Tio
3,
▁Holger
▁8.28
▁pim
uces
▁1.3-3.1).
ubber
▁Aspir
=1.1;
▁modif
bduc
auter
▁weighing
▁0.4-1.06).
▁46.
▁demis
opig
esem
propanolamine
ardiogram
▁nebuliz
esized
xth
▁sequenti
lusively
▁surgical
▁eradic
vip
▁nonst
onerg
▁644
=.2
irthwe
pical
▁enlarge
ctur
▁interferon
▁decu
scopy
▁intensive
▁infor
9-5.
▁MICR
▁glucosamine
▁endobronch
uscular
opor
▁induration
▁verap
romised
plin
rosemide
ightforward
▁lacks
▁bir
andards
▁elevated
astroint
93)
▁4.91
usat
lep
<.01).
▁hypotonia
Naprosyn
▁0.7-1.
▁duodenal
esartan
versy
▁localized
lasia
nography
5-0.5
▁-5.14
]=19).
▁19.
plos
kapp
5.7).
opust
▁heparin
.3;
▁spikes
▁skeletal
spectr
raine
▁prepr
67)
ysi
-0.88).
terog
▁gynecologists
itration
▁pooled
▁Uni
▁30
eart
▁543
▁attrib
▁(0.61
=64.
▁adolescents
▁goiter
▁multistate
onse
normalities
▁42.1%-69.6%
NRIs
osyn
▁pollicis
adicated
▁6-36),
=16
▁sulfam
02).
▁Cum
isoprostol
▁affec
▁Stap
▁reno
▁ADHD
▁effusion
66%
672
▁choline
▁3.6%
▁-152.66
▁sali
=0.5
▁0.2-0.
erned
▁(59%
WHI
▁7,
tation
oephedrine
▁amenorrh
▁dermatological
▁0.0%-33.
▁cerebral
ocated
-0.99;
▁4.2%.
]=1.6
1.6
nation
▁0.21
rein
▁hepati
afil
emory
ilitis
▁inges
▁reductions
▁defects
ibrate
orbable
▁6%,
▁secretolytic
gha
bstr
▁Perception
encom
▁griseof
▁IVC
▁>64
FIT
▁1.4-1.6.).
▁90.
otenti
▁atro
Eff
▁quantitative
eded
itiating
entif
ulc
nz
Vas
▁0.43-1.00
1.2
▁absorbable
▁8.6%
13).
6-7.54)
,448
plification
jou
▁ambulation
imally
-1.58)
116
▁diverticul
glycemia
oace
estion
▁Thiaz
unized
Mos
▁7.8
apular
▁calf
▁Prot
otrop
7%-8
▁righ
▁duplex
lyl
▁discontin
mortem
226
▁adul
▁milnacipran
-40%).
tility
edro
▁stimulus
mostly
▁(43%
▁potenti
openhagen
ormities
▁Phen
vicular
▁reviewing
achol
567
-0.29).
sternally
▁49%
▁proportions
gian
Gs
utos
▁stopp
sus
unctivitis
=0.98;
iazepines
▁>27.
▁84%.
▁dysfunction
elukast
▁ejac
▁315
▁concor
▁Wen
▁valproate
▁hypothe
-0.99).
renatal
▁1.13-1.66).
1.9
▁reflu
rout
pulsion
▁1.31
▁cryptorchidism
2.3%
▁5353
=6.9
timum
▁0.36-0.70).
=24
ibromyalgia
▁counseled
=2.38;
00.
eptide
uloxetine
▁nonfatal
osure
▁(5.
▁nab
ipating
9%),
-95%
trophy
etab
oag
cooling
▁Replacement
aculation
▁2.03-2.74),
-1.86)
▁6.5
▁98%
osporin
▁(11
▁intolerance
85,
▁1513
distal
limin
roim
oxicity
▁prodromal
=9
-0.67.
▁1/2000.
earcher
▁retur
▁enti
ophlebitis
▁insulin
titutes
▁inadver
atible
▁86.5
▁58.01;
0%-3
▁presch
ialists
ulfill
▁deteri
<.02
usting
urvivors
▁vulvovagin
▁undergo
.07)
▁hypothyroid
nally
8.3
▁Ghana
epatic
ectoscop
uad
▁exaggerated
000),
▁2/
ooxygenase
yptorchidism
▁fracture
vasculariz
▁37.5
▁>38.9
onar
▁birthweight
enohumeral
▁unselected
rilling
teroids
=2.35;
98.
7).
tiveness
▁Misuse
▁bronch
▁ferro
=8.
▁predominantly
disciplin
▁expressive
▁-0.
▁spontaneous
ageal
▁superficial
▁clotrimazole
irub
▁>9.
▁1.9
▁(1).
6-1.44
imep
▁(69%
▁monteluk
ervised
piration
▁offsp
umors
apl
Lach
▁radiolog
arkers
72%
▁cotinine
boh
dation
ialt
6-7.
orly
▁arti
▁prochlorper
HAT
▁97.2-9
ollicis
▁17%
oarthritis
▁6.6
▁diathermy
▁91.
bered
FITS
10%
adm
▁CIN
yqu
vity
▁compres
▁identifiable
▁Neosporin
▁VAS
ocrine
▁etretin
tainty
4%-14.7%)
241
▁pretreated
▁flashes
onography
77).
ighted
▁16.7%
acranial
▁cowork
▁thu
▁grou
received
▁Thoracic
ulox
urethritis
▁tabl
-1.1
▁Urea
▁14%,
epati
oprost
▁-0.4
1-13
▁jaundiced
▁(20
▁(84
▁rhinorrhea
ameth
▁>1.
HDRS
istologic
▁gluc
▁methyl
duction
▁Ischa
erral
rificing
▁mupirocin
abdom
urve
Bacit
cholog
▁abdominal
▁adn
=21
)-6
rthov
▁unresponsive
▁NSAID
achm
hies
inning
Celebrex
ugment
ylic
ndm
▁thrus
levision
▁27.6%
roublesome
▁80%,
idined
ialist
▁(122,471
▁classifying
sule
▁709
tisone
▁10%.
▁bromocriptine
-8.0]),
▁oft
fere
osup
orities
(<
▁VISA
Lamisil
]=3.12
=141
▁5.1,
▁conjunc
▁posttest
▁255.22;
▁-7%
▁-1.8
▁93.
▁>7
▁6.5%,
▁excoriation
▁2492
ecolog
alence
▁Haemophilus
ransition
▁Epid
xiety
2-3.
-100
▁47.
nonsystematic
▁respirations
abumet
=85%;
▁orlistat
▁0.59-1.63)
▁infectious
608
50;
▁orgasmic
▁206
VISA
▁relieving
▁(>95
7-0.61).
tomat
344)
ospitals
▁triamcin
▁pharyng
anaflex
▁Comparison
=-1.88
▁fibula
=0.23;
fibrozil
fficacy
▁unnecess
astroph
roh
opril
▁exceptionally
ralfate
26).
72-41.
-95%),
49).
▁Wisner
chiti
▁bri
troban
epez
▁(4.8
=1.90
▁0.30-6
▁cyclosp
etter
▁subclinical
▁2001
]=0.99)
acill
▁1992
▁blac
▁noct
ictive
▁antipyre
iazine
▁hu
trop
22,
seve
yotherapy
▁noncompar
reduced
▁Tramad
▁Thos
uaifen
plants
hth
▁42-78
▁0.7%
emati
ionitis
uliti
nowledges
onr
arbo
ributing
▁92.5%
0.
iomet
▁pne
▁hyperglycemia
8.0
ococcal
viate
lucos
stimul
ughly
uci
7)],
BSS
4-1.
<.002
lovir
2%)
ucom
IPO
ermined
olotrans
=2
defici
▁24,52
=5;
▁underactive
olposcopy
=0%
alys
=.001)
lamed
▁gemfibrozil
timulus
▁20,75
▁dysp
▁0.60-0.87).
<.001),
00,000
ucational
=16.
▁strok
▁Investigators
▁whol
consuming
▁assessm
▁unsch
iof
enohum
negatives
respondingly
55).
eterog
▁300-
onstric
etwe
2.8
▁0.36-10.36).
threatening
▁5.4
▁fluoride
geal
▁1.11-1.
=71)
early
▁pell
▁microbiologic
▁intratesticular
▁emphasized
▁recog
▁posttus
▁simp
8.1).
79)
▁anhydr
▁Nuv
alamic
ingd
vain
71
1-0.75;
urray
▁Polycystic
isits
sink
.1
▁chorion
unadjusted
▁3.26
lamptic
▁nitrof
▁(41%)
toc
▁pharmac
RIPOD
▁Statistically
▁28
▁2004
▁6.4
rovascular
ravachol
=.001,
▁3.2,
allerg
=.17).
pasmod
4.6%,
-4.3)
▁Neurop
▁competent
onber
depres
ussing
▁rG
▁bronchoscopy
8/
xig
urysms
▁(5.1),
▁antigliad
xid
alve
oninergic
ociated
▁(79
▁0.46
cati
<.0005)
▁eigh
tionated
ognitive
confirmed
▁gonadotrophin
ehavioral
inosis
▁(<7
onvulsants
orily
▁untr
▁(74%-9
aerobic
▁Modified
-99%
thmic
▁NDCAs
4-2
oled
citated
onf
▁55%
ultim
▁maturity
SCS
▁(4.6
sustained
rofes
osamine
▁103
▁cros
efaz
5.8).
HOT
adion
▁seaf
▁Successful
ducted
cyclic
990
couraging
sors
meterol
leb
escol
▁308
▁magnitud
▁bilob
12-2.67),
▁relieve
ematosus
▁30%,
▁challen
▁therapeutic
7.8%
▁prevalences
pharmacological
▁kneading
▁visualization
asthma
▁(47/344)
-1.8
adiness
accine
▁5.4%
▁tuber
▁irregular
ittee
▁494
▁48%;
Benzac
gasm
abular
99;
gist
uln
arbon
=.01).
Spect
▁Wors
itus
▁5682
ecklist
66.
▁excision
8,24
-1.69).
▁cardioselective
emoral
death
▁unrel
▁inadequate
▁4723
Imur
▁1103
▁impractical
isabling
ioa
=1.20
acterized
tivar
=2.67;
gical
upun
earc
nigh
orten
▁ischemic
▁amlodipine
▁shedding
aturity
-2.32;
turban
exid
stic
uror
▁polycys
3,61
▁0.5-7.03)
▁conges
▁hypop
▁crut
>1
▁2.72-41.
rion
▁aceton
▁1.04
▁tru
angh
orit
<8
▁outflow
▁Haem
▁16%
▁Lumbar
hiscence
▁antiem
tionis
ingh
upraspin
Ef
▁139
ongus
▁Contro
▁arou
cog
▁hep
-69.6%);
▁8%,
▁hemoglob
▁minorities
osocom
▁lymphoc
12-
athy
▁bladders
OH
▁CU
ightb
ilif
▁provoke
reth
▁levonorgestrel
▁1.05
▁unst
enstrual
vesti
▁elevating
▁syncope
tizer
▁costeffective
20;
▁compli
=23
orch
=0.4
iotropium
▁hypotonic
▁Fluconazole
lati
erac
]=1.3
holics
itl
stitution
▁impinge
▁Bacterial
▁720
▁universally
▁0.86
sicl
▁minoc
▁pancreatic
tbook
▁gabapentin
=5.5;
▁hypertrophy
formations
▁17,671
tituted
▁uti
osensi
rance
▁endea
muno
otension
=.049).
oyment
▁<2.
▁relapses
▁67%-98%),
ygi
▁nondiarrheal
▁0.38-1.3
▁efficac
ivy
▁discontinuing
comparison
oriti
▁Obstetricians
▁protracted
romy
NHA
▁elevate
-4.1
▁41.3%
onably
occal
-1.99
lawed
trihexyphen
47.
▁(99
▁susceptib
▁chor
95-2.
-0.78
▁0.50-0.7
=-1.8
▁166
▁feb
▁nif
ledges
▁nitroglycer
▁Varic
33
▁11.6
▁absol
essionals
iterrane
wak
▁rotavir
▁distinguishing
9-1.6
iphasic
.05
continence
imazole
-1.02).
cedures
itocin
juri
tatin
ithin
▁-1.5
▁1.7
▁(1%
ostatic
▁0.02-0.23).
▁917
▁0.04-0.62).
▁classifications
alform
7.2
Ib
assical
OBT
▁confirms
12-0.9
▁99%.
98).
=160
▁partn
▁expe
▁softening
▁48-2
Mono
▁116,
sation
▁nondiabetic
distant
▁5.8%
4-1.0
▁tamox
epiride
▁(5%
=.026
▁obstruc
▁produc
40/90
icti
▁pirox
eridine
15%
uine
oml
▁intermedi
onpro
ompl
nead
ollected
▁hemochromatosis
amage
▁posttreat
▁18.2%
▁6.1
▁1159
▁Incidence
adictory
8,7
icar
emia
▁amnes
asth
4.8),
resence
▁95%-97%,
▁EMA
hydr
avent
▁Unl
▁hemof
idly
epako
8%-9
▁metocl
▁heartb
▁2973
▁0.64-0.86).
ydoph
▁Richm
uven
yuri
▁duc
▁immunotherapy
natremia
▁1.8-45.2).
andful
98)
screens
▁sunburn
▁6.3-41.
umf
rovas
<.0001,
ularly
▁<3.
4.7
nausea
xant
▁spi
▁0.74-0.99)
▁nitroglycerin
Eac
roxetine
ilu
▁0.79-5.28).
▁Recurrent
,300/
▁imip
▁emerg
ashim
▁parox
ysu
ynd
atogens
▁latex
▁2287
0.8
diagnosis
▁17.6%
▁juven
5-1.02).
▁20,000
1.5%
8),
likowske
▁synth
▁192,
-66)
▁abor
▁mononuc
▁effic
41);
1.0
ohort
enicillin
uscep
langu
▁posed
owske
▁Pentoxifylline
▁refl
-97%
atm
▁testos
▁extrac
▁naf
vulan
▁(25.5
erature
▁Readjus
tinoin
▁candidiasis
Thorazine
troke
-13.16
▁946
▁decar
alat
alant
▁tenosynovi
▁477
erable
=2.2
▁predis
▁antiar
892
▁(97%);
lammatory
▁77%-97%,
iln
5.27
▁graded
▁preec
▁fatigue
▁tuberosity
=90%),
essary
▁1.03-1.40).
peraz
arag
79,6
verus
lactic
▁cran
▁Veterans
-2.3).
Nap
oprim
1.7
=0.68;
3%)
niotic
erosolized
63)
▁biphasic
anb
nons
86)
▁Framingham
nded
Pa
▁sonograms
▁Finkel
]=10)
tior
entifi
▁bilirubin
giotens
89).
acous
petent
osts
orvasc
=7.4%-14.
OCA
associated
-0.87).
galy
7/34
ingococcal
▁defib
ightness
▁2779
▁uncom
horter
▁soluble
oughts
▁scarr
▁Preliminary
▁lifelong
▁secretag
▁Osteoporotic
▁subtherap
omies
▁electromyograph
▁imaging
▁7.
10)].
▁renovascular
osab
1-0.7
rica
besity
6,222
▁hematoma
ropp
▁Vals
34;
▁therapeu
omoxetine
arying
=0.93,
4-0.86).
-20.0
-70%
0-1.0
▁naus
erenti
▁0.91
▁0.84
▁hyposensitivity
▁168
▁nontr
▁Dos
omegaly
▁sinusitis
teroscop
▁etaner
=-2
34-6.0
-1.73).
▁uninter
▁girth
reliable
acorpore
therosclerotic
▁pregest
icor
560
orably
▁remed
▁clus
citon
erati
▁chlam
idism
▁coronary
▁Fifty
▁0.2%.
▁34.
▁antig
8-3.0
inologic
92;
-0.71;
▁crac
ariate
▁exch
60;
echn
seling
esses
▁incep
Ck
CRP
▁0.19-2.33).
lopram
▁regist
-1.66).
▁surveill
edil
ulvin
gnan
cribing
esal
▁nonres
RCA
BH
▁Antidepress
ousness
xten
udin
includ
astrointestinal
-2.95
▁outpatient
mpiric
▁rosiglitazone
▁lymphad
opro
▁urinary
lox
euk
▁uvuloph
▁concludes
▁400-800
▁>27.3
-2.24)
roal
reti
jac
▁circumcised
▁Iber
-2.2
▁landmark
arab
>3.
-1.28;
▁hypergly
aer
▁0.33
▁aerosolized
▁28.
▁32.
Duc
lled
inly
atologists
timate
▁douching
▁195
▁nonac
ysr
tically
ltras
▁satur
MAR
oxazosin
/207
epines
ighing
=33
7-0.82).
▁228
▁overus
broadly
rounds
enomegaly
▁discriminate
▁crosss
vering
▁56%.
tures
▁nimesul
assing
▁randomiz
omnia
▁unclear
5-0.9
▁expectancy
armacy
▁endoscop
tronic
enafine
oneph
▁0.59-1.6
asily
▁30.4
▁analyses
leos
Evalu
terval
sso
=1.
▁ovarian
ylphenidate
▁leukotriene
▁PGA
=12,60
▁(440
▁fetus
0%-
lowering
hieving
boemb
▁cyclospor
alsh
3-0.44;
7-5.7).
2-2
▁hypos
<.001,
▁stu
▁10.0%
▁antisec
▁calcific
uestionnaire
luded
▁(10
tropin
phetamine
terit
▁concussion
ransco
▁Gyn
imodipine
▁infecti
▁sumat
tricted
▁differentiated
]=25),
▁caraw
Tegison
2.8;
▁inp
fiber
3-1.76)
6-1.8
▁dietician
▁complicates
▁hematologic
genation
rhage
▁28.9%
choph
▁150-
96
creening
okeless
▁discus
2.5;
▁Otherw
063;
]=57%;
lment
▁tended
ritation
scarring
neonatal
▁angio
▁unipol
▁arterial
▁Achill
bercle
▁poisoning
lobin
gard
▁pefloxacin
▁sucral
zith
▁26%
▁10-
monitored
volol
▁71.5%
▁1.84-13.16
idemia
▁angioedema
athing
▁HERS
Loven
3.5).
=111;
nosis
▁compares
20%
58-5.1
▁68.3-90.
▁Thiazolid
opec
heterogeneity
▁2.06
▁splinting
▁Sixteen
▁raloxifene
ertussis
IU
0%)
ipramine
▁Assess
ipple
omagn
erapy
▁Wenyang
▁raspberry
=.04
▁delive
▁Afric
ocyt
▁cef
▁potassium
▁Invigor
▁Toddl
▁casted
firmed
ventive
35
asmodic
▁reminders
enadine
▁regularity
▁teratogens
▁>140
omit
ourn
uterine
otrexate
viewed
stanti
▁loratadine
likows
▁athlete
spar
▁dalt
essf
aditional
esig
thi
pant
▁flunar
pated
▁46
ptan
▁Cog
NBS
ablished
▁ence
8)
▁intrap
ritant
▁morphine
ezetimibe
raspin
eel
▁deposition
icarb
etting
▁Rout
gous
-63).
ellul
=.04).
▁pimec
▁cetirizine
Lis
▁suction
▁903
ooxygen
▁Empiric
erran
60)
tative
=0.86;
▁7957
]=11
▁0.87
▁HS
▁recal
▁299
ullness
perinatal
▁0.10-0.34)
ocomp
laxation
containing
▁suppressed
▁contraceptives
oglobulin
▁exten
Bride
numb
36.
ophage
enicil
(0.65%
ifenes
▁Advancing
▁acetaminophen
utc
▁cong
-1.98),
▁80
strual
copies
▁20%-
4.9
▁85%-9
ureus
osor
unp
▁sulfate
vivors
▁psychiatric
loid
▁discretion
acol
▁brev
ortic
01
▁1.11-1.90).
atrop
]=0.43;
ricter
Aid
aiting
ilep
▁1.8
▁mupiro
atigu
95%;
▁cep
ormalized
▁4.91-1
lyti
▁255.2
▁nonpro
ustular
lacental
tisol
▁nonp
▁inadequately
CAB
▁471
ispanics
breastfeeding
▁urodynamic
2-7
▁uncontro
▁nasopharynge
▁16,608
▁equiv
GH
=11
]=2.1;
▁(0.44;
▁gradi
-7.8
▁1.3-1.6).
▁epidural
▁1.66%
-1.30
TNT
▁classif
-7.5
▁3.0
▁Tiss
▁distillate
thox
terns
-220).
munos
rinologists
▁refusal
▁unpred
mograp
▁0.62
acok
▁noncom
0.7%
ongestants
assified
,67
▁fric
▁(1.2%)
=12
ndrome
▁42,448
▁sertral
▁tolmetin
tte
Ear
▁hyperp
raisal
▁aspirin
lof
9-4.
▁reti
omac
▁77%-9
▁acetylcysteine
9%,
▁amitriptyline
=25)
atremia
3.8)
ayna
inearly
▁thre
diab
▁81
rve
amping
▁cystoscopy
nw
▁saphenopopl
▁43,7
gester
articular
▁0.52.
ansop
▁crur
xacetonide
dti
▁hypert
7-5.96)
spon
▁povidone
nk
ticent
bances
roes
ipon
▁45.
▁30%
▁hypo
▁(87.5%)
▁untrained
▁(50%-95%),
▁Epwor
▁(86%)
▁peritone
▁SSR
▁Rarely
riglycer
nexal
compliant
uke
=89%
▁melano
-0.52;
vation
porary
=3.7;
onop
▁shaved
ysici
<6
▁subcutaneous
=-0.9
=.3
aturia
witch
▁guidebo
▁1.15
▁1.58
52%
=1560)
▁serotonergic
▁antifactor
-1.04
▁adverse
▁0.7-1.8).
25%.
etaz
ttom
nized
sulin
▁McMur
erythem
nment
Pati
715)
▁methot
0.22
ceful
4,
ureter
aref
▁Ninete
▁insuffici
asmin
▁18.5%
▁hypoallerg
▁elective
>3
odology
.0-15.8).
▁prevalence
dullness
trophil
fle
havi
▁occurrence
progest
▁Anticholinergic
1),
chlor
▁electrolytes
=19.5),
tents
ORs
▁indet
uctus
istering
▁purul
▁3/1000
irrit
▁surger
8-1.58).9
▁externalizing
mopressin
usate
▁glycerin
▁electroconvul
/0.9
tazapine
tenuation
▁formul
▁embolisms
enzaprine
▁microinvas
-1.11),
▁193
HDL
qui
ABHS
▁suburban
reasing
gil
=16%;
▁658
▁Pantoprazole
▁carbohydrate
▁dex
-15.8).
60-0.
comparative
▁0.12-0.71,
▁metronidazoleor
strati
▁vaccin
▁physici
amipril
otrans
tations
actur
▁elec
▁3.3
chosis
=.027),
idon
ogist
▁0.55-0.9
italized
utritive
=-0.98;
-0.89),
38.
isal
fric
-1.6.
leens
▁biochemical
atology
asionally
▁noncal
naus
000)
▁unrestricted
umc
OSP
▁benz
▁noncalcified
4]).
▁Inventory
▁Sucralfate
standardized
▁95%.
vastatin
▁denser
anad
▁resec
▁aty
"-
AAL
chon
amn
=1.80
orns
▁Antib
▁5%,
olycys
7.9
hydroergotamine
▁(0.5%
ypom
▁acquir
▁Pravach
=0
=0.62;
▁Gail
▁vascular
Difluc
acri
.009
▁71%-86%
lees
▁endometri
economic
uled
▁thrive
▁morbid
ecti
▁Twelve
▁therapists
52),
6-1
=.03,
ecreas
arfarin
-3.8)
lification
▁Diphen
▁2/20
▁ejaculation
8.9%
=2.26;
5.7%
▁dozing
▁exercis
uloph
fication
thot
opharynx
▁UPD
tet
▁prelabor
▁12.0
▁Expert
levations
▁3.2
▁Farr
▁preschool
Wal
▁helical
▁Ure
ytoch
▁0.70-3.
▁13.67
▁10.75
▁glucocorticoids
▁sunbur
▁Insulin
▁(10%-20%).
▁clotrim
wee
]=0.78;
=15;
▁Ancillary
opamine
▁hospitalized
▁Engl
azol
7)
▁validating
▁269
siveness
▁(30-50
▁prophylaxes
▁<.002)
▁8.2-23.
▁0.21-0.43;
▁acetic
ikeli
epat
▁1.84
]=5.33;
▁9.4%
▁dermatologist
onsensus
igran
200
amilton
▁balancing
eredit
Wor
▁5.8
ongly
revalence
often
▁9014
-91%).
▁(9%),
▁(62%)
=101)
▁discriminant
-1.26).
▁14.5
▁0.11-0.
3-0.0
tros
▁sleepiness
]=10.67;
▁-30%
▁1.01
▁impaction
=63
ergics
erases
▁Wad
▁Tis
Tre
reser
▁actinomyces
▁(34.8%)
▁colic
▁Assessment
▁2.8-10.
▁duct
alves
blems
ducing
ioniti
▁toothpast
ulide
▁serot
xercis
loralphenazone
▁ALTS
▁dehiscence
▁2.6-4.
▁spinal
ipients
therland
▁scalp
]=20)
dus
▁ascertain
▁(122,47
▁underway
▁postinj
Eg
▁5.2-
nep
eritis
ogu
aR
risks
▁demonstrating
▁polys
▁extracts
▁accounted
Wes
=140
▁Abstin
▁lessen
ctal
▁senna
ystoscopy
▁-6.9).
▁0.10
▁(3%).
▁hepat
-32.6%
▁0.3%
▁0.48;
▁Significantly
-=0.
osk
▁Cens
trod
▁outnumbered
utw
▁0.42-0.99).
athl
▁Chec
▁33%,
methotrex
(=
▁warfarin
▁infrequent
▁(6/30
▁saphenous
tedly
Amerge
▁9%;
▁inducer
pberry
Arthrotec
▁1.35-1.7
eneity
▁angiogram
Vand
=4.3;
▁musculos
0.2%
▁134
-0.94).
36;
▁rheumat
clinical
▁fallop
aral
ithromycin
tur
▁amoxicillin
mop
▁Atrial
acteri
▁titr
▁antioxidants
▁>55
alamine
timod
▁(22%
eduction
▁1.5-7.1])
162)
uctur
▁alleviate
▁prescribed
iab
istolog
=2.0-2.85).
▁87%
leeping
Las
chological
▁dehydrated
▁0.61-0.75;
miti
▁0.11-0.20).
-2.5
▁cyclob
▁(62%
onopathy
▁POCkit
30.
▁60.
=375)
eralized
10)]
▁nonc
▁uncircum
▁213
▁vulgar
▁Ig
isuse
henyt
inolones
roglycer
▁concus
▁1068
terol
▁nonrandomized
uptured
metab
▁8/
Imuran
▁>27
▁<0.7
reign
▁discharged
absorption
agul
▁200,000
idase
▁cellul
]=3.7).
inem
▁nonver
▁membran
▁whit
-14.
▁nonl
▁tibial
]=15).
▁30/
=96%
hanghai
▁1993
oquin
▁embol
▁(2%)
▁140
▁47%
sumura
▁percep
reso
ichlor
asmolytic
▁hydrolys
imits
▁loos
econds
▁8.8%
002
lations
▁Lovastatin
uic
▁Adverse
urgh
tud
▁hazard
▁DAS
terf
caro
▁IgG
▁4.8
▁Infarction
▁refills
54)
▁1.47-2.91;
▁95%-
-0.85).
ylert
▁4.3%;
▁perihepatitis
ogical
/24
▁4.46).
onoc
austion
mmet
rachial
>14
arazine
icati
ingiti
▁posth
63%
▁induce
▁labored
pion
▁gly
ioedema
▁Indo
▁respir
cerv
▁multimodal
▁1000-1
DLI
▁colos
▁mEq
1.4%
▁dyspepsia
lf
ervic
▁uterine
▁glom
=1.47;
▁(769
dol
▁ceftriaxone
▁elic
▁Pneumococcal
▁flexed
oste
▁rhin
embolic
▁likeli
▁avulsion
▁3.2%.
ffects
LV
▁comparis
adiazine
▁(4.3
opopliteal
ronchial
▁0.98-1.26).
sants
▁(315
▁regurgitation
]=1.
▁1.3-3.3).
▁oils
▁89%-9
-1.9).
ignant
ounsel
▁electromy
otions
agm
irtazapine
▁Progestogens
sychopharmac
Rul
▁pH
respective
inforcement
tomized
ergent
sian
▁Walsh
onogram
▁strictest
dle
▁alend
▁Foll
entilator
intestion
2.1;
▁investigations
▁urol
AISE
otropin
-100%
▁retinopathy
berog
▁actinomyc
▁asymm
▁experienc
acial
osy
▁nonr
tas
▁antioxid
1/36
▁psychophysical
-4.16)
▁Ginkgo
PIs
▁Sixty
▁washout
ondro
athered
aibo
32
ctioning
▁Leuk
gop
=4.7;
▁Addition
ontal
▁decubitus
▁5.5).
▁perin
▁raniti
29%
▁1.03
defin
Demer
roten
▁diat
3-0.7
-1.01).
eflox
gluc
urate
ellb
▁vertic
▁47,888
▁0.56-0.9
quired
▁(1:1:1)
▁1.2-
mear
▁1.38-3.41);
87%
atios
▁23,130
▁(208).
ectomies
rolim
-26.97).
ematical
ohum
rter
▁satisfactorily
▁(1.6%
ewhat
ayc
▁Scale
iopsi
ocro
emicade
ystolic
▁expres
tioner
▁0.82-0.9
▁nati
tiliz
▁110
ucan
ototherapy
veries
▁88%).
▁(17
ochrane
encephal
iological
ntic
▁cholesterol
arachnoid
utely
51
▁suppression
▁adipocyt
▁Transient
▁adhesive
4.1
▁thermometers
olitis
ndin
▁persist
▁positively
▁cremasteric
▁CAH
▁Hispanics
owel
▁angiop
3%).
iclop
▁2002.
=3.01;
▁niacin
erbilt
lactin
comycin
pleasant
▁(12-1
lavulan
Nys
eation
▁(55.
ommendations
rals
▁circumference
henhydramine
angement
biased
-10.
0.89
▁thromboph
jalainen
lyp
phary
relating
▁serology
▁malignanc
▁preven
DV
prodrome
▁0.12-0.
▁lipopro
▁disposable
-6.4).
3.7).
▁Rul
▁trun
▁abl
-81%
iratory
estions
▁tio
▁27%,
▁Recall
orid
temperature
lobulin
lysate
▁Lum
FeSO
▁extracorporeal
▁prematurity
proth
=.36;
▁statewide
▁5
70;
▁allergenic
▁hydrolysate
▁antio
▁cholinesterase
ogroup
gamm
▁Tonglul
-9
ibo
▁bilir
▁2.8%;
7-0.6
argine
▁earli
5-3.
ourinary
Fur
Lip
inkers
eof
ympan
ingul
▁35.8-74.9)
▁sponso
bation
▁duve
▁strains
▁<140
▁intrates
6),
denti
▁nonbreast
tropenia
▁sunb
aryng
95
=2.
▁Acetaminophen
▁10.5-18.
ALLHAT
RBs
onized
▁tenden
▁endob
determined
rthovisc
▁(36.
▁coac
acul
complic
▁37.
ticulocyt
▁encourages
roiditi
▁precurs
▁dissection
▁backg
▁unspecified
prand
ipar
contrast
ampin
diz
ostterm
▁302
umetan
-4.98).
▁occlusive
aigns
ysf
xate
okl
▁TCAs
]=1.0
amcin
renal
stitch
>6
arctions
trad
angiotens
▁endemic
<.001)-
cemia
▁confounders
▁loosened
▁0.64
▁1.1-2.0
▁HOP
▁emergent
aract
omerul
▁arthrography
▁adolescent
▁20,153
▁tonsillar
ventilation
cinol
3-1.63).
▁249
▁eradication
.9%
ozygous
▁0.61
ubsequent
ridine
ABH
▁elevations
▁gastro
91).
▁Inh
▁qualit
▁cosmetic
endic
▁acut
predic
uence
tured
▁dizz
▁anhyd
▁1998
▁unblind
astases
esart
(0.
▁continuation
spectively
▁699
turns
alepl
rment
▁70-1
antag
DAS
▁specif
HSIL
▁encop
▁validity
▁scanning
▁187
▁immunosupp
emide
Related
0-0.
1-0.4
ounders
enorrh
ticularly
05;
agnosed
otients
gm
Ment
.02
▁0.81-1.07),
reening
▁randomized
uris
Amary
▁unab
rres
▁68.3-9
angiotensin
-17.10)].
▁73%
▁deem
▁509
▁27,
▁Progest
▁mU
▁chlor
tus
8).
▁beeswax
FSH
▁minimally
expec
vented
91)
▁(7.
▁Losartan
ghing
ypoth
Gord
arf
erl
Ham
00).
tiqu
atarsal
▁100=
nures
▁depressive
ughters
reams
▁perfusion
loy
viewer
mple
reatic
ifically
ototh
ergone
▁Thin
▁Feeding
▁facet
70)
Ei
▁deformities
puscular
▁Delay
lamydophil
▁0.97-2.32;
▁witho
ritain
ophilic
ondary
nts
▁(7697
82).
ndred
IPID
procedure
icitis
ticip
▁incub
-1.05).
enou
ibrotide
Vioxx
▁Exc
▁Medline
▁pneumococcal
▁colpos
▁Coz
ughage
▁Atla
cortisone
9500
▁benzydamine
60
▁dropout
▁BCG
▁influenza
▁ipr
▁idiopathic
429.
▁1441
▁extrapolate
esicle
essing
▁AFCAP
alab
ydrogesterone
2,012
antibody
ptin
chlorothiazide
▁intramuscular
▁HER
▁85
▁CVD
erotherapy
▁Extr
epatitis
valency
▁77.
culariz
▁estradiol
▁931
-3.5).
alain
▁Prel
▁recei
=5.7).
▁1.05-1.28;
▁CAP
▁pneumon
Both
rican
3.12
▁(10.8),
▁unpleas
given
yld
▁inflamed
prandial
anking
CGs
wals
ailab
▁uter
rosy
=3),
-1.53).
openhag
▁Endpoints
1,752
inopril
▁43.
▁inhaled
earched
ritive
▁>40
amph
▁cholinester
gative
▁brainst
hrom
▁Delayed
▁incid
oquinolone
▁2%;
2-41.8)
ignificantly
-35
-69.6%
▁1.10-2.36;
▁1.3-
.0.
▁oxim
▁>4
andidiasis
iosus
=.045).
▁bullae
kner
erythromycin
nres
enterolog
▁macrocyt
ubg
imepiride
▁defecations
abapentin
▁18.9%
80.
▁indeterminate
cise
1.8%).
iets
▁1.25-1.6
▁cryotherapy
▁seroconverted
enomen
▁FEV
-97%,
32-5
-6.9)
▁hyperarouse
8-2.05).
▁metoc
▁abnorm
▁infusions
etimibe
▁allyamine
▁(75-81
bodies
▁tiotrop
2-0.23).
▁9/1
uide
-2.42)
opw
ocarcinoma
▁311
Garamycin
ortri
▁(32%)
▁adap
inPrep
CMT
▁wea
▁Holter
orvastatin
1035
5-4.
▁confound
-1.12
▁801
9]),
▁2000
▁Diabetes
▁cheilitis
▁antifract
▁(12.
moc
lants
crib
▁echocardiogram
▁infertility
iscip
▁coinfection
▁sputum
▁outweigh
▁hemoglobin
▁evaluations
▁Medicare
▁adjustments
▁Azithromycin
-49%).
rations
▁calcium
plasia
▁sheath
▁18,
unab
neumon
sif
▁(22
avast
tsc
adis
lication
onger
onch
ucosamine
yroidis
▁0.63/0.78,
ibri
▁peaked
▁9454
ayle
inavian
▁norgestimate
phet
fth
entu
4.9)
▁solit
hout
ranul
▁Buten
▁hypot
▁incompet
-1.07
▁cotin
imitations
icade
▁norfloxacin
idual
iliti
sform
atins
▁glycol
▁0.50).
▁1600
]=40
valine
nding
nonfatal
onm
epithelial
▁49
ogrel
▁chlamydial
▁Caucas
▁SWEET
▁1573).
3.5
ESTOR
umul
Gi
ylophora
apar
▁sco
anlin
LLHAT
127
Gro
=1.51;
▁dyslipid
ressi
▁1883
=55)
▁rifampin
teinur
▁athl
▁IVCFs
▁optimizing
▁epidemiological
▁(39
abal
prohib
amentous
cepti
▁anec
akth
▁1.05-1.7
▁enterocol
pli
oacetic
roscop
11;
PCL
rte
▁unl
▁97
otr
▁1%-3%;
tens
perim
itudinal
▁Opinion
▁multic
▁biof
osite
.005).
elow
perts
▁Initi
▁nutri
▁15.2%
ounty
onv
initive
cretion
▁primar
▁plas
▁2.5-5.6),
▁celiac
▁perc
▁70.7%
,730
direc
DNA
▁2.10-3.77).
ravent
▁BMI
▁68
▁529
▁0.5-7.0
▁thist
1.8
68
Vent
llit
▁ulcer
aiw
▁strate
▁leukocyt
onsumption
▁intermenstrual
▁(4.7%
▁Individuals
tichol
addre
009
3-1.7
▁Sevente
▁tympanoscler
▁(>100
harmac
▁Traditional
oiditis
nine
tified
▁repro
▁misoprostol
▁1000-12
GADAb
▁mastoid
▁serotypes
citonin
▁Gibb
4-2.9
▁nonspec
▁hepatic
inland
▁Nine
▁10,730
▁undetermined
doph
istam
gli
▁coadm
DNT
69).
eclin
celes
opped
▁osteoar
itazone
ollowed
94
▁antibiotics
▁antibodies
▁epidid
anuts
▁agonist
▁mening
Mis
▁unsweet
tratif
erichia
leges
▁inadvertent
▁swab
itral
irment
▁1.4
IVP
-1.00
▁tomography
▁statin
▁Regarding
=125),
reatment
▁cardios
ucts
▁indigent
▁(10%
]=10
orce
▁6825
lampsia
▁admis
arized
▁Cuban
elves
▁hund
=16,
=82%,
=91.
adequate
▁56,790
=91)
▁79%
7-2.9
tter
▁Stratified
icu
ofold
▁detecting
ostomies
▁chloride
▁juic
▁fluox
orsened
romog
osable
ACAP
Myc
▁succes
tiem
issing
2),
intention
dition
stet
veres
▁6-36
▁0.5
achyp
▁manu
▁cohort
▁fibrates
▁0.67-5.96)
▁Lach
▁reh
ronou
histamines
▁hepatotoxic
▁antithrombo
▁acidic
▁2.1-11.9]),
=0.49;
inot
onatremia
23%
]=1.2-10.
▁Glucosamine
crom
▁Tyl
oneus
▁ovules
ALLHA
▁conceal
1.4,
either
venience
oddl
jand
▁conti
irc
▁equate
▁adulth
▁inq
▁pathophysiology
▁0.59-0.8
14.4%
▁77-9
▁0.34
▁(4-
enof
▁prodrug
▁hexacet
▁electrosurgical
▁95%,
▁734
ysfunction
-0.1
▁ValHe
5.
illectomy
▁1993-19
salt
wit
llees
ehy
tbo
roven
utb
adenoma
SDS
▁(10.
enem
▁SPF
▁oint
rept
yno
▁seroc
▁(81.
▁unaffec
riad
▁241
verte
antop
otally
▁1.36
enos
dres
thetic
ademic
▁surgeon
-23.21)
epl
ecaus
▁Reviewing
azone
munized
strates
08;
55);
ergonomic
syllium
▁Likew
vestigations
▁revaccin
erence
▁Dental
anazol
▁0.54-0.81)
hormonal
▁Trog
ehavi
elod
orc
3.2
▁immunos
osporins
neumococcal
▁alginate
ulati
▁celandine
▁causal
▁1992,
NIDDM
▁1.62-2.22),
ulfam
osive
▁reviewers
▁Asthma
▁463
▁13.3
▁3.54,
▁prophylax
▁Expectant
2-8.4).
▁smokers
▁1.01-2.76;
STF
▁ketoc
bact
nolog
▁1.19-2.41;
▁Interventions
alep
ancom
ration
▁diaper
▁173
]=19.4;
omethep
▁rehab
culation
▁attit
▁bladder
copresis
adical
elings
fti
itrac
▁0.36-0.60).
▁thei
ilvadene
▁surgeries
yloph
▁wks
6,094
ofenac
37)
▁119
▁nonrig
=1.5-1.9
embry
endon
2,60
amining
96)
=88
ersom
ffer
▁widespre
ecul
trover
kly
=-57.9
▁0.55-0.84),
▁68%
>2
▁bladd
oxifen
trap
elated
▁enl
▁HB
▁subfractions
ophon
medic
epression
▁petrolatum
▁tablets
otreat
cetate
▁lorazep
▁704
▁Reduc
▁heartbur
▁3.80
▁(0.5
7.7%
▁constip
ermin
▁diazep
▁8.15%
unog
-8
-12
ipine
yclic
0/0.
8-4.
artan
▁557
gone
▁SAB
▁paral
reef
izu
=6)
cribed
-80
eraliz
producible
▁nondiarrh
3/
Ti
▁14%
▁lapa
▁-0.01).
bability
▁7.2
▁(175
triglycerid
▁Proges
▁stric
▁(1%)
▁Abstinence
▁nulliparous
▁10.5-1
▁overuse
▁1.40
▁mefl
nth
▁warf
▁-0.22
▁accoun
]=8.1;
▁abnormalities
▁1.2-14.7)
igor
atherogenic
entage
lk
CUS
2,
▁enrolled
ixte
▁atorvastatin
eys
ilmed
irid
▁mammography
oxicil
▁0.1,
▁13.
oniae
▁interim
▁Splenectomy
,42
▁90-
cool
▁reliably
erous
751
onded
ometim
▁optimiz
▁2994
▁41.5
▁Norvasc
=1.24;
aric
hexyphenidyl
87),
▁1.46-7.5
▁1.1-7.0
▁symp
molec
▁98.9%
urad
=2.1;
COPS
enures
itly
